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Abstract 
Clostridium difficile is the leading cause of nosocomial diarrhoea in the world, and a 
considerable burden to healthcare services. For colonisation of C. difficile to occur in the 
gut of an individual, the resident gut flora must first be quantitatively or qualitatively 
altered, normally through antibiotic treatment for an unrelated infection. At present, 
broad-spectrum antibiotics such as vancomycin and metronidazole, the frontline 
choices for the treatment of C. difficile infection; disturb the normal gut flora, suffer 
from poor recurrence rates, and have received reports of sporadic emergence of 
resistance. Development of novel narrow-spectrum antimicrobials would circumvent 
these problems but depend on the identification of novel essential genes. Molecular 
techniques available to identify and study essential genes in other organisms have not 
yet been applied to C. difficile. In this study, we identified 208 candidate essential genes 
via in silico analysis based upon similarity to known Bacillus subtilis essential genes. In 
order to provide experimental evidence of essentiality, we developed a novel method 
utilizing partial diploids and functionally characterised three C. difficile genes as essential; 
CD0274, metK, and trpS. This method not only identified CD0274, a candidate narrow-
spectrum drug target and the first essential genes in C. difficile, but also provides a 
reliable method to identify further essential genes for novel antimicrobial targeting. In 
addition, we developed a lac repressor system, a rationally designed theophylline-
responsive riboswitch, and most importantly, a Tet inducible promoter system able to 
conditionally control expression of a catP reporter through a wide dynamic range in 
both C. difficile and C. sporogenes, to maximum induction factors of 192.89 and 1,275.63, 
respectively. The combinations of these characteristics make this Tet system not only a 
powerful tool for identifying essential genes, but bestows a great potential for further 
analysing gene function far beyond the scope of this project.  
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1. Introduction 
Antimicrobial discovery and development was undoubtedly at the forefront of research 
in the 20th century with a multitude of new products being developed to meet medical 
GHPDQGV:LWKWKLVVXFFHVVFDPHWKHFRPSODFHQF\GHULYHGIURPWKHEHOLHIWKDW´LW>ZDV@
time to close the book on infectious diseaseVµ 86 6XUJHRQ *HQHUDO 
Pharmaceutical companies therefore switched research focus towards other therapeutic 
areas such as the treatment of chronic conditions2. This trend has continued with 
increased regulatory requirements in manufacturing, safety, and efficacy which have 
increased the focus on research and development on chronic conditions for a 
¶FRPPHUFLDOO\DWWUDFWLYH·UHWXUQRQ LQYHVWPHQW2,3. As pharmaceutical companies headed 
for the exit, there has been an unrelenting rise in the occurrence of antimicrobial 
resistance by many common pathogenic bacteria, posing the question; will industry be 
able to meet future needs for new effective antimicrobial products?4 At present, 
physicians commonly have to turn to their second or third choice antibiotics in order to 
combat resistant bacteria. The effectiveness of vancomycin, which is seen as the last line 
of defence against many organisms has already started to waiver5-8. Therefore, there is a 
great demand for the discovery of novel antimicrobial targets to add to our arsenal.  
The last three decades have presented another major drawback of current antibiotic 
usage, namely Clostridium difficile infection (CDI)5-13. C. difficile, a Gram-positive, 
anaerobic spore-forming, multi-drug resistant bacterium is the causative agent of CDI, 
the leading cause of nosocomial infectious diarrhoea worldwide5-13. The pathogen is 
frequently associated with antibiotic treatment and manifestation of disease range from 
asymptomatic carriage, mild diarrhoea to life-threatening pseudomembranous colitis 
(PMC)5-8. Over the past few years there has been an exponential increase in the 
prevalence of C. difficile in the UK with severe CDI being identified in originally low risk 
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groups6,10,11. This change in epidemiology and severity of disease could be due to the 
emergence of hypervirulent and increased microbial resistant strains such as C. difficile 
PCR-ribotype 0276,8,14.  
1.1 Clostridium difficile: Emergence of a Significant Human Pathogen 
C. difficile ZDVILUVWGHVFULEHGLQE\+DOODQG2·7RROe as a slow growing anaerobic 
bacillus that was difficult to isolate from normal new-born infant gut flora15. Due to this 
difficulty in growing the organism in the laboratory, the species name difficile was 
bestowed upon the organism. However, today the name could be construed to 
represent the difficulty in combating the organism which has grown to epidemic 
SURSRUWLRQV 'XULQJ WKH ·V pseudomembranous  enterocolitis was starting to 
emerge as a nosocomial disease attributed to either Staphylococcus aureus, an organism 
whose increasing prevalence at the time was associated with hospital in-patients who 
had undergone antimicrobial therapy, or to Candida albicans5,7. In 1974, a prospective 
study of 200 patients treated with clindamycin showed that 21% of the patients 
developed diarrhoea and 10% pseudomembranous colitis, proposing a direct link 
between antibiotic usage and colitis16. It was not till 1977 that a toxin produced by a 
Clostridium species was proposed as the causative agent of clindamycin-induced 
ileocecitis in hamsters16.  However, by 1978 it was firmly established that C. difficile was 
the causative bacterium of antibiotic-associated colitis5,9,12. Today C. difficile is 
responsible for up to 20-25% of cases of antibiotic-associated diarrhoea and almost 
100% of pseudomembranous colitis (PMC)17. 
According to the Communicable Disease Surveillance Centre (CDSC) for England and 
Wales, CDI reports of inpatients contracting C. difficile have risen from 1,000 in 1990 to 
15,000 in 2000, 35,000 in 2003 and to 60,000 in 200712. Of the patients reported to have 
CDI in 2007, 50,000 were aged 65 years and over. This increase in incidence also 
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manifests as an increase in mortalities mentioning C. difficile on the death certificate. The 
deaths associated with C. difficile have increased steadily from 1999 to 2007, where they 
peaked at 8,200 deaths. Rates however decreased from 2007 to 2010, where deaths were 
2,800, 65.8% lower than 2007 (figure 1.1). This decrease is likely due to increased 
surveillance and quick containment of infected patients.  
 
Figure 1.1. Number of death certificates mentioning C. difficile as either 
an underlying cause or directly implicated, in Wales and England 
between 1999 and 2010. The increase in prevalence in 2004 may be due 
to a mandatory surveillance scheme being introduced. Taken from the 
Office of National Statistics (http://www.statistics.gov.uk). 
A study by McFarland et al, (1989)18, found that about 20% of patients admitted to a 
hospital were already positive, or contracted a toxigenic strain of C. difficile during their 
stay18. In contrast, it is estimated that only about 1% of the total population of healthy 
outpatients are positive for the bacterium11. Recently, community-acquired CDI has also 
seen a striking exponential rise in prevalence from less than 1 per 100,000 people in 
1996 through to 18 per 100,000 in 2004 (figure 1.2)11.  
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Figure 1.2. Risk of total and community-acquired infection rate of C. 
difficile compared to prescriptions of antibiotic and protein pump 
inhibitors per 100,000 patients in the UK between the years 1994 and 
2004. (Taken from reference 13). 
 
1.1.1 C. difficile disease 
C. difficile is able to survive in the environment by producing spores; these spores are 
highly-resistant to many commonly used cleaning agents and can persist for months in 
the environment which are subsequently ingested by the patient19,20. Interestingly, only 
about one third of patients infected with a toxigenic strain of C. difficile develop 
symptoms, the remaining two thirds are asymptomatic and are thought to act as a 
reservoir of infection21,22.  The organism and its spores can be isolated from a variety of 
different areas. As expected, places like commodes and bed frames have a very high 
concentration of the organism, also; toilets, floors, curtains, banisters, door handles, 
telephones, hands of healthcare workers, and many more places have all been 
demonstrated to be contaminated5,17,18. 
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For colonisation of C. difficile to occur in the gut of an individual, the normal gut 
microflora must be qualitatively or quantitatively altered17. Anaerobic microbial flora in 
DQRUPDOLQGLYLGXDOFRQIHUV¶FRORQLVDWLRQUHVLVWDQFH·LQKLELWLQJVRPHSDWKRJHQLFEDFWHULD
such as C. difficile from colonising the gut, although the precise mechanism involved is 
unknown10. The most common risk factor associated with CDI is exposure to 
antibiotics9,10. A meta-analysis study conducted by Bignardi in 1998 assessing risk factors 
compared forty-nine published reports based on comparison of C. difficile cases against 
individuals without diarrhoea9. It was noted that a high number of antibiotics and 
classes have a significant statistically positive association with both C. difficile carriage 
and diarrhoea (figure 1.3)9. Ironically, vancomycin and metronidazole both used in the 
treatment of CDI also have a medium risk for predisposing a patient to CDI9. Age, in 
particular being over 65, is also a major risk factor associated with CDI, possibly due to 
reduced function of the microflora of the gut9. There are many more risk factors which 
can predispose a patient to CDI (figure 1.4). ProtHLQ SXPS LQKLELWRUV 33,·V IRU
example have recently been described to increase the risk three-fold of contracting CDI, 
especially in a community setting (figure 1.2)11 33,·V DUH GUXJV SUHVXPHG WR LQFUHDVH
gastric pH thereby decreasing the destruction of the spores within the stomach.  
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Figure 1.3. Risk of C. difficile diarrhoea associated with individual 
antibiotics or antibiotic classes. Adapted from reference9. 
 
Figure 1.4. Other risk factors associated with the two main 
outcomes of colonisation with C. difficile. Adapted from reference9. 
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The sequence of events that lead to CDI are important: firstly the patient is exposed to 
a factor or factors that alter the microflora of the gut; secondly, exposure to a toxigenic 
strain of C. difficile, and; finally, the presence of additional factors (such as advanced age) 
all determine the subsequent outcome of colonisation. CDI used to be seen solely as a 
healthcare associated infection, however, over the past 6 years the epidemiology of CDI 
has been changing. Between 2003 and 2005, severe CDI was identified in originally low 
risk groups such as; peripartum women within 4 weeks after delivery, patients which 
have not been hospitalised in the previous 3 months which may not have been exposed 
to antibiotics, and young people with no serious underlying illness6. This change in 
epidemiology and severity of disease could be due to the emergence of hypervirulent 
and increased antimicrobial resistant ribotypes such as PCR-ribotype 0276,8.  
1.1.2 Emergence of hypervirulent strains 
Since the turn of the century, the incidence of CDI has increased dramatically in line 
with the emergence of so-called hypervirulent strains. These hypervirulent strains are 
thought to cause more severe disease, higher relapse rates, and increased 
mortality6,8,14,23,24. One of the most prevalent types of hypervirulent strains belong to the 
restriction endonuclease type BI, North American pulsed-field type I (NAP1), and 
PCR-ribotype 027 (BI/NAP1/027). In the past, the isolation of such strains was 
considered rare, however, recently they have become highly represented among clinical 
isolates, so much so that BI/NAP1/027 is now the most common C. difficile type 
isolated in England and is frequently associated with outbreaks (figure 1.5)25. Between 
2007 and 2008, the incidence of PCR-ribotype 027 increased by 15% to represent 41% 
of isolates in 2008, while the incidence of PCR-ribotypes 001 and 106 decreased by 17% 
and 6%, respectively, during the same time period. The presence of representatives of 
the BI/NAP1/027 type has been confirmed in at least 16 countries throughout 
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mainland Europe12,24. In North America, the strain is thought to be associated with the 
increased usage of quinolone class of antibiotics, resulting in greater resistance to 
floroquinolones12. Worryingly, BI/NAP1/027 has also been linked to the emergence of 
community-acquired CDI, removing the nosocomial label and taking the disease out 
into the community11,23.  
 
Figure 1.5. Frequency of isolation of C. difficile PCR-ribotypes in 
England during the period of 2007 to 2008. The data represents a total 
of 677 individual isolates taken nationally. Adapted from reference25. 
The reason why such ribotypes are hypervirulent is unknown. There is evidence to 
suggest that the BI/NAP1/027 strains produce higher levels of toxins in the laboratory, 
and it has been suggested that they are more prolific in sporulation than their non-
hypervirulent counterparts13. Other studies question this latter suggestion, and propose 
sporulation rates are not associated with type26. All in all, the molecular basis of 
hypervirulence remains unknown, but understanding the basis of the contributing 
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factors may allow specific countermeasures to be developed to overcome outbreaks and 
increase the efficacy of treatments. 
1.1.3 C. difficile virulence factors 
Pathogenic strains of C. difficile produce two potent toxins, toxin A (TcdA), an 
enterotoxin, and toxin B (TcdB), a cytotoxin, both of which ultimately mediates the 
severity of disease27. In addition to the two well characterised toxins, a binary toxin, an 
actin specific adenosine diphosphate-ribosyltransferase, can be found in all PCR-
ribotypes of 027 which are thought to make up approximately 41% of clinical isolates of 
C. difficile in 200825. The two large exotoxins, TcdA and TcdB, are some of the largest 
bacterial toxins known, at 308 kDa and 269 kDa, respectively, and exhibit homology at 
the amino acid level of over 45% to each other. The encoding genes (tcdA and tcdB) are 
localised to a 19.6 kb pathogenicity locus (PaLoc) in C. difficile, along with; tcdE, a cell 
wall hydrolase, tcdR an alternative sigma factor involved in positive transcriptional 
regulation, and tcdC, a putative negative regulator28.  
When the toxins come into contact with receptors on the luminal side of the colonic 
epithelium, they are transported into the cytoplasm. Both toxins are 
glycosyltransferases, and once inside, they interact with the Ras superfamily of small 
GTPases. TcdA and TcdB catalyse the addition of a glucose moiety to threonine-37 of 
RhoA, utilising UDP-glucose as a co-substrate27. Both toxin A and toxin B are able to 
target RhoA, -B, -C, Rac, and Cdc42, causing actin condensation resulting in rounding 
of the cells, membrane bleeding and ultimately apoptosis of the target cell27.  
There is currently some debate as to which toxins are required for virulence. A recent 
study concluded that toxin B, not toxin A is essential for virulence in a hamster model29. 
The preeminence of toxin B in disease is supported by the isolation of a number of 
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clinically relevant virulent strains which lack toxin A, and only produce toxin B. 
However, in contradiction to these results, another study published from our laboratory 
suggested that both toxin A and toxin B alone are sufficient to cause virulence in a 
hamster model30. There were a number of differences between these studies, such as the 
strain of C. difficile which was used, which could account for the differences seen. It is 
clear that further research into the role of toxins in virulence is required to elucidate the 
fundamental function of each toxin in causing CDI. 
Apart from the toxins being the main virulence determinants, other virulence factors 
may have synergistic roles; although the extent of their involvement is unclear. The 
unique outer surface layer proteins, predominantly composed of SlpA, make up the S-
layer of C. difficile vegetative cells. It is thought that the S-layer proteins are responsible 
for adherence of C. difficile to host cells which subsequently elicit inflammatory and 
antibody responses31-35. The flagella of C. difficile, composed primarily of FliC and FliD, 
are thought to be involved in adherence to host cells, allowing colonisation of the gut36. 
However, in contrast to the published work, results from our laboratory suggest that 
flagella may not play a role in adhesion (Soza Baban, Sarah Kuehne, and Nigel Minton, 
unpublished results).  
1.1.4 C. difficile treatment 
Treatment of CDI has evolved little in recent years, with only a few proven therapeutic 
options available. At present, oral metronidazole and vancomycin are the antibiotics of 
choice for the treatment of CDI; however bacitracin methylene disalicylate, fusidic acid, 
nitazoxanide and teicoplanin have also been shown to be clinically effective5. Two more 
antibiotics; rifaximin, and ramplanin, and 2 non-antimicrobials, CDA1 (MDX-066) and 
MDX-1388 are currently in developmental phase II or III14. However, all the antibiotics 
mentioned are broad-spectrum and not novel classes so may encounter the same 
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complications as the other commonly used broad-spectrum antibiotics. C. difficile is 
generally susceptible to vancomycin, but occasionally strains have reported resistance to 
metronidazole and vancomycin, coupled with the high rate of recurrence following 
treatment, new treatment options or novel narrow-spectrum antibiotics would be highly 
advantageous6.  
One such novel antibiotic looks promising, fidaxomicin (PAR-101/OPT-80), the first in 
a new class of macrocyclic antibiotics. Fidaxomicin, an RNA inhibitor, has a narrow 
spectrum of activity, almost purely C. difficile specific37. Louie et al, (2011)37, investigated 
its efficacy as an alternative to standard CDI treatments37. The authors subjected 629 
adults to a randomized, double-blind phase II clinical trial. Subjects either were treated 
with fidaxomicin (200 mg twice a day), or vancomycin (125 mg 4 times a day) orally for 
10 days. The experimental endpoint was defined as the patients requiring no further 
treatment 2 days after completion of the trial, determined by the investigators. To 
evaluate relapse, the investigators included a secondary endpoint 4 weeks post therapy. 
The trial determined that fidaxomicin was very similar to vancomycin in treatment of 
CDI, with 88.2% of patients showing no signs of infection after the first endpoint of 
treatment with fidaxomicin, compared to 85.8% for vancomycin. In addition, the 
investigators noted that fidaxomicin treatment resulted in a significantly lower rate of 
relapse, 15.4% vs. 25.3% (P=.005) for fidaxomicin and vancomycin, respectively37. 
There was also no significant adverse side-effects following fidaxomicin treatment. 
From these results, fidaxomicin appears to be an extremely promising drug for treating 
CDI and preventing high relapse rates, outlining the importance and effectiveness of a 
narrow-spectrum antimicrobial. 
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1.1.5 A need for novel antimicrobial targets 
At present, there is a limited selection of antibiotics available for the treatment of C. 
difficile, many of which target the same conserved cellular process or even the same 
enzyme as other antimicrobials, increasing the potential for cross-resistance. Over the 
past 10 years, the search for novel antimicrobial targets and agents against C. difficile has 
acquired a new sense of urgency due to increasing resistance and the chance of 
recurrence after treatment with current broad-spectrum antibiotics. Development of 
QHZDQWLELRWLFVWKDWFLUFXPYHQWWKHVH¶UHVLVWDQFHDQGUHFXUUHQFHSUREOHPV·ZLOOGHSHQG
on novel species-specific targets being exploited. Early efforts have been limited by the 
lack of technology to identify targets38. With the advent and availability of whole 
genome sequencing in the mid-1990s, hundreds if not thousands of potential new 
targets could be identified, leading the way for many novel antimicrobial classes. 
However, even before the sequencing of many organisms had been undertaken, a 
number of possible novel target sites have been identified using classical methods in 
many bacteria; such as CD0274, yet very little, if not no research has been undertaken in 
C. difficile39,40. To date, there has only been one candidate essential gene which could be 
used as a novel narrow-spectrum antibiotic target in C. difficile cited in the literature. 
Liyanage et al, (2003)39,40, hypothesised that CD0274, a suspected alcohol dehydrogenase 
the authors annotated as gldA, was involved in the sole detoxification pathway of the 
toxiFPHWDEROLWHPHWK\OJO\R[DO0*7KHDXWKRU·VLQDELOLW\WRLQDFWLYDWH&' while 
keeping cellular viability led to the suspicion that it was essential. If true, CD0274 would 
make a candidate for antimicrobial targeting. However, further validation is required to 
SURYLGHVWURQJHUHYLGHQFHRI&'·VHVVHQWLDOLW\ 
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1.2 Selection and Validation of Novel Drug Targets 
The ideal microbial enzyme target should have no homology to humans to minimize 
toxicity, have a fully elucidated mechanism of action and function, and be required for 
survival of the bacterium to unsure chemical inhibition will ultimately result in cell stasis 
or death2-4. Generally broad-spectrum antibiotics are preferred as they are cost-effective 
and clinically easy to use, but in the case of C. difficile, a narrow-spectrum antibiotic 
would be of interest due to the complications with gastrointestinal sequelae caused by 
the antibiotic-associated destruction of the normal gastrointestinal flora. The most 
important criterion for a novel drug target is the assessment of the target being essential 
to cell viability during infection, or even better, absolutely required for survival. To 
assess this viability, a number of genetic tools have been employed in other bacterial 
species. Unfortunately, many of these tools have not been developed for usage in C. 
difficile for the purpose of essential gene identification, however, with the advancement 
of current technology and genetic tool developed within our laboratory, it is now 
possible to combine and develop novel tools to identify essential clostridial genes38,41,42.  
1.2.1 Methods to study essential genes 
Essential genes are of significant importance in pathogenic bacteria for the purpose of 
therapeutic drug targeting, as such, many studies have been carried out using several 
experimental and computational approaches to identify essential genes in organisms 
such as; E. coli43,44, B. subtilis45, and S. aureus46,47. There are two ways which to identify 
candidate essential genes, through bioinformatic or experimental approaches. The 
bioinformatic approaches use large-scale in silico screening with the assumption that 
essential genes are likely to be common among different species so will be highly 
conserved48. However, bioinformatic approaches can only identify candidate essential 
genes, to validate them as essential, experimental approaches must be applied.  
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There are two broad strategies to identify essential genes by experimentation, by 
forward genetics, or by reverse genetics. Forward genetics is the term given to an 
approach used to identify genes, or set of genes, responsible for a particular phenotype. 
In this method, no possible targets are identified prior to experimentation. The 
identification of genes is carried out by searching the entire genome through random 
approaches such as; transposon mutagenesis or shotgun-antisense. In contrast, reverse 
genetics already knows which gene to target, and is used to identify a phenotype 
associated to the gene. This targeted approach uses techniques such as the ClosTron, 
plasmid insertion mutagenesis, allelic exchange, or construction of conditional 
mutations. These experimental methods can be classified further into direct or indirect. 
Direct approaches are able to identify essential genes directly, by using conditional 
mutations, i.e., being able to control expression of a gene by the addition or subtraction 
of an inducer49. Indirect approaches are able to identify essential genes by two ways, the 
first is they are able to identify non-essential genes directly by the ability to inactivate 
them; in contrast the genes which cannot be inactivated may be classed as candidate 
essential genes. To provide stronger evidence of essentiality, you can show that the gene 
is able to be inactivated if a second copy of the gene is present within the chromosome, 
thereby constructing a partial diploid and allowing a functional complementation of the 
native essential gene50. However, using reverse genetic techniques such as these, 
candidate essential genes first need to be identified.  
 
1.2.2 Conservation of essential genes 
The strength of negative (purifying) selection is thought to be the main contributing 
factor in determining the rate of evolution of protein-coding regions51. It has been 
proposed that essential genes should evolve slower than nonessential genes within an 
organism because they are, by definition, functionally indispensable for the survival of 
 
16 
 
the organism. Due to the role of purifying selection in determining evolution rates, the 
selection pressure on essential genes to remain functional manifests as a lower rate of 
evolution compared to nonessential genes51. TKLV WKHRU\ LV FDOOHG WKH´NQRFNRXW-UDWHµ
prediction and was established by comparing the synonymous and nonsynonymous 
nucleotide substitution rates of essential and nonessential genes between E. coli, 
Helicobacter pylori, and Neisseria meningitidis51.  
 
In B. subtilis, Kobayashi et al, (2003)52, predicted that out of the 271 essential genes 
identified, 80% have homologues in other bacterial species, and 20% have homologues 
in all bacterial species52. Of those 271 essential genes, 209 have putatively essential 
orthologues in Staphylococcus aureus and 150 are thought to be essential in E. coli, although 
the functions of the genes are unknown52. However in E. coli, there are 67 genes which 
are counted as essential whereas they are non-essential in B. subtilis, and 86 have no B. 
subtilis orthologs53. In the bacterium H. pylori, there are 344 identified essential genes, of 
which only 20 are known to be essential in all three; E. coli, Haemophilus influenza, and 
Mycoplasma genitalium species54. 
 
These publications show that although essential genes are conserved more highly than 
nonessential genes, there can still be variation between species. As such, a genes 
essentiality in one organism does not automatically predict essentiality in another 
organism and as such, each gene must be confirmed to be essential by experimental 
evidence.   
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1.2.3 In silico approaches 
In silico analysis has proven to be a powerful tool to compare genomes of different 
bacteria. In 1995, the first two bacterial genomes were completely sequenced; H. 
influenza55 and M. genitalium56. Based upon the assumption that essential genes are 
conserved across bacterial species, Mushegian and Koonin, (1996)48, derived the 
minimal gene set required for cellular life by comparing the complete genomes of both 
the aforementioned bacteria48. Their theory was that both M. genitalium and H. influenza 
belong to two ancient lineages, i.e. Gram-positive and Gram-negative bacteria, 
respectively. Because of this, the genes which are conserved between the two genomes 
are almost certainly essential for cellular function, as such, it is this category which is 
most likely to approximate the minimal gene set48. Using this theory, the authors 
speculated that 256 genes is the lowest minimal set required for cell viability48. Using an 
experimental approach, Itaya, (1995)57, determined the maximum randomly selected 
genetic loci in B. subtilis which could be disrupted without loss of viability57. Itaya, 
(1995)57, concluded that the estimated minimal genome size of 318 kbp, corresponding 
to 254 genes (the average gene length ca. 1.25 kbp), was the minimal gene set required 
for life in B. subtilis57. Considering the differences in approaches of these two studies, 
both authors predicted a remarkably similar number of genes to be the minimal set 
required for cellular viability48,57. As the publications of complete genomes is increased, 
other in silico predictions to identify essential genes have been made, including 
comparison of up to 5 bacterial genomes, identifying 89 genes which are conserved 
between the large phylogenetic distant organisms58.   
 
While computational approaches are a good starting place, there are significant 
limitations to using such systems to identify essential genes. When using in silico 
approaches to identify minimal essential gene sets of an organism, they are likely to 
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underestimate the total number because only the genes that are conserved through the 
divergence of the species will be recognised, therefore genes which have evolved to 
become species-specific will not have orthologues in other species, and so will not be 
recognised. Also, genes which are known to be essential in one organism might not be 
essential in another organism. In silico identification can also be fallible; a study used 
seven proposed essential genes in H. influenzae identified by concordance analysis48, and 
experimentally analysed them using transposon mutagenesis59. The results showed only 
three of the predicted seven were essential for viability59. As such, using computational 
approaches will give insight and identify candidate essential genes, but as of now, 
computational approaches will need to be backed up by reverse genetic methods to 
confirm essentiality.  
 
1.2.4  ClosTron 
Until 2007, one major problem with the genus Clostridium was the lack and efficiency of 
methods for insertionally inactivating specific genes38. A few authors had published 
reports of single crossover knockout mutants obtained from using a replicative-
defective plasmid, but the mutants generated were unstable40. This was a consequence 
of excision events between the duplicated regions of DNA that flanked the target 
site38,40. Awad and colleagues60 reported a mutant generated via allelic exchange in C. 
perfringens. The isolation of such rare mutants in C. perfringens was possible because of the 
high frequency at which DNA can be transformed into this Clostridium compared with 
others. In response to this extremely low integration frequency observed in other 
FORVWULGLDOVSHFLHVDQRYHOPHWKRGXVLQJEDFWHULDOJURXS,,LQWURQVFDOOHG´7DUJH7URQµ
KDV EHHQ DGDSWHG IRU XVH LQ FORVWULGLD E\ +HDS DQG FROOHDJXHV DQG WHUPHG ´7KH
&ORV7URQµ38,61.   
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The ClosTron is a novel reverse genetic method which uses bacterial group II introns, 
to insertionally inactivate any required target gene. Group II introns are of particular use 
in targeting genes because they can be retargeted to insert into virtually any target gene 
with high efficiency and specificity38,61,62. The group II introns, from the ltrB gene of 
lactococcus lactis (L1.ltrB), mobility is mediated by a site-specific replication mechanism 
termed retrohoming. Retrohoming is when RNA introns are reverse spliced into DNA 
target sites and then transcribed with an intron-encoded protein (IEP)63. The process is 
controlled by the production of a ribonucleoprotein (RNP) particle which contains the 
IEP and excised intron lariat RNA, during RNA splicing. RNPs initiate integration into 
the specific gene by using the IEP, with base pairing of the intron RNA complementary 
to the specific DNA target sequence64. By modifying the base pairing on the intron 
RNA, it is possible to retarget the group II intron to integrate into specific 
complementary DNA sites within the target gene (figure 1.6B). Another advantage of 
using group II introns is the ability to remove the IEP open reading frame (ORF) from 
the intron encoding region and placing it on a distal site on the plasmid without 
affecting intron mobility (figure 1.6A)62. Following the IEP-mediated intron integration 
into the target gene, subsequent loss of the plasmid and the IEP gene, prevents 
subsequent splicing of the inserted intron and the creation of an unconditional mutant.  
 
In the natural group II intron, the IEP gene occupies a non-structural domain (IV), 
which plays no role in the retrohoming process. As the IEP gene has been relocated 
elsewhere on the ClosTron plasmid, this non-structural region can be the location of 
the insertion of alternative ´FDUJRµ DNA, such as a positive selection marker.  
 
To select for integration of the intron within the target gene, an antibiotic selection 
marker is a quick and easy way to positively select for integration events. Zhong et al, 
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(2003)62, describe the XVH RI D ´7ZLQ7URQµ LQ ZKLFK WKH //WU% LQWURQ GRPDLQ ,9
which previously housed the IEP, now contains an antibiotic resistance marker in which 
another group I intron interrupts the marker in the opposite orientation (figure 1.6A)62. 
The orientation of the group I intron, group II intron, and the antibiotic resistance 
marker were designed so when integration of the group II intron into the target gene 
occurs, the group I intron would self-splice out of the anti-sense antibiotic resistance 
marker, restoring function. Therefore, insertion of the group II intron into the target 
gene activates antibiotic resistance to an appropriate antibiotic, allowing positive 
selection. This type of marker is termed a Retrotransposition-Activated selectable 
Marker (RAM), because the restoration of antibiotic activity only occurs when the 
intron has passed through an RNA intermediate62. Using this method it is possible to 
insertionally inactivate genes in clostridia with high frequency and stability38. 
 
Despite the effectiveness of the ClosTron, if a gene is essential, insertional mutants will 
not be obtained. Failure to obtain ClosTron insertions if a number of different 
retargeted plasmids are employed could be taken as evidence that a gene may be 
essential. However, the design of the retargeted ClosTron plasmids is based on an in 
silico algorithm and is not necessarily 100% reliable. As such, the ClosTron alone is 
insufficient to identify essential genes. 
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Figure 1.6. The ClRV7URQ V\VWHP·V element orientation on an 
appropriate vector (pMTL007C-E2) and its site specific recombination 
mechanism. (A) ClosTron construct contained on plasmid pMTL007C-
E2, illustrated is the flanking recognition sites (E1 & E2) re-targeted 
intron region (EBS/IBS), RAM including the group I intron, the LtrA 
gene, and catP for positive selection of the plasmid. (B). Mechanism of 
DNA target site recognition sites; IBS, EBS1d and EBS2 by the L. lactis 
Ll.LtrB group II intron facilitating integration of the intron. 
1.2.5   Targeted conditional expression 
Targeted conditional expression is a means to control the expression of a target gene by 
placing it under inducible control, via an inducible promoter or riboswitch. Conditional 
expression is a powerful tool in analysing gene function, as gene expression can be 
switched on or off in the presence or absence of an exogenously added inducer. One 
such application of such systems is the ability to directly identify essential genes49,65,66. By 
placing an essential gene under conditional expression, the resulting strain is dependent 
upon the inducer for cellular viability67. It can also allow the isolation of a conditional 
mutant genotype which can then be analysed further by defining when the gene is 
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essential during growth, and what effects different levels of expression of the target 
gene have upon the cell.  
 
For selection or development of such a system, it is important that the inducible 
promoter has a dynamic range of expression, tight repression of expression in the 
absence of an inducer, high levels of expression under induction, the inducer should be 
nontoxic to the cell under working concentrations, and the inducer should present good 
bioavailability. Two commonly used inducible promoter systems in prokaryotes are the 
Spac
68 and PXyl/tet
69 systems for the identification of essential genes. The Spac promoter is a 
hybrid between the B. subtilis SPO1 phage promoter and the operator sequences of the 
E. coli lac operon, the latter element provides the facility to control transcription of the 
Spac by the addition of the inducer, isopropyl Ƣ-D-1-thiogalactopyranoside (IPTG)68. The 
PXyl/tet system is a hybrid between the xylose inducible system of B. subtilis and the 
operator sequences of the Tn10 tet gene. In this case, transcription is controlled via the 
addition of the inducer, tetracycline (Tc), or its less toxic analogue anhydrotetracycline 
(aTc)69. In addition to these two, there are a range of other inducible promoter systems 
that have been developed, each with their own characteristics giving them advantages 
and disadvantages depending on their function, environment, and organism.  
 
There are two ways to identify essential genes by conditional expression. The first uses 
an integration method to transcriptionally fuse an inducible promoter to an essential 
target gene, thereby replacing the native promoter52,67. This type of system has been 
used in B. subtilis using the PSpac system present upon the non-replication plasmid 
pMUTIN52. The authors cloned the PSpac V\VWHPDWWKH·RIWhe target gene and used the 
pMUTIN plasmid to undergo a single-crossover recombination event creating an intact 
copy of the target gene under inducible control of PSpac in the chromosome
52. If the 
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recombinant strain is IPTG dependant for cellular viability, the gene can be defined as 
essential. Using this method, 150 genes have been directly identified as being essential in 
B. subtilis45. The big disadvantage to using this system would be if the essential gene is 
present within an operon. Modifying the transcriptional control of an operon would 
have an effect on expression of genes downstream and make the interpretation of the 
results difficult. Also if the target gene is not essential but a gene further downstream is, 
and it is affected by the insertion, the target gene might be misclassified as essential.  
 
The second strategy to conditionally control the expression of an essential gene is to 
introduce an ectopically expressed copy of the essential gene into the chromosome 
under inducible control, creating a partial diploid strain67. The native gene can then be 
removed or disrupted allowing the ectopic copy to take over essentiality in the presence 
of an inducer. This method circumvents the problems associated with essential genes 
present within an operon. This approach has been used successfully in S. aureus to test 
genes for essentiality. Fan et al, (2001)67, transcriptionally fused the PSpac or PXyl/tet system 
to a candidate essential gene and integrated the construct into the geh locus of S. aureus67. 
The resulting recombinant strain were then subjected to allelic exchange mutagenesis to 
replace the native copy with a functionally tetracycline resistance cassette to aid 
selection. The authors identified two genes to be dependent on the presence of an 
inducer for cellular viability, providing direct evidence of the genes essential nature67.  
 
1.2.6    Temperature-sensitive mutants and disruptions 
Temperature-sensitive mutants enable conditional control of the activity of a protein via 
temperature changes, as opposed to controlling transcription or translation. There are a 
few different ways in which temperature-sensitive mutations can be exploited for the 
identification of essential genes. One of the first genome wide searches for essential 
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genes involved the isolation and analysis of temperature-sensitive mutants in Salmonella 
enterica serovar Typhimurium (S. Typhimurium)70. The authors subjected the bacterium 
to chemical mutagenesis and isolated clones which were able to grow at the standard 
permissive temperature, but not at higher-temperatures. The locations of the mutations 
were identified as point mutations within key residues in the protein responsible for 
protein folding, with subsequent destabilisation at the higher temperatures inactivating 
the protein70. However, not all proteins can be destabilised in such ways, and as such 
not all essential genes can be identified using this method. This type of temperature-
sensitive protein destabilisation is commonly found in temperature-sensitive replicons, 
responsible for the plasmids origin of replication71. 
 
Another type of temperature-sensitive disruption involves using the group II intron of 
the TargeTron/ClosTron system72. It is different from the aforementioned temperature-
sensitive mutations as the temperature sensitivity and disruption is not present within 
the same protein, rather the protein responsible for the disruption of a target gene is 
temperature-sensitive. In principle, the ClosTron system can be used for both 
unconditional and conditional disruptions, including conditional disruptions of essential 
genes. This is because the group II intron can be inserted into either the sense or 
antisense orientation relative to the target gene, depending on the group II intron 
targeting sequence38. A group II intron inserted into the antisense strand is transcribed 
into mRNA by the target genes natural promoter, this mRNA encodes the reverse 
complement of the group II intron, removing the recognition sequences of the IEP 
from the mRNA72. This reverse group II intron cannot be spliced out again, yielding an 
unconditional mutation. However, if the group II intron is inserted in the sense 
orientation within the target gene, the target genes promoter is able to transcribe not 
only the target gene, but also a functional group II intron72. This functional group II 
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intron can then be spliced out of the target genes mRNA by the IEP, thereby restoring 
the native mRNA. As the conditional mutation is controlled by the IEP splicing 
reaction, controlling of the IEP splicing reaction will result in conditional disruptions if 
the group II intron is inserted in the sense orientation.  
 
During Yao et al·V 72, study of the group II intron, they identified that the IEP 
splicing reaction is inherently temperature-sensitive, consequently the TargeTron was 
able to splice out the group II intron from the target gene at 37°C but not at 43°C72. 
Using this, the authors were able to identify essential genes in S. aureus by obtaining 
viable cells with an insertion of the group II intron in essential genes at 37°C, due to the 
subsequent splicing of the group II intron from the mRNA, but no viable cells were 
obtained when the temperature was increased to 42°C, meaning the splicing reaction 
could not occur resulting in cell death72. Although the exact temperature-sensitive 
mechanism is unknown, it was hypothesised that the inhibition of the RNA splicing was 
due to the temperature sensitivity of the intron RNA, the IEP, or a combination of 
them both64,72. Employing the temperature sensitive nature of the Group II intron 
present within the ClosTron in such a way as shown by Yao et al· (2006)72should allow 
the identification of essential genes in Clostridium.  
 
1.2.7    Partial diploids 
A partial diploid is the definition of a bacterial cell which contains a second copy of a 
particular region of the chromosome. This can be in the form of a complete operon or 
a single gene, present upon a plasmid or in the chromosome50,73. Partial diploids can be 
useful tools to directly or indirectly identify essential genes when combined with other 
mutational methods such as; inducible promoters, homologous recombination or the 
ClosTron50,67. In essence, an essential gene cannot be inactivated due to the gene·s 
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product being required for survival; however, if there is a second copy of the essential 
gene present within the cell, this second copy can functionally complement the native 
gene·s product thereby negating the native gene·s essentiality. This substitution of 
essential function enables the native essential gene to be inactivated using an 
appropriate method only if the second copy is present.   
 
There are two ways to produce partial diploid C. difficile strains, either by supplying a 
second copy of the candidate essential gene on a plasmid, or by inserting the candidate 
essential gene into the chromosome using an Allele Chromosomal Exchange (ACE) 
system or classical homologous recombination. Once the second copy is present, the 
native gene can be inactivated. Essentiality of the candidate essential gene can be 
determined by the ability to inactivate the candidate gene in the original strain compared 
to the partial diploid strain50,67. If the gene is not essential, then the candidate gene 
should be able to be inactivated in both strains, however, if the gene is essential, then 
only the target gene present within the partial diploid should be able to be inactivated as 
the inactivation leads to the cell being non-viable in the original strain50. Such a system 
provides indirect evidence to the essentiality of the gene, compared to the direct 
methods of conditional expression as it is the study of the target genes ability to be 
inactivated in a partial diploid background.   
 
1.2.8    Transposon mutagenesis 
Transposons are naturally occurring elements which are able to transpose themselves 
from one position within the DNA of a cell to another. There are two different 
PHFKDQLVPV LQZKLFK WUDQVSRVRQV FDQPRYH HLWKHUE\ ´FRS\ DQGSDVWHµ &ODVV , RU
´FXW DQG SDVWHµ &ODVV ,, PHDQLQJ WKH '1$ LV UHSOLFDWHG DQG LQVHUWHG LQWR D QHZ
region or the original DNA element is cut and transposed into a new region of DNA, 
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respectively74. The simplest transposon is a segment of DNA which is flanked by short 
recognition sequences of DNA, normally inverted repeats. These short recognition 
sequences are recognised by the transposase enzyme which is able to enact the specific 
mechanism for that transposase74.  
 
Transposons are valuable tools for large-scale forward genetic experiments to identify 
specific genotypes associated with phenotypes or essential genes. Due to the fact that 
the transposon can insert into DNA sequences, insertion within a coding region can 
cause gene disruption. If the insertion is within a non-essential gene, the cells viability is 
not affected, if however the transposon inserts into an essential gene, the genotype is 
lethal and the cell is non-viable. Using this principle, it is possible to carry out a large-
scale experiment to attempt to insertionally inactivate every gene within a genome, 
thereby creating a mutant library. The genes which cannot be inactivated are candidate 
essential genes.  Such large-scale transposon mutagenesis has been carried out in many 
bacterial species including; E. coli43, Mycobacterium tuberculosis75, Pseudomonas aeruginosa76, H. 
pylori54, Salmonella enterica serovar Typhi (S. Typhi)77, H. infulenzae78, and S. aureus79, to 
name a few.   
 
One of the most interesting studies was carried out by Langridge et al, (2009)77, in which 
they developed a technique called Transposon Directed Insertion-site Sequencing 
(TraDIS) to investigate the minimum essential gene set of the bacterium S. Typhi under 
both standard laboratory and relevant biological conditions77. The authors used a 
derivative  of the Tn5 to create a transposon mutant library of S. Typhi comprising of 
an estimated 1.1 million individual mutants encompassing 370,000 unique transposon 
insertion sites, equating to an average of one insertion every 13 bp or 80 unique 
insertions per gene77. From this mutant library, they were able to define an insertion 
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index based upon the number of insertions within a gene divided by the length of the 
gene, then using this insertion index to compile a frequency distribution for all 
annotated genes in the genome77. The frequency distribution of insertions for S. Typhi 
gave clear bimodal distribution results accounting for two types of genes, the first (left-
most, figure 7A) peak represents the genes in which an insertion significantly inhibits 
cellular growth which leads to the absence or severely reduced insertion frequency in 
these genes (figure 7A)77. The second peak (right-most) represents the genes in which 
an insertion does not significantly affect cellular growth, therefore the transposon can 
insert with high frequency77. From this distribution, they calculated the likelihood of the 
genes being essential (figure 7B). Using this principle, the authors identified 356 genes 
which have a likelihood of being essential for growth under standard laboratory 
conditions77. In contrast, they also identified 4162 genes which had low likelihood of 
being essential, and 19 which could not be placed in either category using their 
likelihood ratio criteria77.  
 
Figure 1.7. TraDIS to identify essential genes in S. Typhi. (A) Bimodal 
frequency distribution of the insertion index (number of inserts per gene 
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divided by the gene length). The left most peak represent genes which 
cannot, or have a very low frequency of insertions. The right hand peak 
(0.05) represents genes which can be readily inserted, i.e. not essential. 
(B) Detailed section of a genome map showing the frequency of 
insertions for a number of genes. The 3 genes labelled (plsC, parC, and 
parE) show an absence of insertions, indicating these genes are possibly 
essential in S. Typhi. Adapted from reference77. 
 
A considerable advantage of using TraDIS is the ability to pool each individual mutant 
and subject the pool to varying conditions or animal models. This allows the 
simultaneous identification of every candidate essential gene within the pool for each 
condition and environment by identifying the presence/absence of the mutant in the 
output pool. This difference in pools under these varying conditions would identify 
JHQHV ZKLFK PD\ EH LGHQWLILHG DV ´DGYDQWDJHRXVµ IRU JURZWK LH, essential under 
specific conditions without being absolutely essential77. There are a few disadvantageous 
of using such methods to identify candidate essential genes. Transposon insertions 
within operons can cause a polar effect downstream of the insertion site, in such cases; 
an insertion within a nonessential gene upstream may disrupt the expression of an 
essential gene downstream resulting in a lethal genotype. This scenario would mean that 
a nonessential gene could be identified as essential due to the low possibility of 
insertions, when in fact it is due to the disrupted expression of another gene blocking 
downstream transcription. Therefore, analysing genes within operons must be done 
with care to rule out possible interference.  Also most importantly, this method is only 
able to identify candidate essential genes, to prove essentiality this method must be 
complemented with indirect or direct methods such as partial diploids or conditional 
expression. 
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1.2.9    Transposon conditional mutagenesis 
Transposons can be used to create conditional mutations as well as the classical 
XQFRQGLWLRQDOPXWDWLRQ7KHWUDQVSRVRQLVDEOHWR´FDUU\µFDUJRZKLFKLVWUDQVSRVHGE\
the transposase, as long as it is within the flanking recognition sites. To create 
conditional mutations, an inducible promoter system can be placed within the 
transposon in such a position that it faces outwards of the transposon (figure 1.8A). If 
the transposon inserts into the promoter region of a gene in the sense orientation, the 
inducible promoter will replace the native promoter allowing conditional expression via 
the presence of an inducer (figure 1.8B). If the gene whose promoter has been replaced 
is essential, cellular viability is dependent on the inducer to activate the genes 
transcription. In this instance, the gene can be directly defined as essential as the 
presence or absence of the inducer will directly correlate with cellular viability. This 
method has been used to identify essential genes in Vibrio cholera80, Salmonella enterica 
serovar Enteriditis (S. Enteriditis) 81, and E. coli44. 
 
Figure 1.8. Conditional lethal mutation of an essential gene by the 
transposition of a transposon with outward facing promoters. (A) 
Transposon is present upon a vector containing a transposase to 
facilitate transposition, as well as catP for selection and an origin of 
replication. (B) Following transposition, the transposon moves into the 
chromosome of the host. If the transposon inserts between an essential 
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gene (red) and its native promoter, cellular viability is dependent upon 
the presence of the inducer. If no inducer is present, the cell dies. Once 
essentiality is ideQWLILHG '1$ VHTXHQFLQJ RI WKH WUDQVSRVRQ·V SRVLWLRQ
can be determined with outward facing primers present within the 
transposon. 
In 2000, Judson and Mekalanos80 developed the TnAraOut system, a transposon-based 
approach to identify and characterise essential genes in V. cholera80. The authors 
constructed a mariner-based transposon with the arabinose-inducible promoter, PBAD, 
ORFDWHGDWWKH·RIWKHWUDQVSRVRQIDFLQJ-outwards80. During the random insertions of 
the transposon, if the transposons inducible promoter transcriptionally fuses with an 
essential gene, the insertionally mutagenesis should display arabinose dependence. Using 
this principle, the authors were able to identify 16 mutations which showed varying 
degrees of arabinose dependence80. Of the 16, 4 were shown to carry insertions 
upstream of known essential genes, whereas the other 12 carried insertions in previously 
known or hypothetical genes not previously identified as essential80. The advantage of 
using such a system is the ability to identify genes which may be unique to the organism, 
as the authors showed one of the 16 was not found in another bacterial species, which 
may represent an example of a narrow-spectrum drug target80. Such a system may be 
developed for use in C. difficile as the mariner-based transposon system is already 
established42, by combining it with an inducible promoter such as the Tet system; it 
would provide a powerful tool for large-scale essential gene identification in C. difficile.  
 
1.3 Other Relevant Clostridia 
Most species of Clostridium are saprophytic organisms found ubiquitously in the 
environment. Certain members may be employed on an industrial scale for the 
production of biofuels, Botox, or Clostridial-Directed Enzyme Prodrug Therapy 
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(CDEPT). Commercially relevant Clostridium include; Clostridium theromcellum, Clostridium 
acetobutylicum, Clostridium botulinum, Clostridium ljungdahlii, and Clostridium sporogenes. 
However, the genus is most famous for those members that are able to cause disease in 
humans and domestic animals. Such members include; Clostridium difficile, Clostridium 
botulinum, Clostridium perfringens, Clostridium tetani, and to a lesser extent, Clostridium sordellii. 
All these species of Clostridium encounter the same limitation of genetic tools to 
genetically manipulate and study as C. difficile38. With the development of new tools 
become available, the ability to utilize the organisms or develop effective counter 
measures is becoming possible.  Ideally, tools which can be developed for C. difficile, will 
also work in other Clostridium for analysis of specific genes or identification of essential 
genes when relevant.  
 
1.3.1 Clostridium sporogenes 
C. sporogenes is a commercially relevant organism due to its potential use in the treatment 
of cancer using CDEPT, and in canning industry for quality control purposes, as well as 
medically important as a surrogate for C. botulinum. C. sporogenes and C. botulinum are both 
genetically related at the species level82. Whereas C. botulinum is notorious for producing 
the most potent neurotoxin known, C. sporogenes is a non-toxigenic bacterium. The 
similarities in the strains allow C. sporogenes to be used as a surrogate in the study of C. 
botulinum, due to its non-toxic nature, in the laboratory as well as quality control against 
C. botulinum contamination in the food industry83. This similarity makes C. sporogenes an 
attractive organism to develop genetic tools for, as they should also work in C. 
botulinum.  
 
As well as being related to C. botulinum, C. sporogenes is important in its own right due to 
current research into cancer treatment using CDEPT. In essence, solid cancerous 
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tumours grow very rapidly often resulting in inadequate blood and oxygen supplies 
within the tumour84. These hypoxic regions are the perfect environment for 
proliferation of Clostridium. If Clostridium spores are intravenously administered, they are 
able to find and colonise, leading to subsequent lysis of the tumours84. The key 
limitation to using Clostridium for lysing tumours is the ability of the cancerous cells at 
the oxygenated periphery to avoid the fate of the cells in the hypoxic core. The lysis of 
the hypoxic core not only kills the cancerous cells, but also the environment in which 
Clostridium can survive meaning the bacterial cells die84. This allows any surviving cells to 
multiply, replenishing the lost cells. One strategy to overcome this limitation is to 
engineer C. sporogenes to convert a prodrug into an active drug within the tumour, 
effectively killing all the cancerous cells84. Development is underway to engineer C. 
sporogenes for CDEPT; however there are certain aspects that require novel genetic tools, 
such as a Clostridium inducible promoter system, to be able to be used effectively as a 
cancer treatment.  
 
1.3.2 Solventogenic Clostridium acetobutylicum and Clostridium beijerinckii 
C. acetobutylicum was first described between 1912 and 1914 for their use in the industrial 
starch-based acetone, butanol, and ethanol (ABE) fermentation process to produce 
acetone for gunpowder production during World War I85. During the 1920s the increase 
in demand for butanol led to the construction of fermentation plants capable of using 
processing molasses using the ABE process. However this interest decreased by the 
1950s as the production of the chemicals via petrochemical production became a more 
cost-effective process. As the oil prices rose during the 1970s, there was a renewed 
interest in the ABE process, leading to the genetic manipulation of the organism to 
increase yield and purity of the solvents, as well as increasing the range of produced 
chemicals85. The advancement in genetic manipulation over the past two decades has 
 
34 
 
accelerated the metabolic engineering for novel biologically derived chemicals, 
combined with the need for renewable energy sources, C. acetobutylicum has become one 
of the most commercially relevant and studied solventogenic organism. 
 
C. beijerinckii (a new species, formally part of C. acetobutylicum) is most well known for 
commercialisation in the same way as C. acetobutylicum, in that it is able to metabolise a 
range of substrates including (but not limited to), starch, glucitol, galactose, and the 
disaccharides cellobiose, lactose, maltose, pentose, hexose, and sucrose to produce 
acetone, butanol, and ethanol via the ABE fermentation process86,87. However, the big 
advantage to using C. beijerinckii is its ability to be genetically modified with relative ease. 
With the isolation of hyper-butanol producing strains and the ability to genetically 
modify C. beijerinckii to utilize many substrates and produce a variety of novel solvents, 
there is great potential of engineering such an organism to produce solvents for 
attractive renewable biofuels which is economically cheaper and cleaner than 
petrochemical processes88.  
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1.4 Aim of This Project 
C. difficile remains the main causative agent of nosocomial diarrhoea in the world. The 
past two decades have seen an increase in incidence of CDI in the hospital, community 
and animals used for food. In addition, emergence of hypervirulent PCR-ribotypes 
associated with; frequent outbreaks, more severe disease, increased mortality rate, higher 
relapse rate, and increased antimicrobial resistance, has compounded the need to 
understand this prominent pathogen, in the hopes to treat CDI effectively.  
 
The identification of essential genes for the development of effective novel therapeutic 
antimicrobials is more important now than ever.  Essential genes are of particular 
importance due to their gene products being required for cellular viability. For an 
antimicrobial to be effective, it must be able to disrupt this essential gene product, 
leading the bacterial cell to become non-viable. It is this loss in viability which defines a 
gene as essential, and a chemical as an antimicrobial. In other bacterial pathogens, there 
have been countless studies to identify essential genes. However, in C. difficile, 
identification has largely been hindered by the limitation of current techniques. If this 
limitation was alleviated through the development of a technique capable of identifying 
essential genes, one hopes that it would lead the way for novel essential gene 
identification and subsequent antimicrobial development to treat CDI. 
 
The aim of this project was to develop novel genetic tools able to identify and study 
essential genes in C. difficile. Specifically, candidate essential genes were identified using 
in silico approaches which were then confirmed using the indirect experimental approach 
of partial diploids combined with the ClosTron system. In addition to this, inducible 
expression systems were developed to directly identify essential genes and modulate 
expression of target genes in not only C. difficile, but other Clostridium. 
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Chapter Two 
Materials and Methods 
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2.1     Materials 
Unless stated otherwise, all chemicals and biochemical were supplied by Sigma-Aldrich 
or Fisher Scientific, enzymes and their buffers used for the purpose of molecular 
biology were purchased from New England Biolabs (NEB) or Promega, chemicals used 
in the purification of proteins were purchased from Invitrogen or GE Healthcare Life 
Sciences, and bacterial growth media was purchased from Oxoid.  
Synthetic DNA less than 100 bp were purchased from Eurofins MWG Operon, DNA 
over 100 bp was purchased from DNA2.0, Mr Gene, or Eurofins MWG Operon. 
2.2     List of Bacterial Strains 
Strain Genotype/Properties Source/Reference 
Escherichia coli TOP10 
F² mcr$ƅmrr-hsdRMS-mcrBC) 
Ɩlac=ƅ0ƅlacX74 recA1 araD139 
ƅara leu) 7697 galU galK rpsL (StrR) 
endA1 nupG 
Invitrogen 
Escherichia coli CA434 Conjugation donor Laboratory Collection  
Escherichia coli C600RK2 
F- tonA21 thi-1 thr-1 leuB6 lacY1 glnV44 
UIE&IKX$ƫ- Laboratory Collection 
Escherichia coli K12MG1655  F- ƫ- ilvG- rfb-50 rph-1 Kim. H. Laboratory 
Collection, Nottingham 
Clostridium difficile 630¨erm 
PCR-ribotype 012 
Erythromycin sensitive strain of C. 
difficile630 
Laboratory Collection 
Clostridium difficile R20291 
BI/NAP1/027 (Stoke Mandeville, UK). 
Isolated in 2004/5 
Anaerobe Reference 
Laboratory, Cardiff 
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Clostridium acetobutylicum ATCC 
824 
Wild-type isolate Laboratory collection 
Clostridium sporogenes NCIMB 
10696 
Wild-type isolate Laboratory collection 
Clostridium beijerinckii NCIMB 
8052 
Wild-type isolate Laboratory collection 
Chromosomal Functional 
Complementation 
 Chapter Three 
Clostridium difficile 630¨erm pyrE:: 
dhaTp 
ACE dhaTp (protected) partial diploid 
insertion in pyrE locus (pyrE-) 
This work 
Clostridium difficile 630¨erm 
pyrE::metKp 
ACE metKp (protected) partial diploid 
insertion in pyrE locus (pyrE-) 
This work 
Clostridium difficile 630¨erm pyrE 
::trpSp 
ACE trpSp (protected) partial diploid 
insertion in pyrE locus (pyrE-) 
This work 
Clostridium difficile 630¨erm 
pyrE::dhaTp dhaT::CT-548a 
CT insertion in native dhaT at position 
548 in strain Clostridium difficile 630¨erm 
pyrE:: dhaTp 
This work 
Clostridium difficile 630¨erm 
pyrE::dhaTp dhaT::CT-623a 
CT insertion in native dhaT at position 
623 in strain Clostridium difficile 630¨erm 
pyrE:: dhaTp 
This work 
Clostridium difficile 630¨erm 
pyrE::metKp metK::CT-548s 
CT insertion in native metK at position 
548 in strain Clostridium difficile 630¨erm 
pyrE:: metKp 
This work 
Clostridium difficile 630¨erm 
pyrE::metKp metK::CT-676s 
CT insertion in native metK at position 
676 in strain Clostridium difficile 630¨erm 
pyrE:: metKp 
This work 
Clostridium difficile 630¨erm pyrE 
::trpSp trpS::CT-436a 
CT insertion in native trpS at position 
436 in strain Clostridium difficile 630¨erm 
pyrE:: trpSp 
This work 
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Clostridium difficile 630¨erm pyrE 
::trpSp trpS::CT-460a 
CT insertion in native trpS at position 
460 in strain Clostridium difficile 630¨erm 
pyrE:: trpSp 
This work 
Inducible Chromosomal 
Functional Complementation 
 Chapter Five 
Clostridium difficile 630¨erm 
Pfdx.tetO:metKp::pyrE 
Tetracycline inducible promoter Pfdx.tetO 
controlling expression of protected metK 
inserted into pyrE locus using ACE 
(pyrE-) 
This Work 
Clostridium difficile 630¨erm 
Pfdx.tetO:slpAp::pyrE 
Tetracycline inducible promoter Pfdx.tetO 
controlling expression of protected slpA 
inserted into pyrE locus using ACE 
(pyrE-) 
This Work 
Clostridium difficile 630¨erm 
Pfdx.tetO:trpSp::pyrE 
Tetracycline inducible promoter Pfdx.tetO 
controlling expression of protected trpS 
inserted into pyrE locus using ACE 
(pyrE-) 
This Work 
Over production strains   
Escherichia coli BL21*(DE3) 
F² ompT gal dcm lon hsdSB(rB- mB-ƫDE3 
[lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) 
Invitrogen 
Escherichia coli C600 
F- tonA21 thi-1 thr-1 leuB6 lacY1 glnV44 
rfbC1 IKX$ƫ- Invitrogen 
Escherichia coli Rosetta 2 
F- ompT hsdSB(RB
- mB
-JDOGFPƫDE3 [lacI 
lacUV5-T7 gene 1 ind1 sam7 nin5]) 
pLysSRARE (CamR) 
Novagen 
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2.3  List of Plasmids 
Plasmid Relevant properties Source 
ClosTron Plasmids  
Chapters Three 
and Five 
pMTL007C-E2 ClosTron Plasmid Reference 38 
pMTL007C-E2::Cdi-
dhaT-213s 
pMTL007C-E2 retargeted to Cdi-dhaT-213 
 
This work 
pMTL007C-E2::Cdi-
dhaT-548a 
pMTL007C-E2 retargeted to Cdi-dhaT-548a This work 
pMTL007C-E2::Cdi-
dhaT-623a 
pMTL007C-E2 retargeted to Cdi-dhaT-623a This work 
pMTL007C-E2::Cdi-
trpS-436a 
pMTL007C-E2 retargeted to Cdi-trpS-436a This work 
pMTL007C-E2::Cdi-
trpS-460a 
pMTL007C-E2 retargeted to Cdi-trpS-460a  This work 
pMTL007C-E2::Cdi-
metK-548s 
pMTL007C-E2 retargeted to Cdi-metK-548s This work 
pMTL007C-E2::Cdi-
metK-676s 
pMTL007C-E2 retargeted to Cdi-metK-676s This work 
pMTL007C-E2::Cdi-
slpA-878a 
pMTL007C-E2 retargeted to Cdi-slpA-878a This work 
pMTL007C-E2::Cdi-
slpA-1267s 
pMTL007C-E2 retargeted to Cdi-slpA-1267s This work 
Modular Plasmids  
All Results 
Chapters 
pMTL82151 Modular plasmid Reference 89 
pMTL82254 Modular plasmid including catP reporter Reference 89 
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pMTL82151-dhaT pMTL8215x containing Clostridium difficile 630¨ermdhaT This work 
Plasmid 
Complementation 
 Chapter Three 
pMTL82151-PdhaT-
dhaT 
pMTL8215x containing Clostridium difficile 630¨erm dhaT 
and its native promoter 
This work 
DNA2.0-dhaT-
synthfrag 
DNA2.0 in-house vector containing protected 
Clostridium difficile 630¨erm dhaT fragment This work 
pMTL-DW2 
pMTLDW1 with a protected copy of Clostridium difficile 
630¨erm dhaT from DNA2.0-dhaT-synthfrag This work 
pMTL-DW3 
pMTLDW2 derived except aad9 has replaced catP 
resistance cassette 
This work 
Chromosomal 
Complementation 
 Chapter Three 
DNA2.0-Pmet-metKp 
DNA2.0 in house vector containing a protected 
Clostridium difficile 630¨erm metK and its native promoter This work 
DNA2.0-Pthl-trpSp 
DNA2.0 in house vector containing a protected 
Clostridium difficile 630¨erm metK and the Clostridium 
sporogenes thiolase promoter 
This work 
pMTL-JH18 ACE plasmid 
Heap J.T. 
Laboratory 
collection 
pMTL-JH18-dhaTp pMTL-JH18 containing insert of pMTL-DW1 This work 
pMTL-JH18-metKp pMTL-JH18 containing insert of DNA2.0-PmetK-metKp This work 
pMTL-JH18-trpSp pMTL-JH18 containing insert of DNA2.0-Pthl-trpSp This work 
Inducible 
Chromosomal 
Functional 
Complementation 
 Chapter Five 
DNA2.0-PslpA-slpAp 
DNA2.0 in house vector containing a protected 
Clostridium difficile 630¨erm slpA and its native promoter This Work 
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pMTL-tet3nO 
Tetracycline inducible promoter system containing Pthl 
running tetR, Pfdx interrupted with a single tetO, cloned 
into pMTL82254 
This Work 
pMTL-ACEtet-dhaTp 
Protected essential gene dhaT under tetracycline 
inducible control in vector pMTL-JH18. 
This work 
pMTL-ACEtet-trpSp 
Protected essential gene trpS under tetracycline 
inducible control in vector pMTL-JH18. 
This work 
pMTL-ACEtet-slpAp 
Protected candidate essential gene slpA under 
tetracycline inducible control in vector pMTL-JH18. 
This work 
lac repressor system 
Plasmids  
 Chapter Four 
pMTL-DW17 
IPTG inducible promoter system containing PtrnA-1 
running lacI, Pfdx interrupted with single lacO cloned into 
pMTL82254 
This work 
pMTL-DW17(b) 
IPTG inducible promoter system containing PtrnA-1 
running lacI, Pfdx interrupted with double lacO cloned 
into pMTL82254 
This work 
pMTL-DW18 
IPTG inducible promoter system containing PtrnA-1 
running lacI and ermB, Pfdx interrupted with single lacO 
cloned into pMTL82254 
This work 
pMTL-DW18(b) 
IPTG inducible promoter system containing PtrnA-1 
running lacI and ermB, Pfdx interrupted with double lacO 
cloned into pMTL82254 
This work 
pMTL-DW18(1) pMTL-DW18(b) with Pfdx from C. sporogenes running lacI  This work 
pMTL-DW18(2) 
pMTL-DW18(b) with PhydA from C. acetobutylicum 
running lacI 
This work 
pMTL-DW18(3) pMTL-DW18(b) with Pthl from C. sporogenes running lacI This work 
pMTL-DW18(4) 
pMTL-DW18(b) with PtrnA from C. acetobutylicum 
running lacI 
This work 
pMTL-DW18(5) 
pMTL-DW18(b) with PDNAk from C. acetobutylicum 
running lacI 
This work 
pMTL-DW18(6) 
pMTL-DW18(b) with PrecA from C. acetobutylicum 
running lacI 
This work 
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pMTL-DW18(7) 
pMTL-DW18(b) with PgyrA from C. acetobutylicum 
running lacI 
This work 
pMTL-DW18(8) 
pMTL-DW18(b) with Padc from C. acetobutylicum running 
lacI 
This work 
pMTL-DW18(9) 
pMTL-DW18(b) with Pptb from C. acetobutylicum 
running lacI 
This work 
pMTL-DW18(10) 
pMTL-DW18(b) with PAT0200 from C. acetobutylicum 
running lacI 
This work 
pMTL-DW18(0) pMTL-DW18(b) with no promoter running lacI This work 
Riboswitches  Chapter Four 
pMTL-Thio1 Thio1 riboswitch cloned into pMTL82254 This work 
pMTL-Thio2 Thio2 riboswitch cloned into pMTL82254 This work 
pMTL-Thio3 Thio3 riboswitch cloned into pMTL82254 This work 
pMTL-V1P1 pMTL-Thio1 containing Pfdx This work 
pMTL-V1P2 pMTL-Thio1 containing PhydA This work 
pMTL-V1P3n pMTL-Thio1 containing short Pthl This work 
pMTL-V1P5 pMTL-Thio1 containing PDNAk This work 
pMTL-V1P7 pMTL-Thio1 containing PgyrA This work 
pMTL-V1P8 pMTL-Thio1 containing Padc This work 
pMTL-V1P9 pMTL-Thio1 containing Pptb This work 
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pMTL-V1P10 pMTL-Thio1 containing PAT200 This work 
pMTL-V2P3n pMTL-Thio2 containing short Pthl This work 
pMTL-V2P3n pMTL-Thio3 containing short Pthl This work 
Tet system plasmids  Chapter Four 
pMTL-tetO 
Tet system containing no tetR promoter, and single tetO 
interrupting Pfdx, present in pMTL82254 
This work 
pMTL-tetO1/2 
Tet system containing no tetR promoter, and double 
tetO interrupting Pfdx, present in pMTL82254 
This work 
pMTL-tet3nO 
Tet system containing short Pthl running tetR, and single 
tetO interrupting Pfdx, present in pMTL82254 
This work 
pMTL-tet3n 
Tet system containing short Pthl running tetR, and no 
Pthl or tetOs, present in pMTL82254 
This work 
Over Expression 
Plasmids 
 T.B.C 
pET-17b T7 expression vector Novagen 
pET-14b-ƢJDO Induction control A Novagen 
pET-17b-dhaT dhaT over production vector This work 
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2.4  List of Oligonucleotides  
Oligonucleotide 6HTXHQFH·-·  
 
ClosTron Re-
targeting 
 
  
Cdi-dhaT-213s-IBS AAAAAAGCTTATAATTATCCTTAGAACACAATCCTGTGCGCCCAGA
TAGGGTG 
 
 
Cdi-dhaT-213s-EBS1d CAGATTGTACAAATGTGGTGATAACAGATAAGTCAATCCTCTTAAC
TTACCTTTCTTTGT 
 
 
Cdi-dhaT-213s-EBS2 TGAACGCAAGTTTCTAATTTCGATTTGTTCTCGATAGAGGAAAGTG
TCT 
 
 
 
 
Cdi-dhaT-F3 GAAATAGGAGGTTTTAGAATGAATTTTAATTATAATTTGCC 
 
 
Cdi-dhaT-R3 
 
TAAATATGTAAAGTCAAATTATAAAGACTTATGGTACATTTCC  
EBS Universal 
 
  
Cdi-dhaT-548a-IBS AAAAAAGCTTATAATTATCCTTAATTATCTGTTTTGTGCGCCCAGAT
AGGGTG 
 
 
Cdi-dhaT-548a-EBS1d 
 
CAGATTGTACAAATGTGGTGATAACAGATAAGTCTGTTTTGGTAAC
TTACCTTTCTTTGT 
 
Cdi-dhaT-548a-EBS2 
 
TGAACGCAAGTTTCTAATTTCGGTTATAATCCGATAGAGGAAAGT
GTCT 
 
Cdi-dhaT-623a-IBS AAAAAAGCTTATAATTATCCTTATCTGCCAGAGGGGTGCGCCCAGA
TAGGGTG 
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Cdi-dhaT-623a-EBS1d 
 
CAGATTGTACAAATGTGGTGATAACAGATAAGTCAGAGGGTTTAA
CTTACCTTTCTTTGT 
 
Cdi-dhaT-623a-EBS2 
 
TGAACGCAAGTTTCTAATTTCGGTTGCAGATCGATAGAGGAAAGT
GTCT 
 
ClosTron Sequencing 
 
  
Spofdx_F1 GATGTAGATAGGATAATAGAATCCATAGAAAATATAGG 
 
 
pMTL007_R1 AGGGTATCCCCAGTTAGTGTTAAGTCTTGG 
 
 
Partial Diploid 
Construction 
 
  
dhaT-ORF-F3+RS GATCGACATATGAATTTTAATTATAATTTGCCAGTAAATATCTTATT
TGGGAGAGGC 
 
 
dhaT-ORF-H6-R3+2RS 
 
GTATAAGGATCCGAATTCTTATTAGTGATGGTGATGGTGATGTAA
AGACTTATGGTACATTTCCTTTATTTGTTCCTTATTAAAATACTTTG
G 
 
Cdi-dhaT-pro-F1 
 
 
AATATCGCGGCCGCTCTAATAAAAAACTCTATTTAGTTAAATATAG
TTAACTTG 
 
Cdi-dhaT-pro-R1 
 
 
AGTAACCATATGAAAACCTCCTATTTCTACTTTAGTAATAATTTTAT
GTTTTTAACAAAGTG 
 
Cdi630-dhaT-R1 
 
CAGCATCCATAATGCTTCCA  
Partial Diploid 
Screening 
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Cdi630-CD0189-R2 
 
GGTTCTGGAACCAGAGATTATTTAG  
Cdi630-pyrE-F2 
 
GATGGGCGGAATAACTAAAGC  
dhaT_in_F1 
 
TGCAGAAGATTGTTCAGATGC  
dhaT_in_F2 
 
GTGCAGAAGATTGTTCAGATGC  
dhaT-inScaI-F 
 
TTTGATGCACTTGCCCATAA  
dhaT-Sil-ScaI-F1 
 
GACGTTCAGGCAATATACGG  
Cdi-trpS-F1 
 
CCC CTT TGA GAT GAG CAA AA  
Cdi-trpS-R1 
 
TAA GGC AGA TGG AAG TGC TG  
Cdi-trpS-iF1 
 
AAA GCA GCA TTT GGA ATT GG  
Cdi-trpS-iR1 
 
GAT GGC TGT GCA CCA CTA AA  
Cdi-metK-F1 
 
CAA TAG GAA CAC CCC CTT CA  
Cdi-metK-R1 
 
GCA ACA TAA GCT CCA GCA AA  
Cdi-metK-iF1 
 
AAA TAT TGT TGC GGC TGG TC  
Cdi-metK-iR1 
 
TTG GTC TCC AGC TCC AAC TT  
Cdi630-CD0189-R2 
 
GGTTCTGGAACCAGAGATTATTTAG  
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Cdi630-pyrE-F2 
 
GATGGGCGGAATAACTAAAGC  
dhaT-inScaI-F 
 
TTTGATGCACTTGCCCATAA  
dhaT-Sil-ScaI-F1 
 
GACGTTCAGGCAATATACGG  
Cdi-trpS-F1 
 
CCCCTTTGAGATGAGCAAAA  
Cdi-trpS-R1 
 
TAAGGCAGATGGAAGTGCTG  
Cdi-trpS-iF1 
 
AAAGCAGCATTTGGAATTGG  
Cdi-trpS-iR1 
 
GATGGCTGTGCACCACTAAA  
Cdi-metK-F1 
 
CAATAGGAACACCCCCTTCA  
Cdi-metK-R1 
 
GCAACATAAGCTCCAGCAAA  
Cdi-metK-iF1 
 
AAATATTGTTGCGGCTGGTC  
Cdi-metK-iR1 
 
TTGGTCTCCAGCTCCAACTT  
lac repressor system 
 
  
SpoFdx-NotI-F1 
 
GCGGCCGCTATGATGATTATTTTGTAGAT  
SpoFdx-NdeI-R2 
 
CATATGTATTTCCTCCTAAAAATTACACAACTTTA  
CttRNA-NotI-F1 
 
AAGACGCGGCCGCTTGAATATTAGTATTAGGGG  
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CttRNA-NdeI-R1 
 
GATCACATATGTTTGGATCCGACTTTTACAG  
Riboswitches 
 
  
ThioF1 
 
 
GCGGCCGCGAGCTCGGATCCGGTGATACCAGCATCGTATGGATGC
CCTTGGCAGCACCCCGCTGCAAGACAACCATATG 
 
ThioR1 
 
 
CATATGGTTGTCTTGCAGCGGGGTGCTGCCAAGGGCATCCATACG
ATGCTGGTATCACCGGATCCGAGCTCGCGGCCGC 
 
ThioF2 
 
 
GGCCGCGAGCTCGGATCCGGTGATACCAGCATCGTATGGATGCCC
TTGGCAGCACCCCGCTGCAAGACAACCA 
 
ThioR2 
 
 
TATGGTTGTCTTGCAGCGGGGTGCTGCCAAGGGCATCCATACGAT
GCTGGTATCACCGGATCCGAGCTCGC 
 
TRS.s-on.F1 
 
 
GGCCGCGAGCTCGGATCCGGTGATACCAGAGTATGCTCTACTCCC
TTGGCAGCACCCCGCTGCAAGAAGAAGAGCA 
 
TRS.s-on.R1 
 
 
CGCTCGAGCCTAGGCCACTATGGTCTCATACGAGATGAGGGAACC
GTCGTGGGGCGACGTTCTTCTTCTCGTAT 
 
TRS.s-off.F1 
 
 
GGCCGCGAGCTCGGATCCTAGACGAAGAGAACGTCGGCATACGAC
GGTTCCCCTCCGTCTAGGAGGACCA 
 
TRS.s-off.R1 
 
 
CGCTCGAGCCTAGGATCTGCTTCTCTTGCAGCCGTATGCTGCCAAG
GGGAGGCAGATCCTCCTGGTAT 
 
Orig.TRS-RBS-F1 
 
GGCCGCGAGCTCGGATCCCCGCTGCAAGACAACCA  
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Orig.TRS-RBS-R1 
 
CGCTCGAGCCTAGGGGCGACGTTCTGTTGGTAT  
TRS.s-on.F1-RBS 
 
GGCCGCGAGCTCGGATCCCCGCTGCAAGAAGAAGAGCA  
TRS.s-on.R1-RBS 
 
TATGCTCTTCTTCTTGCAGCGGGGATCCGAGCTCGC  
TRS.s-off.F1-RBS 
 
GGCCGCGAGCTCGGATCCCCTCCGTCTAGGAGGACCA  
TRS.s-off.R1-RBS 
 
TATGGTCCTCCTAGACGGAGGGGATCCGAGCTCGC  
TRS.s-on.R1 
 
 
TATGCTCTTCTTCTTGCAGCGGGGTGCTGCCAAGGGAGTAGAGCA
TACTCTGGTATCACCGGATCCGAGCTCGC 
 
TRS.s-on.R2 
 
 
TATGTGCTCCTCCTCTTGCAGCGGGGTGCTGCCAAGGGGGTGGAG
CACACCCTGGTATCACCGGATCCGAGCTCGC 
 
TRS.s-off.R1 
 
 
TATGGTCCTCCTAGACGGAGGGGAACCGTCGTATGCCGACGTTCT
CTTCGTCTAGGATCCGAGCTCGC 
 
pET vector screening 
 
  
pTF 
 
CTCGAAAATAATAAAGGGAAAATCAG  
pTR 
 
TGGTAGTGTGGGGACTC  
dhaT-F-Strep 
 
TGATGCTACATATGAATTTTAATTATAATTTGCCAGTA  
dhaTS-BamHI-R3 
 
 
GTCATCGACGGATCCTTATTTTTCGAACTGCGGGTGGCTCCATAAA
GACTTATGGTACATTTCCTTTATTTG 
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Promoter Library 
 
  
rnb-F1 
 
GTCAGCGAGCTCAAAAATAAATTTTAAAAAAGTG  
rnb-R1 
 
CGCGGATCCCGACTTTTACAGTATACAAGTTT  
fdx-F1 
 
GTCAGCGAGCTCGTGTAGTAGCCTGTGAAATA  
fdx-R1 
 
CGCGGATCCTGTAACACACCTCCTTAAAAATTACACA  
ptb-F1 
 
GTCAGCGAGCTCTAAGTCAGCAGAAAGTATAATGAGA  
ptb-R1 
 
CGCGGATCCTTTACTATTTAATTATCTATGTTAAA  
thl-F1 
 
GTCAGCGAGCTCATTCTAAAAGAATTTAGAATGAA  
thl-R1 
 
CGCGGATCCAAATTTTGATACGGGGTAACAGATAA  
hydA-F1 
 
GTCAGCGAGCTCTATTTTTTAATTTAATTATAC  
hydA-R1 
 
CGCGGATCCAAAATGTAAAATATAATTAAAATATATTAATAAACTT
CGT 
 
adc-F1 
 
GTCAGCGAGCTCGATTATTTATGGAGCTTGTA  
adc-R1 
 
CGCGGATCCTTAACATAAAAGTCACCTTCCT  
pyrE-F1 
 
GTCAGCGAGCTCCCAATAAAACCCAATCTTTTG  
pyrE-R1 
 
CGCGGATCCTCCTACTCCTTTACTTTTACT  
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DNAk-F1 
 
GTCAGCGAGCTCATCTAATTCTATAATGTGTGAT  
DNAk-R1 
 
CGCGGATCCTATTAGCACTCACTCTCTTTGAGTGC  
greA-F1 
 
GTCAGCGAGCTCAAATTGTAATTAAAATTATGCACA  
greA-R1 
 
CGCGGATCCATTGTTTTTCTCCCCTCTACAAAAA  
recA-F1 
 
GTCAGCGAGCTCAATGATTTATTTTGCATAAAAT  
recA-R1 
 
CGCGGATCCATATATCCCTTAAGGGTTCACCA  
CA0200-F1 
 
GTCAGCGAGCTCAGTCTATATAAAGCTTTAT  
CA0200-R1 
 
CGCGGATCCAAACTATCTCCTTTACTTTATAATT  
tRNA-F1 
 
GTCAGCGAGCTCGAGAGTTAATGCCAAAGCTTTT  
tRNA-R1 
 
CGCGGATCCTCCTCCTTATATATATCTTTGGTATTGTTT  
2.5  Bioinformatics Methods 
2.5.1  Genome annotation 
Bacterial genomes were visualised using Artemis available at http://www.sanger.ac.uk/. 
2.5.2  BLAST 
Genomic database searches to identify local similarity between sequences was carried 
out using the Basic Local Alignment Tool (BLAST) available at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi, nucleotide queries were performed using the 
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blastn algorithm (nucleotide collection, somewhat similar sequence), translated 
nucleotide queries were carried out using blastx (non-redundant protein sequences), and 
protein database searches using blastp (non-redundant protein sequences).  
Identification of conserved domains within a protein sequence was carried out using 
CDD, an algorithm that searches the Conserved Domain Database (CDD), found at 
http://www.ncbi.nlm.nih.gov/. 
2.5.3  Sequence alignment 
Alignment of two sequence was carried out using EMBOSS Needle available at 
http://www.ebi.ac.uk/ 
2.5.4  Sequence editor and plasmid map designer 
Vector map design was carried out using combinations of Vector NTI and GENtle. 
2.5.5  Codon editor and analyser 
Synthetic genes were designed in silico XVLQJ '1$·V *HQH 'HVLJQHU IRXQG DW
https://www.dna20.com/genedesigner2/, and analysed for codon usage with Graphical 
Codon Usage Analyser available at http://gcua.schoedl.de/. 
2.5.6  Sequence analysis for sequencing results 
Construction and analysis of contigs from sequencing results was performed using the 
contig express feature of Vector NTI or DNA Baser. 
2.5.7  Oligonucleotide design 
Oligonucleotides for the purpose of PCR primers or synthetic DNA inserts were 
designed manually or using Primer3 available at http://frodo.wi.mit.edu/primer3/. 
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2.5.8  RNA folding prediction 
Predictions on RNA folding were performed using MFOLD available at 
http://mfold.rna.albany.edu/. 
2.6  Microbiological Materials and Methods 
2.6.1  Aerobic bacterial strains and culture conditions  
All E. coli strains were routinely grown in Luria-Bertani (LB) broth or agar at 37°C 
except for a few exceptions, with liquid cultures shaken at 200 rpm.  For protein over 
production and when cloning genes thought to be toxic, E. coli strains were grown at 
&/%EURWKDQGDJDUZDVVXSSOHPHQWHGZLWKFKORUDPSKHQLFROƬJPOLQDJDURU
ƬJPOLQEURWKHU\WKURP\FLQƬJPODPSLFLOOLQƬJPO, spectinomycin 
 ƬJPO ,VRSURS\O Ƣ-D-1-thiogalactopyranoside (IPTG 1-3 mM), 
anhydrotetracycline (aTc 0.00031- ƬJPO WKHRSK\OOLQH  ƬJPO-  ƬJPO RU -
bromo-4-chloro-3-indolyl-Ƣ-JDODFWRS\UDQRVLGH ;JDO ƬJPOZKHQDSSURSULDWH  E. 
coli TOP10 was used throughout for the purpose of cloning, and performing inducible 
promoter testing. The conjugation donor strain CA434 was used for plasmid transfer 
into Clostridium. Protein over production was performed in E. coli TOP10, C600, Rosetta 
(DE3), and BL21*(DE3) strains where appropriate.  
 
2.6.2  Anaerobic bacterial strains and culture conditions 
All Clostridium strains were grown in an anaerobic cabinet at 37°C or in anaerobic gas 
jars at 30°C or 42°C where appropriate. C. difficile strains were routinely grown on BHIS 
broth or agar, C. sporogenes NCIMB 10696 was grown on TYG broth or agar, C. 
beijerinckii NCIMB 8052 was grown on CBM broth or agar, and C. acetobutylicum ATCC 
824 was grown on CGM broth or agar supplemented with glycerol. All liquid media was 
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pre-reduced overnight, with agar pre-reduced for a minimum of 4 hours in anaerobic 
conditions before use. Media was supplemented as appropriate with C. difficile 
VXSSOHPHQW F\FORVHULQHƬJPODQGFHIR[LWLQHƬJPO F\FORVHULQH ƬJPO
WKLDPSKHQLFRO  ƬJPO HU\WKURP\FLQ  ƬJPO RU  ƬJPO OLQFRP\FLQ 
ƬJPO VSHFWLQRP\FLQ ƬJPORUSRO\PL[LQ% ƬJPOThe C. difficile single-
crossover ACE mutants were grown on C. difficile minimal media supplemented with 5-
Fluoroorotic Acid (5-FOA) (1 mg/ml) and uracil (5 µg/ml). Double-crossover ACE 
mutants displaying the pyrE- genotype were grown on BHIS supplemented with 5 µg/ml 
uracil. 
 
2.6.3  Preparation of electro-competent E. coli cells 
To prepare E. coli for transformation by electroporation, a 500 ml conical flask 
containing 200 mls of LB pre-warmed to 37°C was inoculated with 1/100 volume (2 
ml) of fresh E. coli overnight culture and shaken at 200 rpm. The cells were grown to an 
optical density of 0.5 at 600 nm (OD600) representing exponential growth phase and 
then chilled on ice for 30 minutes. After the set time, the culture was separated into 50 
ml falcon tubes and spun at 4000 xg for 20 minutes at 4°C to pellet the cells. The 
supernatant was poured off and the pellet re-suspended in an equal volume of ice-cold 
sterile dH2O and pelleted under the same conditions as before. The supernatant was 
then discarded and each pellet was re-suspended in 0.6 ml of filter-sterilised 10% 
glycerol solution, all the samples were pooled into a single falcon and centrifuged again. 
The final pellet was re-suspended in 0.6 ml sterile 10% glycerol and stored in 50 ƬO
aliquots at -80°C for use.  
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2.6.4  Transformation by electroporation of electro-competent E. coli cells 
To transform electrocompetent E. coli cells, 50 ƬODOLTXRWRIHOHFWUR-competent cells was 
thawed on ice for 5-10 minutes. Plasmid DNA was then mixed with the cells gently and 
pipetted into a cold 0.2 cm gap electroporation cuvette and pulsed applied using an 
HOHFWURSRUDWRU DWN9YROWDJHƬ)FDSDFLWDQFHDQGƙUHVLVWDQFH7R UHFRYHU
WKH HOHFWURSRUDWHG FHOOV  ƬO RI ,QYLWURJHQ 62& UHFRYHU\ PHGLD ZDV DGGHG
immediately and the cell mixture transferred into a fresh eppendorf tube to recover at 
37°C, 200 rpm, for 1 hour. The recovery period is recommended to allow the 
expression of resistance cassettes present within the transformed cell before the cells are 
plated onto fresh LB, supplemented with appropriate antibiotics. 
 
2.6.5  Transfer of plasmid DNA into clostridia by conjugation 
Transfer of shuttle plasmids into C. difficile, C. sporogenes, and C. beijerinckii was carried 
out by conjugation as published90. For conjugation into the aforementioned clostridia, 
the donor E. coli strain CA434 was transformed with the required shuttle vector and left 
to grow overnight in liquid media in parallel with the recipient under anaerobic 
conditions. Next day, 1 ml of the donor cell culture was placed into an eppendorf and 
centrifuged at 4000 xg for 1 ml and resuspended with 0.6 ml sterile Phosphate Buffer 
Solution (PBS) to wash the cells of any antibiotic. The cells were pelleted again and 
transferred into an anaerobic cabinet to be mixed with a 5:1 ration of the recipient 
clostridial cells. The mixture were then plated out onto appropriate media, absent of any 
antibiotic, in discrete spots of approximately 200 ƬO DQGDOORZHG WR LQFXEDWH IRU -24 
hours for transfer of plasmids to take place. The conjugation slurry was then picked-up 
ZLWKDƬOLQRFXODWLRQORRSUHVXVSHQGHGLQƬO3%6DQGSODWHG onto fresh media 
containing antibiotic selection for the transferred plasmid, and counter-selection against 
the E. coli donor strain. The plates were incubated anaerobically at 37°C for 24-72 
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hours. Once the transconjugants were large enough to pick, they were purified by sub-
culturing onto fresh media for further analysis.  
 
2.6.6  Lysis of E. coli cells by detergent 
E. coli cells were lysed using Novagen BugBuster Protein Extraction Reagent in 
DFFRUGDQFHZLWKWKHPDQXIDFWXUHU·VLQVWUXFWLRQV 
 
2.6.7  Lysis of clostridial cells by sonification 
Clostridial cell pellets were re-suspended in 1 ml of PBS supplemented with Roche 
Complete protease inhibitor cocktail tablets. The cells were then transferred into a 2 ml 
boiling eppendorf tube and chilled on ice for 5 minutes. Sonication was carried out on a 
Heat Systems, Ultrasonic W-280 sonicator. The samples were subjected to sonification 
by inserting the sonic probe into the eppendorf about half-way down the sample and 
pulsed for 1 second bursts for 45 seconds at a time at 40% power and power-output 
rating 3.5, and then allowed to rest for 30 seconds. This was repeated for 3-6 times until 
the lysates were visibly clear in comparison to the un-sonicated turbid cells. It is 
important that the samples were kept on ice at all times due to the heat accumulated 
during sonication having an adverse effect on the proteins in the sample. Once the 
samples were lysed, the lysates were centrifuged at 13,000 xg for 40 minutes at 4°C and 
the supernatants removed for further analysis. 
 
2.7  Molecular Biological Materials and Methods 
2.7.1  Plasmid DNA extraction and purification 
Plasmid DNA was extracted and purified using Qiagen QIAprep Spin Miniprep kit in 
DFFRUGDQFHZLWKWKHPDQXIDFWXUHU·VLQVWUXFWLRQV 
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2.7.2  Extraction and purification of chromosomal DNA 
Chromosomal DNA was extracted and purified using lysozyme and the Qiagen DNeasy 
7LVVXH.LWLQDFFRUGDQFHZLWKWKHPDQXIDFWXUHU·VLQVWUXFWLRQV2QRFFDVLRQVZKHUHKLJK
quality DNA was not required, i.e. PCR screening, a protocol involving chelex 100 was 
used. In brief, a 1 ml sample was centrifuged at 8000 xg for 10 minutes and the 
supernatant discarded. The pellet was re-suspended in 0.5 ml 5% chelex 100 and 
vortexed for 1 minute, the suspension was subjected to 100°C for 10 minutes and 
centrifuged at 12,000 xg for 10 minutes at 4°C. The resulting supernatant containing the 
desired chromosomal DNA was removed and stored at -20°C for further screening 
purposes. 
 
2.7.3  Spectrophotometric quantification of DNA 
To quantify the DNA present within a sample, 1.5 ƬO RI VDPSOH ZDV SODFHG RQ D
nanodrop ND-1000 spectrophotometer. The nanodrop measues the OD260 of the 
sample and compares it to 50 mg/ml having an OD260 of 1, at a path length of 1 cm. 
Therefore, a sample containing a DNA concentration of 10 mg/ml will have an OD260 
of 0.2. 
 
2.7.4  Amplification of DNA by Polymerase Chain Reaction (PCR) 
Amplification of DNA for screening was carried out using Promega Taq DNA 
SRO\PHUDVH NLW LQ DFFRUGDQFHZLWK WKHPDQXIDFWXUHU·V LQVWUXFWLRQV)RU FORQLQJZKHUH
PCR errors must be mimimalised, a high fidelity Taq was used. Fragments of 0-3 kbp, 
Epicentre Failsafe system in conjunction with Failsafe Premix E buffer, and for 
fragments over 3 kbp, Novagen KOD DNA polymerase system were used in 
DFFRUGDQFHZLWKWKHPDQXIDFWXUHU·VLQVWUXFWLRQV 
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2.7.5  Amplification of DNA by Splicing by Overlap Extension (SOEing) PCR 
Splicing by Overlap Extension PCR was carried out to splice two DNA fragments 
together using appropriate primers, to amplify, and splice together the fragment using a 
either a single or two step reaction mixture. (Horton, et al., 1989; Horton, et al., 1990). 
 
2.7.6  Restriction endonuclease digestion of DNA 
Complete or partial digests were carried out using NEB restriction enzymes in 
DFFRUGDQFHZLWKWKHPDQXIDFWXUHU·VLQVWUXFWLRQV 
 
2.7.7  Blunting of DNA ends 
For blunting DNA to facilitate the ligation of two incompatible DNA ends, NEB T4 
SRO\PHUDVHZDVHPSOR\HGDVSHUWKHPDQXIDFWXUHU·VLQVWUXFWLRQV 
 
2.7.8  De-phosphoylation of DNA 
7RUHPRYHWKH·SKRVSKDWHJURXSVRIGLJHVWHG'1$DQGOLPLWWKHDELOLW\RIWKe DNA 
to re-ligate to the undesired DNA end, NEB Antarctic Phosphate was used as per the 
PDQXIDFWXUHU·VLQVWUXFWLRQV 
 
2.7.9  Ligation of DNA 
Plasmid DNA fragments, which had been previously digested with restriction 
endonucleases, were ligated using NEB T4 ligase as per thHPDQXIDFWXUHU·VLQVWUXFWLRQV 
 
2.7.10  Membrane dialysis of DNA 
The product of ligations were dialysed with a Millipore 0.025 ƬP QLWURFHOOXORVH
membrane over dH2O for 30 minutes prior to electroporation to remove any unwanted 
salts from the solution that can arc the electroporator cuvette samples. 
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2.7.11  Agarose gel electrophoresis 
Separation of DNA whether it be, PCR products, restriction fragments, or plasmid 
DNA, based upon size alone, was carried out in 1% agarose gel in TAE buffer 
FRQWDLQLQJ  ƬJPO HWKLGLXP EURPLGH HOHFWURSKRULVHG DW  9 IRU -60 minutes 
(depending on size of expected fragments). DNA was subsequently visualised under 
Ultra-Violet (UV light). 
 
2.7.12  Extraction of DNA from agarose gels and reaction mixtures. 
PCR products and restriction fragments were purified from their reaction mixtures 
using Qiagen QIAquick PCR Purification kit, or if the samples were subjected to 
agarose gel electrophoresis, the desired fragments were excised from the gel and 
underwent purification using the Qiagen QIAquick Gel Extraction Kit.  
 
2.7.13  Annealing pairs of oligonucleotides 
Primers which are complementary to each other were annealed together to generate 
synthetic DNA inserts with specified cohesive ends. These cohesive ends are designed 
into the primers so the desired over/underhang is present to use directly for ligating 
LQWR D SODVPLG EDFNERQH (DFK ROLJRQXFOHRWLGH SDLU DW FRQFHQWUDWLRQ  Ƭ0 ZHUH
added equally to a PCR tube and diluted with EB buffer to a ratio of 1:100 to yield 1 
Ƭ0RI HDFKROLJRQXFOHRWLGH7KLVPL[WXUHZDV WKHQKHDWHG LQ D3&5 WKHURPF\FOHU WR
95°C for 30 seconds and allowed to cool to room temperature at a rate of 1°C per 
second. This reaction melts the two oligonucleotides together, allowing the resultant 
insert to be used directly in a ligation reaction.  
2.7.14  Nucleotide sequencing 
DNA sequencing was carried out by Geneservice Ltd, Nottingham or by The 
University of Nottingham Biopolymer Synthesis and Analysis Unit, Nottingham. 
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2.8  Biochemical Materials and Methods 
2.8.1  Growth curves and time sampling of clostridial species 
An overnight liquid culture of Clostridium species was used to inoculate fresh liquid 
media supplemented with appropriate antibiotics, and aTc if when applicable, to a final 
concentration of 0.05 OD600. The culture was then grown in a static anaerobic 
environment at 37°C. Samples were taken for biochemical analysis at appropriate time 
points and the OD600 was measured on a photo spectrophotometer. More detailed 
protocols for inducible expression systems can be found in section 2.11. 
 
2.8.2  Over-production of proteins in E. coli  
An appropriate volume of media (normally 200 ml or 1 L) was inoculated at a ratio of 
1:100 from an overnight culture of E. coli harbouring the appropriate expression vector, 
and incubated at 27°C, 30°C, or 37°C, shaking at 200 rpm. The cultures were harvested 
at the appropriate time after inoculation and centrifuged at 10,000 xg for 20 minutes. 
The supernatants were then discarded and the pellets stored at -20°C for up to 24 hours 
for analysis.  
 
2.8.3  Poly-Acrylamide Gel Electrophoresis (PAGE) 
Cell lysates and purified proteins were analysed by PAGE. Invitrogen NuPage LDS 
VDPSOHEXIIHUDQGƢ-mercaptoethanol was added to each sample and boiled at 95°C 
for 10 minutes to denature the proteins. The samples were then loaded onto Invitrogen 
4-12% NuPage Bis-Tris gels in an appropriate PAGE gel tank, and Invitrogen NuPage 
MES Running Buffer was added, enough to cover the electrodes. The samples were 
then subjected to electrophoresis at 150 V for 90 minutes to separate the proteins, after 
which the gel was removed from the cast, washed three times in 100 ml of water for 5 
minutes, stained with Invitrogen SimplyBlue SafeStain for one hour shaking slowly, and 
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finally de-stained in water for 1 hour shaking or static overnight. The resultant gel was 
then viewed under light or by a densitometer. 
 
2.8.4  Densitometry 
Gel scanning was carried out using a Biorad GS-800 Calibrated Densitometer. The data 
was then analysed and stored with Biorad Quantity One software version 4.2.3, Build 
015.  
 
2.8.5  Determination of protein concentration using the Bradford assay 
To determine the concentration of protein in samples, the Biorad Quick Start Bradford 
Protein Assay was used in the 96-well plate format, as per the manufacturHU·V
instructions.  
 
2.8.6  Nickel affinity chromatography purification of histidine-tagged (His-tagged) 
proteins 
His-tagged proteins purified by nickel-affinity chromatography used the Novagen Ni-
17$+LVă%LQG3XULILFDWLRQ.LWDVSHUWKHPDQXIDFWXUHU·VLQVWUXFWLRQV3XULILHGSURWHLQ
samples were stored at -20 °C and analysed within 24 hours. 
 
2.8.7  Cobalt affinity chromatography purification of histidine-tagged (His-tagged) 
proteins 
His-tagged proteins purified by cobalt-affinity chromatography used Clonetech His-Tag 
Purification Resins ² 7DORQ DV SHU WKH PDQXIDFWXUHU·V LQVWUXFWLRQV 3XULILHG SURWHLQ
samples were stored at -20 °C and analysed within 24 hours. 
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2.8.8  Enzymatic assay of Chloamphenicol AcetylTransferase (CAT) 
CAT activity was determined as described by Shaw, (1975)91, with a few minor 
differences. Reagents were added to a clean quartz cuvette to give final assay 
FRQFHQWUDWLRQV LQ D ƬO UHDFWLRQ PL[ RI  P0 7ULV  P0 ·-dithio-bis (2-
nitobenzoic acid), and 0.17 mM acetyl coenzyme A. This reaction was mixed by 
inversion and allowed to equilibrate at 37°C for 5 minutes. Once equilibrated, 10 ƬORI
WKH FHOO O\VDWHZDV DGGHG WR WKH UHDFWLRQPL[WXUH LQYHUWHG WKHQƬORI  ZY
chloramphenicol solution was added to start the reaction. A blank containing the 
reaction mixture minus the cell lysate and chloramphenicol was used as a reference 
during the reactions. The reaction was left to run for 1 minute in a thermostated photo 
spectrophotometer during which the absorbance change at 412 nm was recorded. This 
process was repeated for each sample, with appropriate dilutions made of the lysates 
when necessary. 
 
Analysis of the data and the subsequent calculation of the CAT Units per ml were 
carried out by defining the maximum linear rate using Analytic Jena AG WinASPECT 
software Version 2.3.1.0, and using the equation;  ܷ݊݅ݐݏ/݈݉ ܧ݊ݖݕ݉݁ = (οܣ412/݉݅݊  ݐ݁ݏݐ െ  οܣ412/݉݅݊༌ݎ݂݁݁ݎ݁݊ܿ݁)(0.6)(݂݀))ሺ0.0136ሻ(0.01)  
 
0.6        = Total Volume (in ml) of assay 
df          = Dilution factor, where appropriate 
0.0136 = Micromolar extinction coefficient for TNB at A412
92
 
0.01      = Volume (in ml) of cell lysate 
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In order to define the U/mg protein, quantification of the protein concentration was 
carried out using the Bradford Assay (Section 2.7.3), and the U/mg protein calculated 
using the equation; 
 ܷ݊݅ݐݏ/݉݃ ݌ݎ݋ݐ݁݅݊ =  ܷ݊݅ݐݏ/݈݉ ݁݊ݖݕ݉݁݉݃ ݌ݎ݋ݐ݁݅݊/݈݉ ݁݊ݖݕ݉݁ 
2.9  Plasmid Construction 
All plasmids used in this study are based upon either the ClosTron plasmid pMTL007C-
E238,41, or the pMTL80000 series of plasmids89 
 
2.9.1  pMTL007C-E2 ² ClosTron vectors 
To re-target the group II intron of the ClosTron to insertionally inactivate the candidate 
essential genes, the QXFOHRWLGH VHTXHQFH RI WKH WDUJHW JHQHV ZHUH LQSXW LQWR 6LJPD·V
TargeTron algorithm to identify possible target sites within the sequence.  This 
identified a total of 9 possible target sites ranked in order from 1, being the highest 
score, to 9 being the lowest. The three possible target sites for CD0274; 190a, 213s, and 
280s identified by the algorithm were initially chosen, and the primers sequences 
generated by the algorithm to re-target the group II intron were synthesised. To re-
target the group II intron, the primers IBS, EBS1d, and EBS2 specific to each target, 
EBS primer and the DNA template supplied by Sigma were combined, in varying ratios 
of outer to inner primers, into a SOEing PCR mixture. The ~350 bp PCR product 
containing the re-targeted section of the intron was extracted from the gel and purified.  
 
Having purified the re-targeted intron, both the plasmid pMTL007C-E2 and the intron 
were digested using HindIII and BsrG1 restriction endonucleases. The plasmid is 
linearised with the same pair of restriction enzymes as the re-targeted introns to 
 
65 
 
generate compatible cohesive ends. Ligation of the digested PCR product into 
pMTL007C-E2 was then performed. The resultant re-targeted plasmid was transformed 
into E. coli cloning strain TOP10 by electroporation and plated onto LB agar 
supplemented with chloramphenicol. The ligation plates showed numerous colonies 
compared to the vector-only control plate, suggesting the digestion and incorporation 
of the re-targeted intron was successful allowing the expressed catP gene to confer 
resistance to chloramphenicol. To increase the probability of at least one clone chosen 
to contain the re-targeted intron, 10 clones were chosen at random, re-streaked and 
were used to inoculate overnights. The newly targeted-region of the plasmid contains 
different restriction sites than the original lacZơJHQHWKHUHIRUHUHVWULFWLRQDQDO\VLVFDQ
be performed to distinguish which clones are recombinant. Restriction endonucleases 
SacI and BglII were used to digest the clones and the results analysed using agarose gel 
electrophoresis.  To confirm the intron was correctly inserted and no PCR errors were 
present, 5 recombinant clones were sent for sequencing. One error-free re-targeted 
intron was selected for each of the 3 targets and employed for mutant generation. 
 
For further ClosTron plasmids, the group II intron targeting sequence was identified 
with the Perutka algorithm93 LQVWHDG RI 6LJPD·V ,Q-line with the decrease in DNA 
synthesis, the group II intron targeting sequences were synthesised by DNA2.0, cloned 
into vector pMTL007C-E2, and delivered ready to use. 
 
2.9.2.  Functional complementation plasmid pMTL-DW1 
CD0274 of C. difficile R20291 was amplified using the primers Cdi-dhaT-ORF-F3+RS 
and Cdi-dhaT-ORF-H6-R3+2RS which also include the addition of the restriction sites 
NdeI and Eco5, DW WKH · DQG · UHVSHFWLYHO\ %RWK WKH SODVPLG S0/7[ DQG WKH
excised CD0274 PCR fragment were digested with NdeI and EcoRI restriction 
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endonucleases and ligated together. The recombinant plasmid, pMTL8215x-dhaT, 
containing CD0274 was electroporated into E. coli TOP10 and incubated overnight on 
LB agar supplemented with chloramphenicol. The native promoter of CD0274 was 
amplified using the primers Cdi-dhaT-pro-F1 and Cdi-dhaT-pro-R1 which introduce the 
restriction sites NotI and NdeI into the PCR IUDJPHQW DW WKH · DQG · UHVSHFWLYHO\
Using the restriction endonuclease NotI and NdeI, the native promoter of CD0274 was 
cloned into the plasmid pMTL8215x-dhaT, yielding pMTL8215x-PdhaT-dhaT. 
 
To protect the second copy of CD0274 present upon the plasmid from the targeting 
mechanism of the group II intron, the nucleotide sequence at the recognition sites of 
the group II intron for plasmids; pMTL007C-E2:Cdi-dhaT-548a and pMTL007C-
E2:Cdi-dhaT-623a, were silently altered between the two native SacI restriction sites so 
WKDW WKH LQWURQQR ORQJHUUHFRJQLVHVWKH´SURWHFWHGµVHFRQGFRS\RI&'EXWWKH
amino acid sequence of the gene product is unaltered as outlined in section 3.2.3. This 
synthetic construct was designed using the gene designer software developed by 
DNA2.0 and synthesised by the same company. The synthetically altered CD0274 and 
plasmid pMTL82151-dhaT was digested using the restriction endonuclease ScaI. Both 
the plasmid backbone and the synthetic fragment were ligated together to produce a 
protected CD0274 plasmid-borne copy, representing plasmid pMTL-DW1. 
 
2.9.3  Chromosomal functional complementation plasmids 
As was the case with CD0274, a synthetic version of metK and trpS was constructed 
containing silent mutations at the recognition sites for the 2 re-targeted group II 
introns. As the cost of synthesising DNA has decreased significantly, the whole of metK, 
including the native RBS, promoter, and a SAM riboswitch, were synthesised as a single 
construct to include a NotI and Nhe, UHVWULFWLRQ VLWHV DW WKH · DQG · IRU FORQLQJ
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Following digestion using the aforementioned restriction endonucleases, the synthetic 
metK gene including the natural promoter was cloned from the courier vector DNA2.0-
PmetK-metKp, into the ACE vector pMTL-JH18 with the restriction sites NotI and NheI, 
replacing the reporter gene ODF=ơ and creating plasmid pMTL-JH18-metKp. As trpS 
seems to be a part of an operon, the native promoter could not be reliably identified 
and therefore was substituted for the thiolase promoter of C. sporogenes, and synthesised 
with the protected trpS as a single construct containing restriction sites NotI and NdeI at 
WKH · DQG · UHVSHFWLYHO\ 7KH FRQVWUXFW ZDV VXEVHTXHQWO\ FORQHG IURP WKH FRXULHU
vector DNA2.0-PtrpS-trpSp into plasmid pMTL-JH18, giving rise to plasmid pMTL-
JH18-trpS. In the case of CD0274, the plasmid pMTL-DW1 was subjected to digestion 
using restriction endonucleases NotI and NheI to remove the protected CD0274 and its 
natural promoter, and subsequently cloned into pMTL-JH18, giving rise to pMTL-
JH18-dhaT. Finally, a synthetic version of slpA was constructed containing silent 
mutations at the recognition sites for the 3 re-targeted group II introns. The whole gene 
and the native promoter were synthesised by DNA2.0 to include a NotI and NheI 
UHVWULFWLRQVLWHDWWKH·DQG·IRUFORQLQJ7KHJHQHDQGLWVQDWLYHSURPRWHUZHUHWKHQ
digested with restriction enzymes NotI and NheI and cloned into vector pMTL-JH18, 
yielding plasmid pMTL-JH18-slpA.  
 
Included within the design of all the synthetic genes was an NdeI restriction site over 
the start codon of each synthesised candidate essential gene, enabling the 
removal/substitution of the included promoter.  
 
2.9.4  lac repressor system plasmids 
The Clostridium lac repressor system was designed and constructed as outlined in section 
4.2.1.1.  
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Switching of the lacI promoter was facilitated by using the restriction enzymes SacI and 
BamHI. All promoters used in this study were amplified, using the appropriate primers 
named according to the promoter in table 2.4, under the section promoter library, from 
C. acetobutylicum, with the exception of Pfdx and Pthl which were amplified from C. 
sporogenes. For removal of the lacI promoter, the restriction enzymes SacI and BamHI 
were used in conjunction with T4 polymerase to blunt the ends, and religated using T4 
ligase. Switching of the inducible promoter interrupted with the lac operators was 
facilitated with the use of restriction enzymes BglII and SalI.  
 
2.9.5  Riboswitch harbouring plasmids  
The Riboswitches Thio1, Thio2, and Thio3 were designed and constructed as outlined 
in section 4.2.2.1. Each riboswitch was cloned into plasmid pMTL82254 using the 
restriction sites NotI and NdeI.  
 
Switching of the riboswitch promoters was facilitated by using the restriction enzymes 
SacI and BamHI. All promoters used in this study were amplified, using the appropriate 
primers named according to the promoter in table 2.4, under the section promoter 
library, from C. acetobutylicum, with the exception of Pfdx and Pthl which were amplified 
from C. sporogenes. 
 
2.9.6  Tet system plasmids 
The Tet system was designed and constructed as outlined in section 4.2.3.1. 
Switching of the tetR promoter was facilitated by using the restriction enzymes SacI and 
BamHI. All promoters used in this study were amplified using the appropriate primers 
named according to the promoter in table 2.4, under the section promoter library, from 
C. acetobutylicum, with the exception of Pfdx and Pthl which were amplified from C. 
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sporogenes. Switching of the inducible promoter interrupted with the Tet operators was 
facilitated with the use of restriction enzymes ClaI and AatII.  
 
2.9.7  Essential gene conditional expression plasmids.  
The Tet system present upon plasmid pMTL-tet3nO and the plasmids; pMTL-JH18-
dhaTp, pMTL-JH18-trpSp, and pMTL-JH18-slpAp were digested using NotI and NdeI. 
The tet inducible promoter was removed and cloned into the functional 
complementation plasmids, thereby replacing the previous promoter with the 
tetracycline inducible promoter, yielding plasmids; pMTL-ACEtet-dhaTp, pMTL-
ACEtet-trpSp, and pMTL-ACEtet-slpAp. 
 
2.10  Strain Construction 
2.10.1. ClosTron integrants 
The ClosTron plasmids containing the re-targeted group II intron were electroporated 
into E. coli donor strain CA434 and subsequently conjugated into the recipient host C. 
difficile 630¨erm cell using standard conjugation techniques90. Transconjugants were 
grown on BHIS and selected for using C. difficile supplement and thiamphenicol.  
Conjugation plates were inspected after 3 days incubation, and one large colony was 
selected, re-suspended in 100 µl of BHIS, 10-fold serial diluted and plated into BHIS 
agar supplemented with a C. difficile supplement and 2.5 µg/ml erythromycin and 
incubated at 37°C for 3 days under anaerobic conditions. After the incubation period, 
incubation plates were inspected and erythromycin resistant colonies were picked for 
each target and screened for integration of the group II intron into the desired target 
using PCR. PCR screening was carried out in 2 ways; first was using the flanking 
primers,  for example of CD0274; Cdi-dhaT-F2 and Cdi-dhaT-R2, and the second was 
using primers that amplified across the intron integration site, for example of CD0274; 
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Cdi-dhaT-F2 for a sense insertion and Cdi-dhaT-R2 for an antisense insertion, combined 
with the EBS universal primer. 
  
2.10.2 Construction of partial diploid C. difficile 630ƅerm strains using Allelic 
Chromosomal Exchange (ACE). 
The plasmids containing the protected copy of the candidate essential genes were 
conjugated into C. difficile 630ƅerm via E. coli CA43490. The resultant transconjugants 
were selected for on BHIS media supplemented with thiamphenicol and C. difficile 
supplement. After 2-3 days incubation, the single-crossover event can be selected due to 
the integrants being able to surpass the growth of their replicative-defective free-
plasmid neighbours, therefore appear larger in size. Using this principle, 5 individually 
derived single-crossover colonies were purified and enriched by sub-cloning on fresh 
BHIS supplemented with thiamphenicol and C. difficile supplement. To select for the 
second recombination event, 5 single-crossover colonies were re-streaked onto C. difficile 
minimal media supplemented with 5-FOA (1 mg/ml) and uracil (5 µg/ml). After 24 
hours, 5-FOA resistant colonies are large enough to pick, 50 were selected to undergo 
patch plating on BHIS or BHIS supplemented with thiamphenicol to identify the cells 
that are thiamphenicol sensitive, therefore, have lost the ACE plasmid stopping further 
recombination events. PCR screening to confirm correct insertion was carried out using 
flanking primers Cdi630-pyrE-F2 and Cdi630-CD0189-R2., followed by sequencing. 
 
2.11  Inducible Expression System Testing. 
Appropriate plasmids were transformed into E. coli or conjugated into C. difficile using 
standard conjugation procedures90. The resulting transconjugants/transformants were 
selected using the appropriate media and antibiotics as previously described. After the 
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final cultures are obtained, each is normalised to a 10 ml culture of OD600 1, and pelleted 
by centrifugation at 16,000 rpm for 20 minutes at 4°C. The harvested samples are lysed 
through sonication as previously described in section 2.6.7 and the samples analysed by 
the CAT assay to quantify catP reporter expression, as described in section 2.7.9. 
 
2.11.1 lac repressor system in E. coli and C. difficile. 
For testing the lac repressor system in E. coli, the subsequent transformants were used to 
inoculate a 5 ml overnight starter culture of LB supplemented with erythromycin. The 
next morning, the starter culture was used to inoculate 50 ml of LB supplemented with 
erythromycin to an OD600 of 0.05. Each culture was grown shaking at 200 rpm at 37°C 
until OD600 0.5 was reached, the cultures was then split into 20 ml aliquots with one 
being induced with 1 mM IPTG and the other not. The cultures were sampled every 2 
hours after induction until 12 hours, then 24 hours, then the results analysed by the 
CAT assay.  
 
For C. difficile testing, the appropriate transconjugants were grown overnight in liquid 
BHIS, supplemented with erythromycin, and used to inoculate 40 ml BHIS 
supplemented with erythromycin to an OD600 0.05 starter culture. The samples were 
grown to an OD6000.5 and split into 20 ml samples, with one being induced with 1 mM 
IPTG. After 4 hours, the cells analysed by the CAT assay. 
 
2.11.2  Riboswitches in E. coli and C. difficile 
In E. coli, the transformants were used to set up a 5 ml culture of LB supplemented with 
erythromycin, and incubated overnight at 37°C and 200 rpm shaking. After the 
transformants had been incubated for at least 13 hours, the cultures were used to 
inoculate a 20 ml starter culture of LB supplemented with erythromycin to an OD600 
 
72 
 
0.05 and incubated at 37°C at 200 rpm until an OD600 0.5 was reached. Each culture was 
split into two 10 ml cultures, with one being induced with 2 mM theophylline, and the 
other acting as an un-induced control. The cultures were then left to grow for a further 
4 hours and analysed by the CAT assay. 
 
Further experiments in E. coli were carried out using the riboswitches in which varying 
concentrations (0, 1, 2, 5, 10, 20 mM) of theophylline were used to induce catP 
expression. For these, the same procedure was carried out as above, except the volume 
of media for cultures was adjusted as appropriate.  
 
2.11.3  Tet system in C. difficile, C. sporogenes, C. acetobutylicum, and C. beijerinckii 
For quick testing to ascertain if system works at one concentration and one time point 
in C. difficile, C. acetobutylicum, and C. beijerinckii, a transconjugants/transformants 
harbouring the Tet system plasmid pMTL-tet3nO was used to inoculate an overnight 
culture of appropriate liquid media supplemented with erythromycin. These overnight 
cultures were used to inoculate starter cultures of 20 ml of liquid media supplemented 
with erythromycin to an OD600 of 0.05. The starter culture was grown to an OD600 of 
0.5 and split into 10 ml samples, one of the samples was induced with 316 ng/ml aTc, 
whereas the other was left not induced and left for 4 hours, after which the samples 
were normalised to an OD600 of 1 at 10 ml, and the cells harvested. The harvested cells 
were lysed by sonication and analysed by the CAT assay, as previously described 
(Section 2.7.8).  
 
For testing the dynamic range of the Tet system in C. difficile and C. sporogenes, the 
plasmid was grown in an overnight culture and used to inoculate a starter culture of 200 
ml of appropriate liquid media supplemented with erythromycin to an OD600 0.05. The 
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culture was left to grow to an OD600 0.5, split into 10 ml aliquots, and induced with 
varying concentrations of aTc. As it is unknown what concentrations of aTc will induce 
CatP production, 2-log dilutions of 1 µg/ml of aTc was used to induce catP expression, 
with the lowest concentration being 0.31 ng/ml. The cultures were incubated for 6 
hours, after which the cells were harvested, lysed, and analysed.  
 
To ascertain the speed of induction, stability of expression, and bioavailability of 
inducer, the Tet system (pMTL-tet3nO) was tested at a single concentration of aTc over 
multiple time points in C. difficile and C. sporogenes.  A transconjugants was used to 
inoculate an overnight culture and subsequently used to inoculate starter cultures of 200 
ml of liquid media supplemented with erythromycin. C. difficile and C. sporogenes 
harbouring plasmid pMTL-tet3nO was grown to an OD600 0.5 and induced with 316 
ng/ml aTc and sampled every hour after induction for 6 hours, after which the cells 
were harvested, lysed, and analysed.  
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Chapter Three 
A Novel Method for the Identification of Essential Genes 
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3.1  Introduction 
The treatment of CDI has evolved little in recent years with only a few proven 
therapeutic options available. Current first choice antimicrobials vancomycin and 
metronidazole, although effective in clearing an initial infection, can in certain cases 
exacerbate the infection due to destroying the natural gut microflora, predisposing a 
patient and inciting a relapse9.  In addition to this, sporadic reports of resistance to the 
front-line antimicrobials have arisen, compounding the need for the development of 
novel antimicrobials.  
The development of novel antimicrobials is dependent on the identification of 
microbial target proteins which are required for survival of the bacterium to unsure 
chemical inhibition will ultimately result in cell stasis or death94. Normally broad-
spectrum antibiotics are preferred due to their cost-effectiveness and of clinical use. 
However, in the case of C. difficile, a narrow-spectrum antibiotic would be preferable due 
to the possibility of the infection relapsing after initial treatment. To assess an 
antimicrobial target·s effectiveness, specific gene disruptions are required to ascertain 
the effect inhibition has on cellular viability3,4,94. 
3.1.1  Genetic tools in clostridia 
Exploitation of clostridial genomes has been hampered by the historical inability to 
genetically manipulate the Clostridium species. With the tools developed or under 
development such as; directed mutagenesis38,41, random transposon-mutagenesis42, and 
multiple allelic exchange techniques, the secretive world of the clostridial genome is 
opening up allowing forward and reverse genetic approaches to identify essential genes 
for the purpose of antimicrobial design.  
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The ClosTron is a revolutionary system able to insertionally inactivate target genes by 
using a bacterial group II intron38,41. Group II introns are effective because they can be 
targeted to insert into virtually any gene with high efficiency and specificity38. In the case 
of identification of essential genes, the group II intron can be targeted against the 
candidate essential gene in an attempt to insertionally inactivate the gene. If the gene is 
essential, then it should not be able to be insertionally inactivated due to this genotype 
being lethal. However, this inability to inactivate the gene does not prove it to be 
essential, only that it cannot be insertionally inactivated. One method which has been 
previously used to identify essential genes is to provide a functioning second copy of 
the candidate gene on a plasmid or chromosome, effectively producing a partial 
diploid50,95,96. This second copy is able to functionally complement the native essential 
JHQH·VSURGXFW, allowing the native essential gene to be inactivated. 
There are effectively two ways to construct a partial diploid, by providing the second 
copy on either an autonomous plasmid or inserted into the chromosome. Both have 
their advantageous and disadvantageous which will be discussed within the results 
section. In the case of the plasmid-based partial diploid, the plasmid can be introduced 
into the cell using standard conjugation techniques90, followed by the ClosTron 
procedure to inactivate the native copy38,41. The chromosomal-based partial diploid is 
more intricate in that the gene needs to be integrated into the chromosome using a 
homologous recombination technique. This has recently become possible in Clostridium 
species with the advent of ACE (Heap et al, unpublished), allowing a stable recombinant 
chromosome to be constructed, and subsequent inactivation of the native candidate 
essential gene. These two techniques provide further indirect evidence that a gene is 
essential. 
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3.1.2  Aim of this study 
Genetic tool development in C. difficile has advanced rapidly recently with the advent of 
the ClosTron38 and mariner transposon systems42, although both systems are able to 
identify genes which cannot be inactivated, they are unable to provide enough evidence 
to identify essential genes. Development of a new system which is able to use the 
information from such systems and define genes as essential is paramount in identifying 
new antimicrobial targets for the treatment of CDI. 
The study presented in this chapter aims to develop a novel technique for the 
identification of essential C. difficile genes, and using the technique, identify candidate 
antimicrobial targets. 
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3.2  Results 
3.2.1  Identification of candidate essential genes 
Bioinformatic analysis of genome data assumes that genes which are essential are likely 
to be common to, and therefore highly conserved among multiple species. To identify 
possible targets prior to experimentation, all known essential genes in B. subtilis were 
compared to potential homologs in C. difficile through in silico analysis. In B. subtilis, there 
have been 271 essential genes identified out of 3,830 genes, making up 6.6% of the total 
genome52.  
Screening was performed in silico as follows: The amino acid sequence of each essential 
protein identified in B. subtilis was used to search the C. difficile ƅerm translated 
nucleotide database with the blastp algorithm. The translated nucleotide sequence was 
then used to identify the gene which encodes for the similar protein. All the genes 
which were found to be essential in B. subtilis and their C. difficile homolog, along with its 
gene qualifier, amino acid sequence similarity, and gene size, are listed in appendix 1. 
Out of the 267 genes which could be identified in B. subtilis, 59 were not found in C. 
difficile based upon similarity or gene identifier.  
To narrow down the 208 C. difficile candidate essential genes for use in this study, three 
criteria were introduced. The criteria in order of importance: translated nucleotide 
sequence similarity to B. subtilis (with a cut-off of 70% positive identity), size of the gene 
(less than 2.2 kbp for synthesis time and costs), and its genomic context. These three 
criteria were selected because a higher amino acid similarity could suggest that the 
related proteins have similar or the same function increasing the chance of the C. difficile 
protein being essential, expense and synthesis time of the synthetic protected gene, and 
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to minimise potential polar effects of insertionally inactivating the native gene using the 
ClosTron38,41. 
Table 3.1. List of candidate essential genes of C. difficile 
Category B. subtilis Gene 
C. difficile    
CD Number 
Protein Similarity Size 
DNA 
metabolism 
dnaA CD0001 350/448 (78%) 1.3 kbp 
 dnaC CD3657 325/431 (75%) 1329 bp 
 ligA CD3309 498/667 (74%) 2 kbp 
 topA CD1274 501/691 (72%) 2.1 kbp 
RNA 
metabolism 
sigA CD1455 297/371 (80%) 1173 bp 
 cspR CD0566 117/159 (73%) 471 bp 
 rnpA CD3679 72/101 (71%) 345 bp 
 trmD CD1256 168/226 (74%) 696 bp 
 nusA CD1307 255/313 (81%) 1115 bp 
tRNA 
synthetases 
cysS CD0052 343/463 (74%) 1407 bp 
 metS CD3540 465/660 (70%) 1938 bp 
 serS CD0014 322/418 (77%) 1272 bp 
 trpS CD2610 242/330 (73%) 1002 bp 
 frr CD2137 144/185 (77%) 558 bp 
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 prfB CD0144 251/339 (74%) 987 bp 
Cell envelope accA CD1936 225/302 (74%) 945 bp 
 gpsA CD2630 242/337 (71%) 1032 bp 
 plsX CD1178 220/313 (70%) 1023 bp 
 murAA CD0123 331/419 (78%) 1272 bp 
Cell shape and 
division 
ftsZ CD2646 293/387 (75%) 1161 bp 
 mreB CD1145 275/332 (82%) 1062 bp 
Glycolysis eno CD3170 364/427 (85%) 1293 bp 
 pgm CD3171 376/516 (72%) 1153 bp 
 tpiA CD3172 193/247 (78%) 744 bp 
Nucleotide 
synthesis 
adk CD0091 162/216 (75%) 651bp 
 gmk CD2588 141/199 (70%) 618 bp 
 hprT CD2691 130/165 (78%) 528 bp 
 cmk CD1816 148/204 (72%) 651 bp 
 gylA CD2726 313/414 (75%) 1245 bp 
Cofactors metK CD0130 348/396 (87%) 1194 bp 
Other era CD2437 219/295 (74%) 894 bp 
 gcp CD0152 251/336 (74%) 1017 bp 
Unknown ymdA CD1329 416/498 (83%) 1563 bp 
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A total of 33 candidate genes which fitted the criteria were identified representing 10 
broad categories of function within B. subtilis (table 3.1)52. To narrow down the selection 
further for experimental analysis, the potential for therapeutic targeting was taken into 
account. Due to its high protein homology at 87%, and its known potential as an 
antimicrobial drug target97, metK was selected. In S. aureus, the metK gene encodes an S-
adenosylmethionine (SAM) synthetase, thought to be essential in both survival and 
virulence97. Its translation is in turn controlled by a class 1 SAM-binding riboswitch 
ORFDWHG EHWZHHQ LWV SURPRWHU DQG ULERVRPH ELQGLQJ VLWH LQ WKH ·-UTR97. An 
antimicrobial agent that targets MetK would, in principle, prevent SAM biosynthesis 
and inhibit growth and/or virulence in S. aureus. There are numerous other class 1 
SAM-binding riboswitches found in other bacterial species, Bacillus anthracis alone has 17 
highly conserved class 1 SAM-binding riboswitches that collectively regulate 36 genes 
which are required for sulphur metabolism97. Although the known number of 1 SAM-
binding riboswitches present within C. difficile is unknown, metK has a high probability of 
being essential and therefore would make a good target to develop a system for essential 
gene identification.  
The second candidate essential gene which was selected for further analysis was trpS. In 
S. aureus, trpS encodes for a tryptophanyl-tRNA synthetase, an enzyme that plays a 
crucial role in protein biosynthesis by catalysing the synthesis of aminoacyl-tRNAs (aa-
rRNA) by the following reactions98:  
1. AaRS + aa + ATP = AaRS·(aa-AMP) + PPi 
2. AaRS·(aa-AMP) + tRNA = AaRS + aa-rRNA + AMP 
aa= amino acid,  aa-AMP = aminoacyl-AMP 
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In the first reaction (1), the amino acid and ATP yield an activated, hydrolysable, 
aminoacyl-adenylate intermediate. The amino acid moiety is then transferred to its 
cognate tRNA allowing the resultant aminoacyl-tRNA to act as a substrate for protein 
synthesis on the ribosome. In the second reaction, the amino acid moiety is then 
transferred to its cognate tRNA, resulting in an aminoacyl-tRNA which can act as a 
substrate for polypeptide synthesis on the ribosome98. If either of these reactions are 
inhibited, uncharged tRNA molecules are accumulated which bind to the ribosomes and 
interrupt polypeptide chain elongation. This interruption leads to the stringent response 
being induced by relA98. Induction of this pathway leads to the biosynthesis of tetra- 
(ppGpp) and pentapeptide guanine (pppGpp) which subsequently inhibits RNA 
polymerase activity and down-regulates a number of high-energy processes including; 
RNA, DNA, protein, and peptidoglycan biosynthesis98 (figure 3.1). Therefore, in 
principle, if you could target an aminoacyl-tRNA synthetase such as trpS, you could 
interfere with synthesis of aminoacyl-tRNAs and induce the stringent response pathway. 
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Figure 3.1. Pleiotropic effects in response to relA mediated stringent 
response following amino-tRNA deficiency. Induction of this pathway 
results in accumulation of tetra- (ppGpp) and penta-peptide guanine 
(pppGpp), inhibiting RNA polymerase activity and down-regulation 
other high-energy processes such as; DNA, RNA, and protein 
metabolism. Adapted from reference98. 
Both of the chosen candidate essential genes were selected due to their high probability 
of being essential in C. difficile. Assuming these candidates are essential in C. difficile, an 
antimicrobial targeted against them would also target a broad-spectrum of bacteria, 
indicative of a broad-spectrum antibiotic. Generally broad-spectrum antimicrobials are 
preferred, but in the case of CDI a narrow-spectrum antimicrobial would be of interest. 
There has only been one candidate essential gene which could be potentially used as a 
novel narrow-spectrum antibiotic target in C. difficile reported in the literature39,40. The 
authors hypothesised that the gene CD0274, a putative alcohol dehydrogenase which 
they annotated as gldA, was involved in the sole detoxification pathway of the toxic 
metabolite methylglyoxal (MG) and as such was essential40. 
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Liyanage et al, (2000)39, first came to study gldA in the solventogenic C. beijerinckii 
NCIMB 8052 to isolate and characterise a butanol-tolerant mutant using random-
transposon mutagenesis. It had been previously described that some butanol-tolerant C. 
acetobutylicum mutants produced more butanol than their wild-type counterparts39. To 
characterise and isolate a butanol-tolerant mutant in C. beijerinckii, they carried out a 
mutagenesis experiment with transposon Tn1545 and selected for transposon-inserted 
butanol-tolerant mutants on 1-1.1% 1-butanol, where wild-type NCIMB 8052 has a 
tolerance up to 0.4%39. It was noted that mutants that were tolerant to butanol had an 
insertion of Tn1545 in the intergenic region downstream of gldA39. The transposon was 
positioned in such an orientation as the promoter used in selection for transposition 
was able to transcribe gldA in the reverse orientation, downregulating gene expression 
through antisense RNA production.  
In a subsequent study, Liyanage et al, (2001)40, set about creating mutants with an 
insertionally inactivated gldA gene. Using the BLAST sequence analysis for the amino 
acid translation of the nucleotide sequence using C. beijerinckii NCIMB 8052 as the 
query, they identified CD0274 as the closest match to gldA within C. difficile. They 
carried out gene disruption experiments in both organisms using a replicative-defective 
plasmid that contained an internal fragment of gldA and CD0274 lacking both the 
translational start codon and ADH signature motif 2 which would create single 
crossover knockout mutants. It was shown that transconjugants which were confirmed 
to have a mutation in the gldA gene, showed limited growth on medium with pin-point 
sized colonies being formed. When the pin-prick colonies were re-streaked onto fresh 
media, no viable cells were recovered after 2 days in either C. beijerinckii or C. difficile40. 
Liyanage et al, (2001)40 also measured free methylglyoxal (MG) levels and sensitivity of 
wild-type strains of C. beijerinckii compared to the transposon-inserted butanol-tolerant 
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mutant produced in their previous paper39,40. It was found that butanol-tolerant mutants 
contained significantly more free MG than their wild-type counterparts and that the 
downregulated gldA mutants showed increased sensitivity to exogenously added MG. 
Methylglyoxal is a toxic electrophile inevitably produced as a side-product of glycolysis 
in both eukaryotic and prokaryotic cells99. Under certain conditions, there is an 
excessive production of toxic sugar phosphates produced during glycolysis40. From this 
evidence they ruled out gldA playing a role in central sugar catabolism, in which there 
are high metabolite fluxes as the observed activity of gldA was too low. They also ruled 
out the participation of gldA in another pathway whose flux is lower than that of a 
primary fermentative pathway. This led them to the hypothesis that GldA plays a 
primary role in MG detoxification in both C. beijerinckii and C. difficile40 (figure 3.2A). 
However, Liyanage et al, (2001)40, did not go as far as to absolutely prove that gldA and 
CD0274 are essential in C. beijerinckii and C. difficile. 
A BLAST sequence analysis for the amino acid translation of the nucleotide sequence 
using CD0274 of C. difficile 630¨erm as the query, showed that the highest similarity was 
to a 1,3-propandiol dehydrogenase of C. beijerinckii and a 1,3-propandiol dehydrogenase 
(dhaT) of C. butyricum. Raynaud et al, (2003)100, noted that DhaT had very high similarity 
to other sequenced DhaT proteins and has all the common features of class III alcohol 
dehydrogenases. The authors functionally characterised 1,3-propanediol dehydrogenase 
of C. butyricum  and found dhaT to be located within a 1,3-propandiole (1,3-PD) operon 
consisting of three genes; dhaB1, dhaB2 and dhaT100. Production of 1,3-PD from glycerol 
involves all three genes; DhaB1 and DhaB2 are responsible for the glycerol dehydratase 
activity which converts glycerol to 3-hydroxypropionaldehyde, which is subsequently 
converted to 1,3-PD by DhaT (figure 2C). In C. butyricum the transcript was only 
detected and 1,3-PD produced, when the cells where grown on a glucose-glycerol 
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mixture as substrate. This demonstrates that the operon including dhaT is not required 
for growth under all conditions and as such is not essential in C. butyricum. 
The best known example of the role of an alcohol dehydrogenase in dihydroxyacetone 
and methylglyoxal metabolism is in E. coli K1299 (figure 3.2B). Subedi et al, 200899, in 
their study characterised the substrate specificity and kinetics of GldA. Enzyme activity 
was measured for 7 substrates, glycerol and 1,2-PD for oxidation, and hydroacetone, 
methylglyoxal, DL-gyceraldehyde, glycolaldehyde, and dihydroxyacetone for reduction. 
The highest specificity of GldA was found to be dihydroxyacetone which was converted 
to glycerol; next highest activity was the conversion of glycolaldehyde to ethylene glycol. 
The specificity and specific activity of GldA in converting MG to lactaldehyde was 
about 6 times lower than the specific activity for dihydroxyacetone99. This data suggests 
that GldA in E. coli primarily regulates intracellular levels of dihydroxyacetone by 
converting it to glycerol99. The location within the genome of E. coli K12 further 
supports this by the fact that gldA lies immediately downstream of the gene that 
encodes fructose-6-P aldose (talCRYHUODSSLQJ WKH· UHJLRQE\ bp. Also the gene 
encoding a putative phosphotransferase system enzyme (ptsA) lies upstream of the talC 
gene forming an operon of the three genes99. Due to the complex mechanism of MG 
detoxification and protective measures in E. coli, a disruption of gldA in E. coli does not 
result in a lethal phenotype99. This would suggest that gldA plays a minor if not 
insignificant role in MG detoxification in E. coli. 
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Figure 3.2. (A) Hypothetical pathway proposed by Liyanage et al, 
(2001)40, for the role of GldA in the synthesis and detoxification of 
methylglyoxal in C. beijerinckii and C. difficile. Taken from reference40 (B) 
Pathway for dihydroxyacetone and methylglyoxal metabolism of E. coli 
K12 involving GldA. Taken from reference99. (C) Pathway for 
production of 1,3-PD from glycerol in C. butyricum involving DhaB1 and 
DhaB2 at step 1, and DhaT at step 2. Taken from reference100. 
 
3.2.2   Attempted gene inactivation of CD0274, trpS, and metK in C. difficile 630¨erm 
and R20291 
Essential genes are required for survival of the organism, and as such cannot be 
inactivated without the cell being non-viable. To experimentally test whether CD0274, 
trpS or metK can be inactivated, ClosTron technology was employed to insertionally 
inactivate at specific target sites within the target gene. In the first instance, CD0274, 
being of high priority due to the possibility of being an essential gene in a narrow range 
of organisms was targeted. To re-target the group II intron of the ClosTron to 
A B 
C 
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insertionally inactivate CD0274, the nucleotide sequence of CD0274 was entered into 
6LJPD·V7DUJH7URQVRIWZDUHWR LGHQWLI\SRVVLEOHWDUJHWVLWHVZLWKLQWKHVHTXHQFH 7KLV
identified a total of 9 possible target sites each with target scores above the threshold 
imposed by the software. The targets were designated in order from 1, being the highest 
score, to 9 being the lowest (figure 3.3). The three possible target sites, 190a, 213s, and 
280s identified by the algorithm were initially chosen, and the primers sequences 
generated by the algorithm to re-target the group II intron were synthesised and 
constructed, yielding plasmids pMLT007C-E2:Cdi-dhaT-190a, pMLT007C-E2:Cdi-dhaT-
213s, and pMLT007C-E2:Cdi-dhaT-280s, respectively. 
 
Figure 3.3. ClosTron target sites generated by the Sigma TargeTron 
algorithm in order of preference. The checked arrows represent the 
ClosTron targets identified by the algorithm and the orientation of the 
group II insertion. 7KH UHG DUURZ DW WKH · RI &' LQGLFDWes the 
position of the native promoter followed by the RBS downstream. The 
smaller blue arrows show where the primers anneal for PCR screening 
flanking CD0274. 
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Re-targeted plasmids pMLT007C-E2:Cdi-dhaT-190a, 213s, and 280s containing the re-
targeted group II intron were electroporated into E. coli donor strain CA434 and 
subsequently conjugated into the recipient host C. difficile 630¨erm cell using standard 
conjugation techniques90. After the conjugation had taken place, incubation plates were 
inspected and erythromycin resistant colonies were picked for each CD0274 target and 
screened for integration of the group II intron into the desired target using PCR. A large 
number of individual integrants were screened for an insertion of the group II intron 
into CD0274 but mostly the method did not provide any viable insertions. However, 
using the flanking primers, 2 out of 40 integrants of target Cdi-dhaT-213s were negative 
for CD0274 suggesting that the intron had inserted within the gene causing the flanking 
primers to be positioned too far apart to successfully amplify the PCR fragment within 
the selected annealing time (figure 3.3A). To screen for a correct insertion within 
CD0274, the primer combination Cdi-dhaT-F2 and the EBS universal that amplify 
across the intron-exon junction was employed. The two integrants for target Cdi-dhaT-
213s which showed a negative PCR for CD0274 had a PCR fragment of the expected 
size using the primers which amplified across the gene/intron junction (figure 3.3B). 
The product was sent for sequencing and was verified to be CD0274 with a successful 
integration of the group II intron between nucleotides 213 and 214.  
Surprisingly, the two C. difficile 630¨erm clones which were harbouring the Group II 
intron within the CD0274 gene were viable after subsequent re-streaking on fresh BHIS 
agar, indicating either that CD0274 was not essential or that they still produced a fore-
shortened but functional DhaT protein. The knock-out protocol was repeated to 
reproduce the results; however, none of the 20 further integrants screened were positive 
for insertion of any re-targeted group II intron within CD0274.  
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Figure 3.4. PCR screening of erythromycin resistant colonies for the 
integration of three retargeted group II introns into CD0274. (A) 
Screening for the CD0274 gene of C. difficile in integrants of 3 targets, Cdi-
dhaT-190a (lanes 4-12), -213s (lanes 22-31), and -280s (lanes 13-21) using 
primers Cdi-dhaT-F2 and Cdi-dhaT-R1 which flank CD0274. (B) Further 
PCR screening of the Cdi-dhaT-213s integrants using the intron-exon 
junction primers Cdi-dhaT-F2 and EBS universal showed a product of 
~500 bp.  
In the original paper which identified CD0274 as a candidate essential gene, Liyanage et 
al, (2000)39, noted that when they used a replicative-defective plasmid that contained an 
internal fragment of CD0274 lacking both the translational start codon and ADH 
signature motif 2, they could effectively knock-out the gene leading to the hypothesis 
that CD0274 is essential40. However, when they used a replicative-defective plasmid that 
contained an internal fragment that had both the ADH motifs present, the gene could 
still produce a functional fore-shortened protein which allowed the cell to be viable40. 
This suggests that if both of the ADH motifs are unaltered, the protein is still functional 
- Control
w/t control
Cdi-dhaT-190a (1-9) Cdi-dhaT-280s (1-9) Cdi-dhaT-213s (1-10)
Integrants 3 and 4 
both negative for 
CD0274
Cdi-dhaT-213s (1-10)- control
w/t control
A
B
10 kbp
1 kbp
500bp
10 kbp
1 kbp
500bp
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and does not cause a lethal phenotype and should have the same phenotypic 
characteristics as the wild type. To test this, the phenotype of the CD0274 integrant was 
characterised. The integrant was grown on BHIS agar and CBM media in which glucose 
was replaced with either glycerol or casein at an equivalent concentration. C. difficile 
630¨erm was used as a control. As expected, there was no difference in growth between 
the integrant and the control in either the first plate, or any subsequent re-streaks up to 
the 4th passage. It was noted that both integrant and control strains grew slower on the 
CBM and its variations than BHIS agar, of which the casein variation grew the slowest 
and produced smaller colonies.  
As it would seem the ADH motifs need to be disrupted to inactivate the gene, two 
additional introns were designed, re-targeted to the centre of CD0274 between 
nucleotides 548-549, and 623-624 to reduce the possibility of a functional fore-
shortened protein being produced. As this study continued, the advancement of 
commercial DNA synthesis technology allowed us to outsource to DNA2.0 for the 
synthesis and construction of further ClosTron plasmids41. The same procedure as 
described above was repeated to attempt to insertionally inactivate CD0274 with the two 
new targets. Due to the complications seen with target 213s, a larger number of 
integrants were screened to confirm that CD0274 could not be insertionally inactivated. 
After multiple attempts to insertionally inactivate the candidate essential genes, a total of 
70 independent erythromycin resistant colonies were screened as above, for each target 
for the correct integration into the target gene. Out of the 140 possible integrants 
screened for CD0274, none contained an insertion at the target site. These results could 
suggest that CD0274 is essential in C. difficile, however further evidence was considered 
necessary to confirm this hypothesis.  
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In order to strengthen the evidence that the system being developed allows the 
identification of essential genes, the two other candidate essential genes, trpS and metK, 
were additionally targeted using the ClosTron system. In excess of 30 conjugations were 
required to obtain 70 independent erythromycin resistant colonies for each ClosTron 
target, and screened as before using the primers EBS and either Cdi-trpS-R1 for trpS, or 
Cdi-metK-F1 for metK. The 70 integrants were screened for each target, totalling 140 
for each gene. As seen before, none of the colonies screened contained an insertion at 
the target site. These results suggest that along with CD0274; metK and trpS cannot be 
insertionally inactivated, and as such, could be essential for survival.  
3.2.3   Testing the temperature sensitive nature of splicing of the group II intron 
It was previously noted by Yao et al, (2006)72, that the IED-assisted splicing reaction of 
the TargeTron system could produce conditional temperature-sensitive mutations in S. 
aureus72. It was shown that if the intron was inserted into the host chromosome in the 
VHQVHRULHQWDWLRQPHDQLQJWKDWWKHWDUJHWJHQH·VQDWXUDOSURPRWHUZDVWUDQVFULELQJWKH
intron, the IEP could splice the intron out of the target genes transcript at 32°C, but 
not at 42°C72. Although the exact temperature-sensitive mechanism is unknown, it was 
hypothesised that the inhibition of the RNA splicing was due to the temperature 
sensitivity of the intron RNA, the IEP, or a combination of them both72. 
To determine if the group II intron has the same RNA splicing temperature-sensitive 
characteristics in C. difficile as the group II intron in S. aureus, the two targets of metK; 
pMTL007C-E2:Cdi-metK-548s and pMTL007C-E2:Cdi-metK-676s, were employed to 
attempt to insertionally inactivate metK in the sense orientation. Each target was 
conjugated into the C. difficile host strain and transconjugants grown at 32°C or 42°C on 
erythromycin to select for RAM activation. To ascertain if an integration event had 
occurred, PCR screening for the correct insertion was carried out on 50 possible 
 
93 
 
integrants for each target at each temperature, using the same primer combinations as 
before. The results showed that no PCR positive colonies were obtained for either of 
the temperatures, and as such any possible insertions into metK were not viable (table 
3.2). Although the reason for this result is unknown, the only difference between Yao et 
al, (2006)72 and our study apart from the organism, was the presence of the RAM. The 
inability of the group II intron to splice out of the precursor mRNA might be due to a 
decrease in splicing efficiency caused by the increase in the overall group II intron size. 
This decrease in efficiency might decrease the expression of the essential gene, causing 
an ineffective protein concentration and subsequent lethal genotype. 
Table 3.2. Insertion frequencies of the group II intron re-targeted to metK 
using targets 548s and 676s at 32°C and 42°C in C. difficile 630¨erm. 
3.2.4    Construction of the CD0274 partial diploid plasmid 
In the first strategy investigated, an attempt was made to use the conditional 
temperature-sensitive nature of the IEP-assisted splicing of the group II intron to 
identify essential genes; unfortunately this method was not possible in C. difficile, so an 
alternative strategy by creating a partial diploid was attempted. A partial diploid is a term 
used to describe a cell which contains a second copy of only part of its genome50,73,101; in 
this case, the second copy is the target gene being tested. In theory, if CD0274 is 
essential, the presence of a second copy will allow the chromosomal copy of CD0274 to 
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be insertionally inactivated. If this disruption of the native CD0274 takes place, then the 
plasmid borne CD0274 will become the essential copy, and as such the plasmid would 
become 100% stable and should not be lost over time (figure 3.5).  
 
Figure 3.5. Graphical representation of the partial diploid method. (A) 
In the case of an essential gene, if the group II intron insertionally 
inactivates the essential target gene, the genotype is lethal and the cell is 
no longer viable. Due to this, the insertion cannot be identified as the cell 
does not grow. (B) If there is a second copy of the essential gene present 
upon plasmid pMTL-DW1, the group II intron can successfully 
insertionally inactivate the target gene, with the second copy functionally 
complementing the essential function, allowing the recombinant cell to 
grow. If the cell is able to grow, the integrated intron can be detected by 
PCR.  
Target
Essential gene
RAM
Group II intron
Essential gene
Gene Inactivation,
Cell NOT Viable
Target
Essential gene; Partial Diploid
RAM
Group II intron
Gene Inactivation,
Cell Viable
Essential gene; Partial Diploid
A
B
pMTL007C-E2
ClosTron Plasmid
pMTL007C-E2
ClosTron Plasmid
pMTL-DW1 pMTL-DW1
 
95 
 
Implementation of the partial diploid requires three different antibiotic resistance 
markers; thiamphenicol for pMTL007C-E2:cdi-dhaT-548a and -623a, erythromycin for 
selection of integration using the RAM, and a third for positive selection for the 
plasmid containing CD0274, thus C. difficile strain R20291 was used for this method. C. 
difficile R20291 is naturally sensitive to spectinomycin 750 µg/ml, whereas C. difficile 
ƅerm is not41. Therefore plasmid pMTL82151 was chosen, into which CD0274 and 
its native promoter of C. difficile R20291 were cloned, yielding plasmid pMTL82151-
PdhaT-dhaT.  
Within plasmid pMTL82151-PdhaT-dhaT, CD0274 contains the exact same nucleotide 
sequence as the native copy, therefore there needs to be a way to protect the gene from 
disruption, i.e. prevent the group II intron insertion. The group II intron is able to 
insert within a target site by recognising a 45 bp sequence. Each retargeted group II 
intron recognises a unique, highly specific sequence. It follows that, if the sequence is 
altered, the group II intron will not be able to recognise the altered target site, 
preventing insertion. To protect the second copy from the group II intron, the 
nucleotide sequence at the recognition sites of plasmids; pMTL007C-E2:Cdi-dhaT-548a 
and pMTL007C-E2:Cdi-dhaT-623a were silently altered, i.e. the changes made did not 
cause any alteration to the amino acid sequence of the encoded CD0274 gene product 
(figure 3.6). The site between the two ScaI restriction sites was chosen as it could be 
switched with the synthetically altered fragment with ease, and includes the two target 
sites for the plasmids pMTL007C-E2:cdi-dhaT-548a and -623a. This synthetic construct 
was designed using the gene designer software developed by DNA2.0 and synthesised 
by the same company and cloned into plasmid pMTL82151-PdhaT-dhaT, yielding pMTL-
DW1.  
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Figure 3.6. Protection of the synthetic partial diploid copy of the 
candidate essential gene. The group II intron recognises a 45 mer target 
site displayed by a box encompassing the two target sites for each 
candidate essential gene. In bold red is the silent nucleotide changes made 
in the synthetic protected copy of each candidate essential gene compared 
to the native gene, to alter the group II introns recognition sequence and 
block integration, but allow the same translated nucleotide sequence.  
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Plasmid pMTL-DW1 was conjugated into C. difficile R20291, followed by the ClosTron 
plasmids and subsequent disruption experiments were carried out to inactivate the native 
CD0274. It was noted that the conjugation efficiency of pMTL-DW1 was very low 
compared to the pMTL84151 empty vector control, and that the resultant pMTL-DW1 
transconjugants grew very slowly in comparison to the control, and could not be 
propagated onto fresh solid media, only liquid culture, growing to low cell densities 
overnight (OD600 0.1, compared to OD6001.2-1.6 for the parent strain). The 
transconjugants containing pMTL-DW1 were subjected to another round of conjugation 
to conjugate the ClosTron plasmids into the cell to allow subsequent insertional 
inactivate the native CD0274. This proved to be problematic, with no positive double-
transconjugants being obtained after 20 independent conjugation attempts. 
Transconjugants containing the ClosTron plasmids were obtained, but without the 
pMTL-DW1 plasmid being identified, suggesting either the double-transconjugants had 
not been detected or the pMTL-DW1 plasmid had been lost during the second 
conjugation. 
The four antibiotics used for selection and the presence of two plasmids could cause the 
double-transconjugants to take longer to grow than the single transconjugants, allowing 
background growth to dominate. C. difficile supplement was being used for negative 
selection against the E. coli after plating out the conjugation, but background growth was 
found to predominate after about 60 hours. Cycloserine and cefoxitin (C. difficile 
supplement) are both bacteriostatic antibiotics therefore once the antibiotic activity is 
decreased over time, the background growth becomes visible. Due to this, another 
antibiotic which lasts longer or is bactericidal to select against the E. coli donor would be 
advantageous. One such antibiotic is polymyxin B. To test the efficacy of polymyxin B 
compared to, and in combinations with, C. difficile supplement in selecting for double-
 
98 
 
transconjugants, conjugations were carried out using E. coli C600RK2 harbouring the 
ClosTron plasmids and the recipient C. difficile R20291 harbouring pMTL-DW1. It was 
found that polymyxin B was able to suppress background growth for a longer period of 
time, but it was not effective in combination with the C. difficile supplement. The reason 
for this is unknown. However, no double-transconjugants were obtained after further 
conjugations and screening. These results suggest that the plasmid pMTL-DW1 is being 
lost during the subsequent conjugation transfer of the ClosTron plasmid; therefore the 
order in which the plasmids were conjugated into C. difficile R20291 was reversed. 
8QIRUWXQDWHO\ WKLV GLGQ·W FLUFXPYHQW WKH SUREOHPV as no double-transconjugants were 
obtained. Other attempts at improving the stability of the plasmid by changing the 
Gram-positive replicon and changing the antibiotic resistance marker also proved to be 
ineffective.  
It would seem the presence of CD0274 upon a plasmid within C. difficile R20291 effects 
the growth of the cell dramatically, inhibiting the passage of pMTL-DW1 
transconjugants onto fresh agar, ultimately resulting in cells that rapidly loose the 
plasmid when selective pressure is removed. This apparent instability suggests that the 
presence of CD0274 leads to detrimental level of the DhaT protein. 
3.2.5    Construction of chromosomal partial diploid strains 
As it was not feasible to use the plasmid-borne CD0274 method to construct a plasmid-
based CD0274 partial diploid strain, an alternative strategy was investigated in which the 
gene was introduced into the C. difficile ƅerm chromosome using ACE (figure 3.7). 
ACE is a new method developed in our lab which allows integration of plasmid DNA 
into the chromosome without the need for a counter-selection marker (figure 3.8A). In 
conventional plasmid-based allelic exchange systems, the use of a positive selection 
marker is required to select for a single-crossover integration event which inserts the 
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plasmid DNA into the target chromosome, then the presence of a negative-selection 
marker within the integrated DNA is used to select for the second-crossover event and 
loss of the exchanged allele-containing plasmid, culminating in allelic exchange. ACE 
has a few important differences which circumvent the use of a plasmid-borne negative-
selection marker, allowing integration of cargo DNA into the pyrE locus, and producing 
only the genotype desired. The pyr operon of C. difficile is responsible for the 
biosynthesis of pyrimidine nucleotides with pyrE encoding an orotate phosphoribosyl-
transferase resulting in sensitivity to 5-fluoroorotic acid (5-FOA)102,103. Therefore, if the 
pyrE gene becomes inactivated, the mutant strain becomes resistant to 5-FOA as it can 
no longer utilise 5-FOA103. 
 
Figure 3.7. Comparison of the plasmid and chromosomal partial diploid 
strategies (A) The strategy used in chapter 3.2.3. The plasmid pMTL-
DW1 containing a protected copy of CD0274 able to functionally 
complement the native copy, allowing the native copy to be inactivated 
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via ClosTron (B) Due to the strategy in (A) not working, a second 
strategy of placing the protected second copy within the chromosome 
was undertaken. This second copy functions in the same way as the 
native copy, allowing the native to be inactivated only in the presence of 
the ectopic protected copy.  
In the first instance, metK was used to test the chromosomal-borne partial diploid 
system. As was the case with CD0274, a synthetic version of metK was constructed 
which contains silent mutations at the recognition sites for the two re-targeted group II 
intron ClosTron plasmids; pMTL007C-E2:Cdi-metK-548s and pMTL007C-E2:Cdi-metK-
676s, between nucleotides 516 and 686, but keeping the same translated nucleotide 
sequence (figure 3.6). This construct was subsequently cloned into plasmid pMTL-
JH18, yielding plasmid pMTL-JH18-metK. The synthetic construct is now flanked by a 
300 bp internal fragment of pyrE DWWKH·DQGDES'1$IUDJPHQWKRPRORJRXVWR
the sequence downstream of pyrE at the · $lso present on the plasmid is a catP 
chloramphenicol/thiamphenicol antibiotic resistance marker, and the pIM13 replicon.  
The E. coli strain CA434 was used as a conjugative donor strain to transfer the pIM13 
based plasmid pMTL-JH18-metK into C. difficile using standard conjugation techniques90. 
The pIM13 replicon is replication defective in C. difficile89. Consequently, as the catP gene 
responsible for thiamphenicol resistance is carried by the pMTL-JH18-metK, the growth 
rate of the transconjugants in the presence of thiamphenicol is restrained by the rate at 
which the plasmid replicates. Integration of the plasmid by single-crossover integration 
and concomitant relocation of the catP gene to a chromosomal location removes this 
constraint, allowing the cells to grow faster in the presence of thiamphenicol. Such 
single-crossover integrants therefore have a growth advantage in antibiotic 
 
101 
 
supplemented media. The single-crossover event can, therefore, be selected through the 
isolation of faster growing colonies.  
The integration of the plasmid is dependent on homologous recombination of the two 
homology arms which flank the gene (metK) to be integrated. In classical methods of 
allele exchange, the two homology arms are of equal length to stop bias of which arm 
recombines in the first crossover event. In ACE the homology arms are asymmetric, 
with the left-hand homology arm (LHA) being 300 bp long, and the right-hand 
homology arm (RHA) being 1200 bp in length. This 3:1 ratio of right-hand to left-hand 
length difference allows the RHA to recombine in the first cross-over event at a much 
greater frequency than the shorter LHA. Integrants at the RHA, therefore predominate. 
Such cells retain sensitivity to 5-FOA as a functional, intact copy of pyrE is still present. 
Using this principle, 5 individually derived single-crossover colonies were purified and 
enriched by sub-cloning on fresh BHIS supplemented with thiamphenicol and C. difficile 
supplement.  
Next, the second-crossover event occurs between the smaller 300 bp LHA. There are 
theoretically two possible outcomes of this recombination event, the type strain in 
which the original integrated plasmid carrying the mutant allele is excised, or the desired 
genotype in which the plasmid excises together with the type strain allele. The net result 
is allelic-exchange. To select for the desired event, single-crossover colonies are re-
streaked onto C. difficile minimal media supplemented with 5-FOA to select for the 
creation of the mutant cell. As pyrE becomes inactivated, the media is also 
supplemented with uracil to allow the growth of the created auxotroph. After 24hours, 
5-FOA resistant colonies are large enough to pick, and undergo patch plating on BHIS 
or BHIS supplemented with thiamphenicol to identify the colonies that are 
thiamphenicol sensitive due to the loss of the excised plasmid. Loss of the plasmid is 
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important to prevent further recombination events. The 5-FOA resistant colonies are 
then subjected to PCR screening using primers that amplified across the insertion locus 
to confirm allelic exchange has taken place at the desire site (figure 3.8C). 
As this method of introducing the metK into the chromosome at the pyrE locus was 
shown to be successful, the other candidate essential genes, CD0274 and trpS, were also 
delivered into the chromosome using an identical procedure. As with metK and CD0274, 
trpS also needs to be protected from group II intron targeting. The nucleotides around 
the two ClosTron target sites were silently altered for each target gene(figure 3.6). In 
addition, as trpS forms part of an operon, and therefore lacks a promoter immediately 
XSVWUHDPRILWV·-end, the thiolase promoter of C. sporogenes was positioned immediately 
upstream of the coding region. The candidate essential gene was subsequently cloned 
into plasmid pMTL-JH18 giving rise to plasmid pMTL-JH18-trpS. Both candidate 
essential genes, CD0274 and trpS, were introduced into the C. difficile 630¨erm 
chromosome as before, and their expected insertion confirmed by PCR(figure 3.8D).  
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Figure 3.8. DNA integration at the pyrE locus of C. difficile 630¨erm (A) 
Selection of double-crossover clones using plasmid pMTL-JH18. The 
first recombination event is directed by the long right-hand homology 
arm consisting of 1500 bp downstream of pyrE on the C. difficile 630¨erm 
chromosome. The resulting single-crossover clones have their replication 
deficiency conferred by pIM13 alleviated allowing them to grow quicker 
B.
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than the freely-replicating plasmid containing cells. Subsequently, the 
second crossover event between the 300 bp left homology arm of 
pMTL-JH18 containing an internal fragment of pyrE completes the 
allelic-exchange. Two possible outcomes can occur, the parent strain or 
the double-crossover clone. To select only for the desired event, 
selection on 5-FOA allows only pyrE- strains (double-crossover clones) 
to grow. (B) PCR screening of 3 CD0274 double crossover clones using 
primers Cdi630-pyrE-F2 and Cdi630-CD0189-R2 which anneal on the 
parent strain chromosome flanking the insertion site. MW is a 2-log 
DNA Ladder (NEB) molecular weight marker, lane 1 is water only 
negative control, lane 2 is (expected size ~2 Kbp) C. difficile 630¨erm 
DNA control, lanes 3-5 are candidate clones (expected size ~ 3.3 Kbp). 
(C) PCR screening of 3 metK clones using the same primers and order as 
(B) (expected size ~ 3.3 Kbp). (D) PCR screening of 3 trpS clones using 
the same primers and order as (B) (expected size ~ 3 Kbp). 
3.2.6    Inactivation of CD0274, trpS, and metK in a partial diploid strain 
The insertion of the candidate essential genes in to the chromosome allows the 
functional complementation of the native candidate essential genes. This in theory 
means that the native candidate essential genes are no longer essential due to the second 
ectopic copy taking over the essential function96, allowing the native copy to be 
insertionally inactivated using the ClosTron38. To test this, each partial diploid strain was 
subjected to the ClosTron procedure to disrupt the native copy. 
After the selecting for erythromycin resistant colonies representing integration of the 
group II intron, 20 colonies for each ClosTron target was screened by PCR using the 
same primers as used before which amplify across the intron-exon junction of the 
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intron insertion. Each target showed a high frequency of integration ranging from 75% 
for the 623a target of CD0274, to 100% for targets: 548a of CD0274 460a of trpS, and 
both targets of metK (table 3.3B). This result demonstrates that; the targets used in this 
study can efficiently target the group II intron to insert at its respective target site, and 
that these candidate essential genes can only be insertionally inactivated in the presence 
of a second protected copy, identifying them as essential for viability. 
 
Table 3.3. Insertion frequencies of the group II intron re-targeted to 2 
target sites for each of the 3 candidate essential genes in C. difficile 
630¨erm at 37°C. (A) Attempted candidate essential gene inactivation 
using the group II intron in C. difficile ƅerm parent strain. (B) 
Attempted candidate essential gene inactivation using the group II intron 
in the ACE created partial diploid.  
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3.3 Discussion 
Over the past 10 years, the search for novel antimicrobial targets and agents to treat 
CDI has acquired an increased sense of urgency. Current front-line broad-spectrum 
antimicrobials are starting to waiver, with the sporadic emergence of resistant strains 
and increasing rates of relapse following successful treatment. The identification of 
novel antimicrobial targets is essential if CDI is to be controlled in the coming years5-
10,13,14,38,104-112. The reason for our lack of novel drug targets and essential genes is largely 
a consequence of the availability of woefully inadequate methods for generating 
clostridial mutants38,41.  To date, only a single putative gene has been identified as 
essential in C. difficile39,40. CD0274 was identified through the generation of a single-
crossover mutant using a replication-deficient plasmid. Cells with the desired mutant 
genotype appeared to be lethal, with the mutant cells being unable to be propagated40. 
Whilst this strategy appears to have provided reasonable preliminary evidence that 
CD0274 is essential, it was reliant on the transient, detectable growth of the mutant, in 
WKH IRUP RI ¶SLQ-SULFN· FRORQLHV 7KXV LQ WKLV LQVWDQFH JURZWK RI WKH RUJDQLVP ZDV
possible until the build-up of a toxic metabolite curtailed further multiplications. Such a 
strategy could, therefore, only be applied to similar circumstances and would not be 
applicable when a particular gene and its encoded product was absolutely required for 
growth. Moreover, the use of single-crossover mutants can complicate interpretation of 
data, due to the reversion to the type strain following excision of the plasmid as a 
consequence of recombination between duplicated DNA. 
In this study, we wanted to develop a method to more definitely identify essential genes 
in C. difficile, and a procedure that could be more universally applied. After 
demonstrating that the candidate essential genes were not able to be insertionally 
inactivated using the ClosTron, we tested the temperature sensitivity of the group II 
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intron as it had been previously shown that the TargeTron system could be used to 
identify essential genes in S. aureus72. To test out this ability in C. difficile using metK as the 
target gene and the pMTL007C-E2 ClosTron plasmids targeted to metK, we attempted 
to insertionally inactivate metK at both temperatures. Unfortunately this technique did 
not provide any integrants with an insertion in the target gene, even at the permissive 
temperature. The reason for this is unknown but suggests that intron splicing of the 
metK mRNA is insufficient for the production of MetK at a viable level. The big 
difference between the method employed here and Yao et al·VZLWKWKHH[FHSWLRQ
of the organism, was that they did not use a RAM to positively select for integrants, 
whereas we did72. This could mean that the increase in size of the intron decreases 
mobility frequency of the IEP-assisted intron splicing to a level below effective 
expression for viability of the cell62. If the RAM was removed from the intron to 
counteract this, the proportion of cells in which an integration event had taken place 
would be very low compared to the population. This low frequency would make the 
successful isolation of an integrant challenging. 
In other bacterial species such as M. tuberculosis, a partial diploid in which a second copy 
of the essential gene is present within the cell is used to functionally complement the 
native essential gene, allowing the native copy to be inactivated95,96. Unfortunately our 
attempts at this method with CD0274 were unsuccessful. Multiple attempts at 
conjugating the partial diploid plasmid into C. difficile failed to provide stable 
transconjugants which could be propagated. Efforts to overcome this instability by 
changing the Gram-negative replicon and/or resistance marker were unsuccessful. It 
was hypothesised that the increased gene dosage of CD0274 that results from its 
localisation to a plasmid is detrimental to the cell. 
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In order to overcome the instability seen in the plasmid-based partial diploid method, 
we used a second protected copy of a candidate essential gene and created a stable 
partial diploid by inserting the gene into the chromosome using ACE. Using these 
strains, we were able to insertionally inactivate the native copy of the essential genes 
using the ClosTron system with high frequency and efficiency only when the second 
copy was present. Using this approach, we identified three genes which are essential for 
viability in C. difficile; CD0274, trpS, and metK. Although the reason why CD0274 is 
essential is unknown, it has been hypothesised that it is involved in detoxification of 
toxic metabolite39,40. At present, this is the only known reported method to functionally 
demonstrate essentiality of a gene in C. difficile. However, this novel exploitation of the 
group II intron could be used in any bacteria that the TargeTron/ClosTron system is 
viable in. Further research on the subject could be very advantageous in identifying and 
characterising potential drug targets for the treatment of CDI and other bacterial 
infections. 
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Chapter Four 
Development of Clostridium Conditional Expression Systems 
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4.1  Introduction 
The combination of biochemical, physiological and genetics studies in genetically 
engineered bacteria have provided a wealth of information for studying essential 
biochemical processes113-115. Such examples include; enhanced or ectopic transcription 
and translation of enzymes and regulatory proteins, and the expression of anti-sense 
RNA which interferes by sequestering mRNA116, decreasing translation of a gene 
product.  
Conditional expression of a gene or operon is a means to control transcription or 
translation by the addition of an external stimulus (inducer)113,116-119. Conditional 
expression systems are of great importance due to their ability to control any desired 
gene expression throughout the cells growth. One such application for conditional 
expression systems is the means to identify essential genes67,72,80,116,120. By placing a 
candidate essential gene under conditional control, cell viability is dependent upon an 
inducer being present46,47,65,115,121,IQRLQGXFHULVSUHVHQWWKHFDQGLGDWHHVVHQWLDOJHQH·V
expression is turned off, and as a result the genotype is lethal45,46,52. This is direct 
evidence that defines a gene as essential, rather than non-essential. Using conditional 
expression also allows the strain to be used for further analysis, as opposed to the 
genotype being lethal.  
There are two main ways to control gene expression in prokaryotes, by controlling 
transcription67 or translation1,122. Current methods to control transcription use a class of 
promoter which is able to modulate levels of RNA polymerase II-dependent 
transcription in response to a signal113. Controlling translation is not as common, but 
recently advances in riboswitch117,122,123 and anti-sense RNA39,47,116,124 have allowed 
researchers to harness the potential of using such regulatory systems. 
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4.1.1     Inducible promoter systems 
A broad range of promoters that differ in their ability to modulate the temporal and 
spatial expression patterns of target genes are currently available in other bacteria119; 
unfortunately, no such appropriate systems had been developed in Clostridium species at 
the start of this project. Recently however, a tetracycline inducible promoter system has 
been used in C. difficile120. As the name suggests, inducible promoters are able to 
modulate transcription by the presence or absence of an external stimulus. There are 
two main groups of inducible promoters, the physically-regulated promoters; whose 
promoters are regulated by physical stimuli such as light or temperature125, and 
chemically-regulated promoters; whose promoters are regulated by a variety of chemical 
compounds126-128. Due to our requirements, chemically-regulated promoters would be 
more suitable as varied concentration of inducer can be applied easily, a favourable 
characteristic. In other bacterial species, there are a number of small molecule 
chemically-regulated promoters, including the lac repressor system, and the Tet 
system126-128. 
The lac repressor system is based upon the natural regulation of the lac operon of E. coli, 
a paradigm for negative control of gene expression at the transcription level. The lac 
operon is required for the transport and metabolism of lactose68. It consists of three 
structural genes; lacZ (Ƣ-galactosidase), lacY Ƣ-galactoside permease), and lacA Ƣ-
galactoside transacetylase), co-transcribed from the promoter Plac immediately upstream 
into a polycistronic mRNA molecule (figure 4.1)129. Contained within the promoter are 
three operator sequences which are capable of binding the repressor molecule LacI, 
transcribed upstream of the operon130. In the absence of lactose, LacI is produced and 
binds to the operator sequences of Plac, inhibiting RNA polymerase II-dependant 
transcription130. RNA polymerase II-dependant transcription resumes when the 
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repressor molecule is removed from the operator binding sites by an inducer130. The 
LQGXFHU ELQGV WR WKH /DF, UHVXOWLQJ LQ D FRQIRUPDWLRQDO FKDQJH ZKLFK GHFUHDVHV LW·V
affinity to the operators significantly, thereby inhibiting the binding of the repressor to 
the operators, allowing transcription of the operon68. In the natural system, lactose is 
converted to allolactose by Ƣ-galactosidase (the product of the lacZ gene) which acts 
upon LacI. However, as allolactose can be metabolised by the cell, the levels of inducer 
decrease over time, therefore the non-metabolized lactose analogue isopropyl-thio-b-D-
galactoside (IPTG) is used (Figure 4.2)131.  
 
Figure 4.1. Natural regulation of the lac operon of E. coli. (A) The lac 
operon of E. coli contains three genes; lacZ, lacY, lacA, under 
transcriptional control of a promoter upstream of lacZ containing three 
lac operators. Upstream of the operon is lacI whose gene product LacI is 
able to bind to the lacO (red square designated with O above) thereby 
inhibiting RNA polymerase II-dependant transcription (yellow thought 
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bubble). (B) In the presence of lactose, LacZ converts lactose to 
Allolactose (blue circle) which is able to able to bind to and cause a 
conformational change in the structure of LacI (diagonally shaded 
brown/blue square), disabling its ability to bind to lacO, allowing RNA 
polymerase II to bind to the lac operon promoter and transcribe the 
operon, which in turn allows E. coli to utilize lactose as an energy source. 
(C) In the absence of lactose, LacI (brown square) is able to bind to lacO, 
inhibiting transcription of the operon.  
 
Figure 4.2. Diagram showing the structural differences between 
allolactose (left), and its structural non-metabolised analogue, IPTG 
(right). 
Another commonly used inducible promoter system is the Tet system69,114,118,119,126,132,133. 
Tetracyclines are among the most commonly used class of broad-spectrum antibiotics. 
They are able to inhibit polypeptide elongation by binding to the small ribosomal 
subunit, although the exact mechanism is unknown118. As with most antibiotics, many 
Gram-negative bacterial species have developed resistance mechanisms to overcome 
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WHWUDF\FOLQH·V 7F OHWKDOLW\134. The most commonly used mechanism employs tetA, a 
membrane-associated protein that is able to actively export the antibiotic out of the cell, 
thereby stopping its action against the small ribosomal subunit118. High levels of tetA 
expression is lethal to the bacterial cell due to the nonspecific cation transport leading 
to a collapse of the cytoplasmic membrane potential, therefore regulation of tetA is 
under tight control118,119. Up-stream of tetA and divergently orientated is tetR, whose 
transcription is mediated by divergent promoters containing two palindromic tetR 
operators (tetO1 and tetO2) 11 bp apart118,119 (figure 4.3). Expression of both tetA and tetR 
is controlled by the tetR gene product, a homodimer capable of binding to the 
palindromic DNA operator sequence which inhibits RNA polymerase II-mediated 
transcription113,114,118,119,133,135. As the mode of action of Tc is to inhibit protein synthesis, 
the tetR/tetA switch has to be particularly sensitive; meaning very low levels of Tc can 
induce tetR/tetA expression. In the absence of Tc, the tetR gene product is expressed 
and binds to the tetOs, inhibiting tetA and tetR expression (Figure 4.3A). However, in 
the presence of Tc, Tc coupled with Mg2+ binds to TetR causing a conformational 
change, decreasing the affinity of TetR to the tetOs by nine-orders of magnitude 
compared to TetR alone (Figure 4.3B)118.  This difference in affinity allows the silent 
(TetR bound to tetO) and the active (TetR bound to [MgTc]+) to be delineated and sub-
inhibitory concentrations of Tc allow transcription to proceed. Due to the nature of Tc 
being an antibiotic, the Tc analogue anhydrotetracycline (aTc) is commonly used as a 
replacement. It has the higher affinity for TetR compared to Tc, but has a decreased 
toxicity136. 
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Figure 4.3. The natural tetA and tetR repressor system of E. coli. (A) In 
the absence of Tc, the TetR repressor (olive square) is able to bind to the 
two tetO operator sites (red squares) inhibiting RNA polymerase binding 
to the divergent promoters which control transcription of tetA and tetR. 
(B) In the presence of Tc (blue circles), Tc binds to Mg2+ which 
subsequently binds to TetR triggering a conformational change which 
GHFUHDVHV 7HW5·V DIILQLW\ WR the tetOs by nine orders of magnitude, 
allowing binding of RNA polymerase II and transcription of tetR and 
tetA. As a consequence, TetA (white cloud) binds to [MgTc]+and pumps 
the Tc out of the cell, thereby conferring resistance to Tc.  
 
The Tet system is unique in that with a few base pair mutations of the class B TetR, 
TetR shows an increased affinity to tetO, instead of the aforementioned decrease upon 
binding of the inducer to the effector protein133,137. This reverse Tet repressor depends 
tetA
tetA
tetR
tetR
No expression of tetR or tetA - Absence of Tc
TetR
Expression of tetR and tetA - Presence of Tc
A
B
TetR
+TcMg
Tc TetA [MgTc]
Pumped out of the cell
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on the specific mutations, originally identified using random mutagenesis, causing TetR 
to form a non-inducible conformation when no Tc is present (Figure 4.4A)137. 
However, when [MgTc]+ binds to TetR, the protein undergoes a conformational change 
which increases its affinity to tetO (Figure 4.4B). Due to these characteristics, the Tet- 
and Tet-reverse systems are the most efficient inducible systems for transcriptional 
regulation currently known; as such they are commonly used for targeted gene 
regulation in prokaryotes and eukaryotes118.  
 
Figure 4.4. The synthetic revTetR system. (A) In the absence of Tc, the 
revTetR repressor (light blue square) is unable to bind to the tetO (red 
squares) sequences. (B) In the presence of Tc (blue circles), Mg2+ binds 
to Tc which subsequently binds to the revTetR protein causing a 
conformational change (two tone blue square) which increases revTetR 
affinity to tetO, bringing about binding. This binding of the revTetR 
repressor to its complementary tetO sequence inhibits transcription of 
the target genes. 
Target Gene
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4.1.2    Riboswitches 
Riboswitches are natural RNA aptamers that are able to modulate translation of a high 
number of bacterial metabolic genes in response to small molecule ligands without the 
need for proteins1,97,122. There are two structurally significant features of riboswitches; 
the aptamer domain which recognises the ligand, and the expression platform which 
links the ligand-binding to a change in gene expression1. Recent studies have identified a 
variety of synthetic riboswitches which respond to nonendogenous small molecule 
ligands138. Synthetic riboswitches can be, in principle, engineered to respond to any 
permeable, non-toxic molecule that can interact with RNA. As such, synthetic 
riboswitches have great potential to detect and respond to theoretically any small 
molecules in a ligand-dependant fashion to modulate gene expression levels of any 
target gene.  
Identification of aptamers that bind to small molecules have been previously 
demonstrated123, however, developing the aptamers into a functional riboswitch has 
proved difficult in the past. A procedure called SELEX (systematic evolution of ligands 
by exponential enrichment) allows isolation and amplification of RNA or DNA 
nucleotides with selective affinity for specific small molecule ligands117,138. This 
technique has allowed the identification of RNA oligomers that are capable of binding 
with high affinity and specificity to both proteins and small molecule targets including; 
T4 DNA polymerase, adenosine-5'-triphosphate (ATP), theophylline, and several amino 
acids117. The theophylline ligand is an unusual ligand compared to the others as 
theophylline is not found in prokaryotes, as such; there are no natural aptamers in the 
bacterial genome. Identification of the theophylline ligand was carried out by generating 
a pool of 1014 RNA molecules that contain a 40-nucleotide region of random 
sequence117. Affinity chromatography was then carried out using theophylline cross-
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linked to a sepharose column. Any RNA bound to the theophylline was converted to 
DNA, PCR amplified, then sequenced to ascertain the sequence of the bound RNA. 
From this the authors identified a number of RNA ligands capable of binding 
theophylline with an affinity of 10,000 times greater than caffeine, which only differs in 
its structure by a single methyl group at the N-7 position117.  
The ligand is only the first part of a riboswitch, the second is expression platform. 
Soukup and Breaker, (1999)123, were able to bind a pre-existing catalytic and aptamer 
domain via a structural bridge. In this case, the authors bound aptamers of FMN (flavin 
mononucleotide), theophylline or ATP to a 32P-labeled self-cleaving ribozyme with 
varying lengths of bridge sequence connecting the two123. Using these constructs the 
authors showed it was possible to construct precision RNA molecular switches that 
trigger translation only in the presence of their corresponding ligand123. This 
simultaneous use of rational and combinational approaches to enzyme engineering will 
prove to be a powerful approach in the design of new ribozymes and riboswitches with 
enhanced kinetic characteristics. This would be hugely advantageous for applications in 
directed evolution or metabolic engineering. 
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4.1.3  Aim of this study 
Research into the molecular microbiology of Clostridium species has been limited by the 
lack of tools that most bacterial geneticists take for granted. Inducible systems are one 
of the most fundamental tools used in the biochemical, physiological and genetic 
studies, providing a wealth of information in a vast array of areas. However, inducible 
systems have remained problematic in Clostridium species, with very few shown to work 
or the inducers being metabolised, therefore inappropriate for our work.  
The aim of this chapter was to develop a genetic tool able to modulate transcription or 
translation in the presence of a small molecule ligand that meets the criteria of tight 
repression in the absence of an inducer, low likelihood of gratuitous induction, and 
good bioavailability.   
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4.2  Results 
4.2.1.1 Design and construction of a Clostridium lac repressor system 
Over the years, a multitude of inducible expression systems have been developed for 
use in controlling gene expression in many bacterial species, unfortunately there had 
been no system developed in C. difficile that have met the required criteria for our use at 
the time of this study. There are several characteristics which would make an inducible 
promoter system desirable. Ideally, the promoter system would work in a number of C. 
difficile strains, and hopefully different species of Clostridium as there is a wide variety of 
Clostridium that are medically or industrially important. It would be easy to add and 
remove the inducer in vitro or in vivo depending on the environment of the Clostridium 
(mammalian cells or bioreactor). It would have a wide range of activity based upon the 
concentration of inducer added, combined with tight repression in the absence of the 
inducer. The bioavailability of the inducer must be high, i.e., the administered dose of 
the inducer that is inside the cell must remain unchanged and not metabolised by the 
cell. These characteristics would allow high production of the target gene·V product for 
potential purification or analysis of the effects on phenotype or over production. 
Addition of the inducer would increase/decrease target gene expression rapidly for 
short-term studies on phenotype. The range of response to inducer would allow a 
specific controlled dose-responsive range of target gene expression, and tight repression 
ZRXOG OLPLW WKH ¶OHDNLQHVV· of the system and remove the possibility of toxic gene 
products becoming toxic to the cell, and in the case of essential genes, removal of the 
inducer would be lethal to the cell. Finally, the inducer concentration would remain 
unchanged over time allowing long-term studies of potential phenotypes. 
A classical-example of a plasmid-based system that met the above requirements is the 
lac repressor system68,126,129,139. The lac repressor system is currently used in many other 
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bacterial species, but has not been adapted for use in Clostridium effectively68,121,126,140. 
The addition of the non-metabolised inducer IPTG, is easy, subsequent effects are 
rapid, and the system is known to be dose-dependent, meaning an intermediate 
expression level can be obtained accurately (figure 4.5)126.  
 
Figure 4.5. Example of dose-dependent curve of the IPTG lacI 
inducible promoter system (PLlacO-1) from E. coli in response to varying 
concentrations of IPTG. Production is quantified as luciferase activity 
(arbitrary units). Adapted from reference126. 
Construction of the IPTG inducible promoter was carried out in silico using Clostridium 
components or components optimized for use in C. difficile. The functionality of the lac 
repressor system is based upon two main components; the LacI repressor, and the lacOs 
interrupting a promoter, which is placed in such a way that inhibition of transcription 
occurs upon repressor binding. As there is no natural lacI gene or lacOs present within 
C. difficile·s genome, the lacI gene from E. coli MG1655 was chosen to fulfil the 
expression of the repressor, as it is the best characterised. To increase the efficiency of 
translation in C. difficile, lacI was codon optimized by DNA2.0 using their proprietary 
algorithm.  
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It has been shown that a high ratio of repressor expression to operators is required for 
tight repression of the target gene116. Due to this requirement, an rrnA promoter from 
C. sporogenes was chosen due to its function; it should, and has been shown to be 
constitutively expressed throughout growth41. The usage of a C. sporogenes promoter over 
a C. difficile promoter was selected to decrease the possibility of homology to the 
chromosome, which may lead to homologous recombination between the plasmid and 
the chromosome. It is thought high-expression of LacI is toxic to the cell; therefore the 
rrnA SURPRWHUZDV¶ZHDNHQHG·E\WKHUHPRYDORIRUESIURPWKHVSDFHUVHTXHQFH
between the -35 and -10 of the promoter (figure 4.6). The removal of the basepairs of 
the spacer sequence was based upon the findings of Jensen and Hammer, (1998)141, that 
promoters with a 16 bp spacer were significantly weaker than their 17 bp counterparts. 
The basepair(s) selected for removal were chosen at random. However, during synthesis 
of the two constructs, it was found that it was not possible to synthesise pMTL-DW17 
or pMTL-DW18 without errors in the rrnA promoters, possibly due to the high volume 
of LacI production causing toxicity. Because of this, we selected to use the mutant 
variations of the two promoters isolated by DNA2.0 (shown in figure 4.6.) to transcribe 
lacI. 
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Figure 4.6. The original PrrnA sequence and the two variations PrrnA-1 and 
PrrnA-2 showing the removed basepairs in the spacer sequence between the 
-35 and -10. Below those marked with asterisks are the two mutated 
promoters isolated with the mutations shown in red. 
To obtain high levels of target gene transcription modulation, the ferredoxin promoter 
of C. sporogenes was chosen for the same reasons as the previous promoter. The 
positioning of the lacO within the context of the promoter is crucial for inhibition of 
RNA polymerase II binding and subsequent transcription of the target gene, because of 
this, two different lacO configurations were designed (Figure 4.7). The first lacO 
configuration is the perfect palindromic synthetic operator Oied
142. It has previously been 
shown that the synthetic Oied has a higher affinity to LacI resulting in higher repression 
than the natural lacOs139,142. Due to this knowledge, the first inducible promoter was 
designed to have a single Oied at the ·RI Pfdx, as this has been previously demonstrated 
to work effectively68. The second lacO configuration contains two lacOs, the O1 
PrrnA -35 -10
AAAAAAGTGTTGACAAGTTTAAAAAAAACTTGTATACTGTAAAAGTCG
PrrnA-1 -35 -10
AAAAAAGTGTTGACAAGTTTAAAAAAACTTGTATACTGTAAAAGTCG
PrrnA-2 -35 -10
AAAAAAGTGTTGACAAGTTTAAAAAACTTGTATACTGTAAAAGTCG
PrrnA-1*                       -35 -10
AAAAAAGTGTGGACAAGTTTAAAAAAACTTGTATACTGTAAAAGTCG
PrrnA-2* -35 -10
AAAAAAGTGTTGACAAGTTTAAAAAACTTGTATTCAGTAAAAGTCG
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(strongest natural lacO) in the same position as the other configurations Oied, and the O1 
positioned 95 bp upstream (This was a mistake, the distance separating the two 
operators should have been 70.5 bp. It was not corrected due to reasons that become 
apparent in section 4.2.1.2) due to a study conducted by Muller et al, (1996)139., that 
showed that the highest levels of repression was identified when the inter-operator 
distance was 70.5 bp139.  
 
Figure 4.7. Pthl inducible promoter sequences interrupted with lacOs. (A) 
Pthl interrupted with the synthetic Oied downstream from the -1 
transcriptional start site. (B) Pthl interrupted with two lacO sequences; the 
first Oied placed 95 bp upstream of the second O1 operator, which is 
positioned in the same place as the Oied from (A).  
The consensus RBS (AGGAGGA) from the alanyl-tRNA synthetase of C. sporogenes was 
selected for translation initiation of both lacI and the target gene to be induced, and 
placed 7 bp upstream of the start codon of each gene. As the orientation of the lacI and 
the inducible promoter are on the same strand, this increases the probability of read 
through interfering with the transcription of lacI from a gene upstream, depending on 
the genetic context, and the target gene from lacI·V SURPRWHU 7KHUHIRre, two 
transcriptional terminators were identified from C. tetani using WebGeSTer DB ² A 
7UDQVFULSWLRQDO7HUPLQDWRU'DWDEDVHDQGZHUHSRVLWLRQHGDWWKH·RIWKHlacI PrrnA, and 
·RI lacI. To facilitate easy removal or substitution of each component in the system, 
TCAATTGTGAGCGCTCACAATTCATAGAAAATATAGGTTATACAGTTATATAAAAATTACTTTAAAAATT
AATAAAAACATGGTAAAATATAAATCGAATTGTGAGCGATAACAATTTATAA
AAAATTACTTTAAAAATTAATAAAAACATGGTAAAATATAAATCGAATTGTGAGCGATAACAATTTATAA
-35 -10 Oied
Oied -35
-10                                                O1
A
B
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appropriate restriction sites were introduced between the components to allow easy 
cloning of new components, and to be compatible with the pMTL80000 modular 
vector series of plasmids89 (Figure 4.8).  
Finally, the purpose of this system is the systematic functional analysis of C. difficile 
genes using conditional mutations similar to the pMUTIN strategy previously 
published45. In this strategy, the inducible system is inserted into the chromosome 
EHWZHHQ WKH WDUJHW JHQH·V SURPRWHU DQG VWDUW FRGRQ WKHUHE\ DOORZLQJ WKH LQGXFLEOH
system to modulate expression in response to a ligand45. Integration of the system into 
the chromosome of C. difficile requires employing an allelic exchange system using a 
negative selection marker such as codA. There are theoretically two possible outcomes 
after the second-crossover event; the allelic exchange vector being excised resulting in 
the parent genotype, or the desired allelic exchange event resulting in a recombinant 
chromosome. To ensure that the recombinant genotype is selected, a positive selection 
marker was inserted upstream of lacI to form an operon. This allows the rapid 
identification of the recombinant cells through the selection of ermB by growing on 
erythromycin after the loss of the integration plasmid. This was originally designed in 
one of the two constructs, however, with the restriction sites present; the ermB can be 
cloned into the other construct with ease (Figure 4.7B). The two different constructs 
shown in Figure 4.8 were synthesised by DNA2.0 and cloned into pMTL82254 using 
the restriction endonuclease NotI and NdeI, to create plasmids pMTL-DW17 and 
pMTL-DW18. 
Once the constructs were synthesised, the double operator configuration of pMTL-
DW18 was digested using the restriction endonucleases SalI and AatII, and cloned in to 
plasmid pMTL-DW17, using standard cloning techniques, to create plasmid pMTL-
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DW17b. This allows the direct comparison of the operator configuration efficiency at 
repressing the catP reporter gene present upon pMTL82254. 
 
Figure 4.8. Schematic diagram showing the main features of the 
plasmids (A) pMTL-DW17 containing lacI and (B) pMTL-DW18 
containing both lacI and ermB. Each of the vertical lines above which a 
number (1-9) is placed represents the placement of restriction sites (listed 
on the far right) designed into the system for quick switching of 
components. The double hooped structures labelled T are 2 bidirectional 
transcriptional terminators positioned to inhibit any read-through from 
natural promoters upstream or into the inducible promoter. The small 
arrows indicate the position of the two promoters (PtRNA-1/PtRNA-2 and 
Pfdx) in each construct, and finally the red boxes with the letter O 
represent the positioning of the lacOs relative to the Pfdx. 
4.2.1.2 Testing the Clostridium lac repressor system 
In order to test if the synthetic constructs were constructed correctly and the system 
functions as expected, the plasmids pMTL-DW17, pMTL-DW17b, and negative control 
pMTL82254, were transformed into E. coli TOP10. The reason for carrying out the 
lacI O
lacI OO
A      pMTL-DW17
B      pMTL-DW18
1            2     3    4 5             6           7   8  9
1            2     3                               4                                             5          6               7 8 9
T T
T T
PtRNA-1
PtRNA-2
Pfdx
Pfdx
1 ± NotI
2 ± SacI
3 ± BamHI
4 ± XbaI
5 ± BglII
6 ± SalI
7 ± AatII
8 ± NdeI
9 - NheIermB
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initial testing in E. coli is because classical IPTG inducible promoter systems are known 
to work in E. coli, and therefore in theory, this system should also function in this host.  
The quantification of CatP production showed that there was no large difference in 
expression or repression of catP between the plasmids pMTL-DW17 and pMTL-
DW17b (Figure 4.8). It was noted that plasmid pMTL-DW17b had an increase in 
expression compared to pMTL-DW17 until 6 hours after IPTG induction, when 
expression levels started to decrease from its peak of 94,000 CAT U/mg protein, to 
90,000 CAT U/mg protein, whereas pMTL-DW17 peaked at 8 hours with a CAT level 
of 102,000 U/mg protein. After 8 hours, both plasmids showed a sharp decrease in 
CAT U/mg protein. Each plasmid showed its greatest induction at 8 hours after 
induction; pMTL-DW17 with a maximum induction factor (expression/repression) of 
8.45, and pMTL-DW17b with a maximum induction factor of 6.19. The downfall of 
this current system is the leakiness of catP expression without induction. However this 
does not equate to the systems characteristics in C. difficile. 
Hour Read
CA
T 
U/
m
g 
Pr
o
te
in
0 5 10 15 20 25
0
50000
100000 pMTL-DW17 IPTG
pMTL-DW17
pMTL-DW17b IPTG
pMTL-DW17b
pMTL82254
 
Figure 4.9. The production of CatP produced by plasmids pMTL-
DW17 and pMTL-DW17b  in E. coli with and without 1 mM IPTG over 
24 hours. E. coli cultures harbouring the plasmids pMTL-DW17 and 
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pMTL-DW17b were grown to an OD600 0.5 and either, allowed to 
continue growing or were induced with 1 mM IPTG. Each time point 
after induction (hour 0), CatP production was quantified (CAT U/mg 
protein). pMTL82254 is an empty vector control harbouring but not 
expressing catP. This data is only from a single experimental. 
Using plasmids pMTL-DW17 and pMTL-DW17b, it has been shown that the system 
works in E. coli, however surprisingly there is no difference in induction factors between 
the single and double operator configuration as expected139. As the system has been 
shown to work, the decision to test it in C. difficile was taken. Due to the requirement of 
a positive selection marker present within the inducible promoter system as described 
above, the ermB gene was cloned into plasmid pMTL-DW17 yielding plasmid pMTL-
DW18. To ascertain if the presence of the ermB gene upstream of lacI affects the 
production of CatP, the same experiment with pMTL-DW17b was carried out. The 
results showed that the presence of the ermB gene did not affect the modulated 
production of CatP, with no significant differences in induction factors recorded for 
either; pMTL-DW18, max induction factor 8.42, or pMTL-DW18b, max induction 
factor 6.45, compared to the absence of the ermB gene. 
To test the effectiveness of the systems in C. difficile, plasmids pMTL-DW17 and pMTL-
DW18 were conjugated into C. difficile using the standard conjugation procedure90 and 
tested appropriately (Materials and Methods, section 2.11.1). The results showed the 
system did not repress in the absence of an inducer, with the expression of catP in the 
presence and absence of IPTG being equal for both pMTL-DW17 and pMTL-DW18 
(figure 4.10). This suggests that the system is not being repressed, possibly due to low or 
no production of the repressor LacI. To test if the PrrnA-1* or PrrnA-2* are active in C. 
difficile, the promoters were amplified using primers PrrnA-F1 and PrrnA-R1, 
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introducing restriction sites NotI and Nde, DW WKH · DQG · UHVSHFWLYHO\  7KH 3&5
fragments were cloned into pMTL82254 and conjugated into C. difficile and analysed. 
The results showed that the mutations acquired during synthesis of pMTL-DW17 and 
pMTL-DW18 was deleterious to the promoter being viable in C. difficile, and as such, 
they are no longer active in the organism (Figure 4.10). This could account for the no 
repression identified in using pMTL-DW17 and pMTL-DW18. 
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Figure 4.10. Comparison of the levels of CatP production between 
different promoters transcribing lacI in plasmids pMTL-DW17 and 
pMTL-DW18. C. difficile ƅerm harbouring the palsmids was grown to 
an OD600 0.5 and either, induced with 1 mM IPTG or let to grow, for 4 
hours, afterwhich CatP production was quantified (CAT U/mg protein).  
Also, the strengths of PrrnA-1 and PrrnA-2 transcriptionally fused to catP in 
pMTL82254 were accessed after 4 hours growth past OD600 0.5 in C. 
 
130 
 
difficile ƅerm. The error bars indicate standard error of the means from 
three experiments. 
To circumvent this problem, another set of promoters were selected to act as the 
promoter for lacI transcription. The C. sporogenes promoters; Pfdx, PhydA, PrecA and PpyrE were 
amplified using the forward and reverse primers specific to each promoter, named 
according to the promoter, e.g. Pfdx was amplified using fdx-F1 and fdx-R1. The 
promoters were then cloned into the construct pMTL-DW18 to replace the PrrnA-1, using 
standard cloning techniques (Materials and Methods, section 2.9.4). To act as a positive 
control for reporter expression and inducible control for lacI expression, the 
aforementioned restriction enzymes were used to digest pMTL-DW18, and blunted 
with T4 polymerase to remove the promoter present, followed by a blunt end ligation. 
Each construct was conjugated into C. difficile and analysed as previously described, with 
an induction of 1 mM of IPTG for 4 hours, after which the cells were harvested and 
analysed using the CAT assay. The promoters used to transcribe lacI were also amplified 
from C. sporogenes DQGFORQHGLQWRS07/DWWKH·RIcatP to test for transcription 
activity in C. difficile and tested the same way as the promoter variations of pMTL-
DW18. 
Following analysis of the pMTL-DW18 lacI promoter variations, the results shown in 
figure 4.11 were unexpected. There was no measurable level of CatP production when 
the lacI repressor was expressed with the promoters: Pfdx, PhydA, or PpyrE, in the absence or 
presence of IPTG. However, when PrecA transcribes lacI, measurable levels of 1,562 CAT 
U/mg protein without IPTG, and 1,356 CAT U/mg protein induced with IPTG were 
detected, compared to no promoter transcribing lacI showing previously seen maximum 
levels of 7,256 CAT U/mg protein. The promoters were then cloned in front of catP to 
test the strength of each promoter. The strongest C. sporogenes promoter was Pfdx 
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showing 8,141 CAT U/mg protein, followed by PhydA at 4,968 CAT U/mg protein, PpyrE 
at 1,341 CAT U/mg protein, and finally PrecA at 146 CAT U/mg protein. The 
comparison of promoter strengths transcribing lacI shows that Pfdx, PhydA, and PpyrE are 
strong promoters in comparison to PrecA (Figure 4.12). This result suggests a super-
repressed state is being observed when a mid to strong promoter is expressing LacI, and 
the super-repression is not able to be reversed with the addition of IPTG. However, 
when the weaker PrecA promoter is initiating transcription of lacI, there is a low 
expression of catP which again, is not affected with the addition of IPTG. 
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Figure 4.11. Comparison between the strengths of the different 
promoters transcribing lacI in their ability to produce CatP in C. difficile 
ƅerm in repsonse to IPTG. Each promoter was transcriptionally 
fused to lacI in vector pMTL-DW18 and grown in C. difficile ƅerm to 
an OD600 0.5. Once the OD had been reached, 1 mM of IPTG was 
added to induce CatP production for 4 hours. Subsequently, CatP 
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production (CAT U/mg protein) was compared between cultures. This 
data is only from a single experiment. 
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Figure 4.12. The strength of different promoters in their ability to produce 
CatP in C. difficile ƅerm Each promoter was transcriptionally fused to 
catP in vector pMTL82254 and CatP production was quatified (CAT 
U/mg protein) 4 hours after growth from OD600 0.5. This data is only 
from a single experiment. 
4.2.2.1 Design and construction of a Clostridium theophylline-responsive riboswitch 
Riboswitches are RNA-encoded inducible elements, able to modulate gene translation 
in response to a ligand without the need for protein interaction117,123,143. The 
combination of a ligand recognition domain (aptamer) and an expression platform 
allows changes in gene translation in response to a ligand123. In nature, riboswitches are 
 
133 
 
widespread in both prokaryote and eukaryote genomes, being responsible for regulating 
gene expression for a number of metabolic processes97. In addition to naturally 
occurring riboswitches, the rise in synthetic riboswitches, identified through high-
throughput screening techniques and rational design, to respond to endogenous and 
non-endogenous metabolites have provided great tools for directed evolution and 
metabolic engineering117,123,143.  
To choose a riboswitch for modulation of gene expression in Clostridium species, the 
same criteria that were required for the lac repressor system were sought. The 
riboswitch would ideally work in a number of Clostridium species, display good 
bioavailability, be easy to add/remove inducer, and addition of inducer would result in a 
subsequent increase/decrease in target gene expression. One drawback to using a 
riboswitch is there is no wide dynamic range of dose-dependent expression in response 
to a ligand due to each switch only being able to turn gene expression on or off. The 
small range available is due to the difference in number of mRNA molecules that are 
exhibiting the on or off conformation within a cell.  
The synthetic theophylline-responsive riboswitch clone 8.1 developed by Lynch et al, 
(2006)1, was chosen for testing in C. difficile due to its induction factor of 36 being the 
most efficient riboswitch published1. Their riboswitch was identified by composing a 
library using oligonucleotide-based cassette mutagenesis1. Mutagenic primers with 
degenerate regions were designed to create randomised spacer sequences between the 
previously published theophylline aptamer mTCT8-4, and the RBS of the IS10-lacZ 
reporter gene (figure 4.13)1. Using the sequencing data from the high-throughput 
screen, the authors were able to make presumptions on the possible mechanism of 
action for the riboswitch clone 8.1. Using the program mFOLD, they predicted the 
VHFRQGDU\VWUXFWXUHVRIFORQHLQWKHUHJLRQH[WHQGLQJIURPWKH·RIWKHDSWDPHUWR
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WKH·RIWKHVWDUWFRGRQVKRZQLQILJXUH7KH\K\SRWKHVLVHGWKDWLQWKHDEVHQFHRI
the ligand, the aptamer is paired with the RBS and start codon, thereby inhibiting 
translation1. In the presence of the ligand theophylline, the experimentally determined 
secondary structure appears to free the RBS and the start codon, allowing translation to 
proceed. This appears in the calculated differences in Gibbs free energy between the 
two conformations, which is less than the difference of theophylline binding to the 
ligand. The difference suggests the conversion between the two conformations is 
thermodynamically favourable in the presence of theophylline. The mechanism of 
action is consistent with previous studies by de Smit and van Duin144-146, who noted that 
secondary structure in close proximity to the RBS drastically reduces translation 
efficiency of the downstream mRNA144-146. 
 
Figure 4.13. Predicted mechanism of action of the synthetic riboswitch 
clone 8.1 developed by Lynch et al, (2007)1. In the absence of 
WKHRSK\OOLQH OHIW WKH VHFRQGDU\ VWUXFWXUH RI WKH · P51$ ELQGV
H[WHQVLYHO\WR·UHJLRQZKLFKLQFOXGHVWKH RBS and start codon. In the 
presence of theophylline (right) the structure of the riboswitch shifts in 
such a way as to release the RBS and start codon, allowing translation to 
 
135 
 
initiate. The structure was predicted by mFOLD and confirmed by 
NMR1. Modified from reference1. 
Using this predicted mechanism of action, it is theoretically possible to make 
modifications to the sequence as long as the nucleotide secondary structure is 
complementary in both configurations, and the ligand is still able to bind to the 
aptamer.  Using this theory, the sequence of the clone 8.1 riboswitch1 at nucleotides 54 
and 56 were changed from A and G to C and T, respectively, to introduce an NdeI 
restriction site for cloning. Due to the requirement of modifying one side of the 
secondary structure, the complementary nucleotides 18 and 20 were changed from C 
and T to A and G respectively to create Thio1 (figure 4.14). The restriction sites NotI, 
SacI, and Bam+,ZHUH LQWURGXFHGDWWKH·VRWKHULERVZLWFKFRXOGEHFORQHG LQWRWKH
pMTL80000 series of modular plasmids89 using NotI and NdeI, and an appropriate 
promoter could be cloned into the restriction sites SacI and BamHI. The primers 
ThioF2 and ThioR2 were synthesised and annealed together using the method 
described in section 2.7.13. The oligonucleotide fragment was then cloned into to 
vector pMTL82254 using the restriction sites NotI and NdeI. Subsequently, the thiolase 
and ferredoxin promoters from C. sporogenes, and ptb, hydA, adc, DNAk, gyrA, and 
CD0200 from C. acetobutylicum, were amplified using primers the appropriate primers 
and cloned into the pMTL82254 vector containing the riboswitch, using the restriction 
sites SacI and BamHI, yielding plasmids: pMTL-V1P3n, pMTL-V1P1, pMTL-V1P2, 
pMTL-V1P4, pMTL-V1P5, pMTL-V1P6, pMTL-V1P7, pMTL-V1P8, respectively. 
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Figure 4.14. Predicted mechanism of action of Thio1. The mechanism 
of action is proposed to be the same as clone 8.1 shown in figure 4.13. 
The red star with black circumference represents theophylline, and 
aptamer binding location on the right conformation. Secondary structure 
predicted by mFOLD. 
The RBS present within the Thio1 riboswitch, is to our knowledge, not found in C. 
difficile, as such, it is possible it might not be able to initiate translation of CatP. 
Therefore, the decision was taken to develop two variations of the riboswitch which 
contain different RBSs. In the first instance, the RBS AGAAGAA was chosen as it is 
most likely initiates transcription for pyc in C. difficile. To build the new RBS into the 
riboswitch, a total of 22 nucleotides were changed to keep the secondary structure the 
same as riboswitch Thio1, without changing the sequence or structure of the proposed 
aptamer. This also included the addition of three basepairs at nucleotides 54, 55, and 56. 
+
_RBS
Start
Start
RBS
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To counter the addition of the three basepairs, the last complementary sequence 
between nucleotides 53 and 62 bp was increased by 2 bp, and the last nucleotide was 
not bound to a complementary nucleotide. The proposed structure and mechanism of 
action are shown in figure 4.15A, and the sequence alignment for Thio1 and Thio2 are 
shown in figure 4.15B. 
 
Figure 4.15. Predicted mechanism of action of Thio2. (A) The 
mechanism of action is proposed to be the same as clone 8.1 shown in 
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figure 4.13. The basepairs outlined in blue are the proposed theophylline 
aptamer. The basepairs outlined in red are the basepairs which were 
changed to introduce a new RBS and to keep the same complementary 
bases resulting in the same secondary structure. (B) An alignment of the 
riboswitch comparing Thio1, our original riboswitch, with the new RBS 
present upon Thio2. In total 13 basepairs were changed and 3 added to 
Thio2. Secondary structure predicted by mFOLD. 
Another variation of Thio1 was developed using the RBS AGGAGGA, as this RBS is 
known to initiate translation within C. difficile38,89. The introduction of the new RBS into 
the riboswitch was based upon the same theory as the design of Thio2, where the RBS 
was designed around the aptamer and mechanism of action being unchanged, but in 
order to conform to the secondary structure, a total of 26 nucleotides were changed, 
including the addition of 7 nucleotides between nucleotides 50 and 57. This was 
required to allow the riboswitch to conform to the same secondary structure in the 
absence of theophylline as it is the predicted lowest energy conformation the riboswitch 
FDQ IROG LQWR 7KLV LQFUHDVHV WKH FRPSOHPHQWDU\ ERXQG QXFOHRWLGHV DW WKH · WR 
compared with 6 for Thio1, which also includes a mismatch at nucleotide 58. This 
results in the RBS not being bound into the theophylline free mRNA riboswitch 
structure, however, the RBS is, and should be sufficient to inhibit translation. The 
proposed structure and mechanism of action are shown in figure 4.16A, and the 
sequence alignment for Thio1 and Thio2 are shown in figure 4.16B.  
Each newly designed riboswitch was cloned into pMTL82254 using the restriction sites 
NotI and NdeI and subsequently the same thiolase promoter used to promote 
transcription of pMTL-V1P3n was cloned into Thio2 and Thio3, making plasmids 
pMTL-V2P3n and pMTL-V3P3n. 
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Figure 4.16. Predicted mechanism of action of Thio3. (A) The 
mechanism of action is proposed to be the same as clone 8.1 shown in 
figure 4.13. The basepairs outlined in blue are the proposed theophylline 
aptamer. The basepairs outlined in red are the basepairs which were 
changed to introduce the 2nd RBS variation but keeping the same 
complementary bases resulting in the same secondary structure. (B) An 
alignment of the riboswitch comparing Thio1, our original riboswitch, 
with the new RBS present upon Thio3. In total 26 basepairs were 
= Aptamer
= Changed Basepair
= Theophylline
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changed and 7 added to Thio3. Secondary structure predicted by 
mFOLD. 
4.2.2.2 Testing the Clostridium theophylline-responsive riboswitch 
In the first instance, we decided to test Thio1 with a variety of different promoters to 
identify the induction factors of each promoter in E. coli. To do this, we transformed 
each of the 7 promoter variations of Thio1 into E. coli TOP10, along with negative 
control pMTL82254. The results showed that the Thio1 promoter variants were able to 
repress production of CatP tightly in the absence of theophylline, and induced it in 
response to addition of theophylline (figure 4.17). The strongest CatP production was 
pMTL-V1P5 (DNAk); with a peak production of 3,955.27 CAT U/mg protein, an 
induction factor of around 20.5, came as no surprise as it has been shown to be an 
extremely powerful promoter compared to other clostridial promoters, however, it has 
been suggested that DNAk may not be constitutively expressed in C. acetobutylicum 
(Hengzheng Wang, Unpublished). Thus, the second strongest promoter, thiolase, was 
selected for studying the other variations of riboswitches as it is known to be 
constitutively expressed41.  
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Figure 4.17. Comparison of the strength of different promoters placed 
upstream of the Thio1 riboswitch which is transcriptionally fused to the 
catP reporter system present on pMTL82254 within E. coli. Each Thio1 
promoter variation was accessed in its ability to produce CatP (CAT 
U/mg protein) in the presence (+) or absence of 2 mM theophylline 
after 4 hours from induction at OD600 0.5. The error bars indicate 
standard error of the means from three experiments. 
To test whether the two rationally designed riboswitches would work in E. coli, Thio2 
and Thio3 were tested using the thiolase promoter in the same way as the promoter 
variations in Thio1. The results showed that pMTL-V2P3n was able to repress CatP 
production to levels below the detection of the photo spectrometer, and upon addition 
of 2 mM theophylline was able to produce CatP to a level higher than the original 
pMTL-V1P3n (figure 4.18). Unfortunately, pMTL-V3P3n was not as successful and was 
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not able to repress CatP production in the absence of theophylline. As Thio2 was able 
to achieve greater induction than Thio1, the dynamic range of catP expression was 
characterised in response to varying concentrations of theophylline. To do this, pMTL-
V1P3n and pMTL-V2P3n were selected and treated in the same way as previously, 
except at OD600 0.5, the cultures were induced with either: 0, 1, 2, 5, 10, or 20 mM 
theophylline, and incubated for 4 hours, after which CatP production was quantified.  
The results were surprising in the fact that the riboswitches had a degree of dose-
dependence in response to increased concentration of theophylline up to 10 mM, which 
delivered the maximum production of CatP. At 20 mM, the production of CatP was 
reduced by around 50% compared to 10 mM. In light of these results for both Thio1 
and Thio2 in E. coli, the decision was taken to test the riboswitches in C. difficile. 
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Figure 4.18. Comparison of pMTL-V1P3n and pMTL-V2P3n in their 
ability to produce CatP in response to varying concentrations of 
theophylline in E. coli. The Pthl ZDVSODFHGDWWKH·RI7KLRDQG7KLR
riboswitches which are transcriptionally fused to catP present on plasmid 
pMTL82254. At OD600 0.5, the cultures were induced with varying 
concentrations of theophylline (0, 1, 2, 5, 10, 20 mM) for 4 hours, after 
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which CatP production was quantified (CAT U/mg protein). The error 
bars indicate standard error of the means from three experiments. 
In the first instance, the thiolase promoter was retained and a simple experiment to 
ascertain whether the riboswitches would work was carried out by growing a starter 
culture to OD600 0.5 and inducing with 10 mM theophylline for 4 hours, after which 
CatP was quantified. Unfortunately, neither riboswitches were able to elicit a response 
in the presence or absence of theophylline. In case the problem was promoter related, a 
selection of promoters including the ferredoxin promoter and DNAk were cloned into 
the riboswitches and varying concentrations of theophylline was used to induce the 
cultures, as well as carrying out longer induction times. Thio1 and Thio2 were still, 
however, unable to express CatP to a detectable level. As it could be possible the RBSs 
are not able to initiate translation in C. difficile, the RBSs alone for Thio1 and Thio2 were 
cloned downstream of the thiolase promoter and placed in the appropriate position to 
H[SUHVVWKHUHSRUWHURIS07/,QWKHFDVHRI7KLR·V5%6QRproduction of CatP 
was detected; however, the RBS of Thio2 was able to produce 7,200 CAT U/mg 
SURWHLQ LQ FRPELQDWLRQ ZLWK WKH WKLRODVH SURPRWHU VKRZLQJ WKDW 7KLR·V 5%6 GRHV
work as expected in C. difficile, and in-line with previous results (figure 4.11).  
4.2.3.1 Design and construction of a Clostridium Tet inducible promoter system 
Our preceding attempts to develop a Clostridium genetic tool able to control 
transcription using a lac repressor system, and translation using a theophylline-
responsive riboswitch, had proven challenging. A number of other inducible systems 
were considered for use in C. difficile, including the PXyl-xylR-inducible promoter from B. 
subtilis, and the arabinose-inducible PBAD promoter system from E. coli. Both, however, 
have deficiencies. The xylose-inducible promoter system is able to be repressed by the 
presence of glucose, which is commonly found within mammalian cells, therefore 
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invalidating its usage for in vivo studies114. This repression cannot be overcome easily by 
a higher concentration of the inducer, making the system un-controllable. The 
arabinose-inducible PBAD promoter system has been shown to be ineffective in S. 
aureus114 and B. subtilis, possibly due to poor penetration of arabinose into the Gram-
positive cells. The possibility of poor penetration does not bode well for the probability 
that the same occurrence would happen in C. difficile; therefore the selection of a system 
used commonly in Gram-positive bacteria would be advantageous. 
The Tet inducible promoter system, developed for use in B. subtilis and E. coli has been 
shown to work in many organisms including; S. aureus114, M. tuberculosis113, Streptococcus 
intermedius147, and most recently C. difficile120, it has even been shown to work in 
transgenic plants148 and mammalian cells149. The broad-range of hosts which this system 
is known to work in, the knowledge that tetracycline does in fact enter into the 
Clostridium cell, and has recently been shown to work in C. difficile120, means the system 
should work efficiently in Clostridium.  
Design of the Clostridium Tet inducible promoter system was based upon the 
architecture of the pRMC2 plasmid132, which in turn is based upon pALC2073114, 
derived from pWH35369, the original tetracycline-inducible promoter system.  The 
tetracycline-inducible Pxyl/tetO promoter from pWH353 was derived from the Tet 
regulatory element originating from the transposon Tn1069.  
All of these derivatives contain the Pxyl/tetO inducible promoter which transcribes the 
target gene, and the tetR repressor gene transcribed from the divergently orientated PtetR. 
One interesting point is the positioning of a second tetracycline operator between the -
35 and -10 of the PtetR. This means that in the absence of Tc, there is a negative feedback 
loop, repressing both the tetR gene and the gene of interest, however, in the presence of 
low levels of Tc/aTc, the repression is alleviated quickly due to the low expression of 
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TetR, allowing expression of both TetR and the gene of interest. This placement of the 
second tetO within PtetR means that the induction of Pxyl/tetO is very sensitive, giving the 
inducible promoter a limited intermediate range (figure 4.19)126. 
 
Figure 4.19. A comparison between the dose-dependent activation of 
transcription and the dynamic range of the Tet inducible promoter 
system (left) and the lac repressor system (right) in response to varying 
concentrations of aTc and IPTG in E. coli, respectively. Transcription 
was quantified by luciferase activity (arbitrary units). Adapted from 
reference126.  
As previously discussed, the ideal inducible promoter system should possess a wide 
dynamic range. Consequently the intermediate induction capabilities of the Pxyl/tetO would 
be in appropriate. To circumvent this limitation, the Tet inducible promoter system was 
redesigned using Clostridial components and incorporating components that could be 
easily changed, in keeping with the compatibility of the pMTL80000 modular vector 
system89. 
The Tet system is constructed from three main components, the inducible promoter 
which will be interrupted with a tetO, the tetR repressor, and the tetR UHSUHVVRU·V
 
146 
 
promoter. For construction of the Clostridium Tet inducible promoter system, the same 
design principles used for the lac repressor system were adopted. For the inducible 
promoter, the C. sporogenes ferredoxin promoter, previously used in our lac repressor 
system, was selected. To make the promoter inducible, two different promoter/tetO 
configurations were developed; the first consisted of inserting a 15 bp palindromic tetO 
fragment between the -35 and -10 of the ferredoxin promoter, as this positioning has 
been previously published as being effective in other bacteria118.  The second was to 
introduce two tetOs, the first tetO1 was inserted in between the -35 and -10 of the 
ferredoxin promoter, and the second tetO2 was inserted downstream of the -10 (Figure 
4.20B). The double operator configuration was chosen to be tested in parallel to the 
single operator configuration, as the double operator configuration has been previously 
described to increase the repression of the inducible promoter, thereby reducing the 
leakiness in the absence of an inducer69. As there is no need to synthesis the whole 
construct to include only the second operator configuration, the tetO1/2 was 
synthesised as a separate construct with the restriction endonucleases ClaI and AatII 
SUHVHQWDWWKH·DQG·UHVSHFWLYHO\WRHQDEOHHDV\VZLWFKLQJRI3fdx/tetO. 
For the repressor protein, the tetR gene of pRMC2 was selected and codon optimised 
for usage within C. difficile by DNA2.0132. Initially, no promoter was selected to initiate 
transcription of tetR for two reasons, the first being the companies constructing the 
synthetic constructs have encountered problems in the past when synthesising 
constructs which contain repressors that are expressed at high levels, and secondly, it 
was predicted that testing if the inducible promoters are able to initiate transcription of 
the reporter gene, it would be more straightforward in the absence of a repressor.  
To stop unwanted transcription from promoters upstream of the inducible promoter 
system interfering with the regulation of the system, a dual transcriptional terminator 
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identified from C. tetani was positioned upstream of the tetR gene, at the beginning of 
the inducible promoter construct. Finally, to enable quick introduction and switching of 
components of the system, a number of restriction sites were introduced into the 
designs which are not found within the pMTL80000 series of plasmids89 (figure 4.20A).  
  
Figure 4.20. Schematic diagram of the main features of the tetracycline 
inducible promoter system and its operator configuration placement. (A) 
The construct pMTL-tetO synthesised by DNA2.0 with the tetR gene on 
the reverse strand codon optimized for C. difficile and taken from 
pRMC2, also shown is the Pfdx/tetO configuration (shown magnified) and 
the placement of the restriction endonuclease sites shown above their 
UHVSHFWLYHSODFH7KHKRSHGVWUXFWXUHDW WKH·RI tetR is a bidirectional 
transcriptional terminator to inhibit transcriptional read-through 
interfering with genes upstream. (B) The original Pfdx sequence at the top 
followed by the two tetO configurations. The bold red text represents the 
tetO present within Pfdx/tetO, and the tetO1 and tetO2 present within 
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Pfdx/tetO1/2. Underlined are the proposed -35 and -10 sequences of the Pfdx 
and its variations. 
Another application that was built into the design, but unfortunately not tested due to 
time constraints, was the ability to reverse the function of the Tet system.  It has been 
previously found that a few mutations in the TetR-based eukaryotic transactivator can 
reverse the function of the inducer aTc, from an inducer into a co-repressor150,151. To 
explore if the TetR protein can be converted to a revTetR protein by mutagenesis, 
Scholz et al, (2004)137, set about creating a tetR mutant library in E. coli, from which more 
than 100 TetR mutants were identified that required aTc to function as a repressor137. 
Their most notable TetR mutant, r1.7, was capable of reaching induction factors of 
102137. It was found that the mutations involved in the reversal of TetR were 
substitutions at amino acids, 15, 17, and 25, from glutamic acid, leucine, leucine, 
substituted to, alanine, glycine, and valine, respectively. These changes caused the native 
TetR conformation to have a low affinity to tetO; however, the binding of aTc increased 
the affinity to tetO, increasing binding and subsequently repressing transcription137. 
Incorporation of this into the revTetR system was carried out by synthesising a 
fragment of DNA which could be cloned into the tetR gene between the restriction 
endonuclease sites Bpu10I and XbaI. Within this fragment were 4 bp changes which 
HQFRGH IRU WKH VXEVWLWXWH DPLQRDFLGV FKDQJLQJ WKHRULJLQDO7HW5 LQWR6FKRO]·V FORQH
r1.7 revTetR137 (figure  4.21).  
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Figure 4.21. Overview of the changes to the DNA sequence to reverse 
the function of TetR into a revTetR system. (A) The original TetR DNA 
sequence with the changes underlined and red. In bold black are the 
recognition sites for the restriction enzymes Bpu10I and XbaI which can 
be used to replace the fragment. Underneath is a close-up of the DNA 
sequence on top with the required changes in red, and the original amino 
acid sequence in red below. (B) The synthesised fragment which can be 
switch with the original to reverse the function of TetR. On the top is 
the DNA sequence outlining the changes undertaken to reverse the 
function flanked by the appropriate restriction recognition sites from the 
original (A). Below is a close-up of the DNA sequence with the 
implemented changes showing the subsequent change in codons; E, L, 
L, to A, G, V, respectively. 
The final construct was synthesised by DNA2.0, which includes the Pfdx/tetO 
configuration, termed DNA2.0-tetO. The second Pfdx/tetO1/2configuration and revTetR 
fragments were synthesised separately. Once the constructs were received, the construct 
was removed from plasmid DNA2.0-tetO and introduced into plasmid pMTL82254 
TCTAGACTTGATAAAAGTAAAGTTATCAATAGTGCATTGGAATTACTAAATGAAGTTGGAATAGAAGGACTAACTACAAGAAA
GTTAGCTCAGAAACTTGGAGTAGAACAACCTACGTTGTATTGGCATGTGAAGAATAAGAGAGCTTTACTTGACGCCTTAGC
TCTAGACTTGATAAAAGTAAAGTTATCAATAGTGCATTGGCATTAGGAAATGAAGTTGGAATAGAAGGAGTAACTACAAGAA
AGTTAGCTCAGAAACTTGGAGTAGAACAACCTACGTTGTATTGGCATGTGAAGAATAAGAGAGCTTTACTTGACGCCTTAGC
A. TetR
B. revTetR
TTG GAA TTA CTA AAT GAA GTT GGA ATA GAA GGA CTA
L      E L      L N      E       V     G      I       E       G      L
TTG GCA TTA GGA AAT GAA GTT GGA ATA GAA GGA GTA
L       A L      G N     E      V      G      I       E       G     V
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using restriction endonucleases NotI and NdeI, yielding plasmid pMTL-tetO. For 
comparison of the two difference operator configurations, the tetO1/2 configuration 
was digested from the DNA2.0-tetO1/2 vector and cloned into pMTL-tetO using 
restriction endonucleases ClaI and AatII, yielding plasmid pMTL-tetO1/2. 
The plasmids now have the inducible promoter able to transcribe the reporter gene catP; 
however, at this stage the inducible promoter is not inducible as the TetR repressor is 
not expressed. To allow expression of TetR, the thiolase promoter from C. sporogenes 
was selected to transcribe tetR, due to its known strong constitutive properties. The 
resulting DNA fragment was cloned into pMTL-tetO and pMTL-tetO1/2 using 
restriction endonucleases SacI and BamHI, yielding the final plasmids pMTL-tet3nO and 
pMTL-tet3nO1/2, respectively. Nomenclature: tet represents the tetracycline inducible 
construct, 3n represents Pthl, and finally the O represents the single operator 
configuration, and tetO1/2 the double.  
4.2.3.2 Toxicity of anhydrotetracycline in Clostridium species 
Before testing of the tetracycline inducible promoter system can be undertaken, the 
bacteriostatic activity of aTc on the Clostridium species used in this study must be 
evaluated. Tetracycline is a known bacteriostatic antibiotic; however, aTc is thought to 
be less toxic to cells than its original counterpart136. To test if this is the case, the 
plasmid pMTL-tet3nO was digested with restriction enzymes ClaI and AatII, blunted 
with T4 polymerase, and re-ligated together using T4 ligase. This yields plasmid pMTL-
tet3n, which includes the tetracycline inducible promoter system minus the inducible 
promoter upstream of the catP reporter to be used as a control. C. difficile, C. sporogenes, 
and C. beijerinckii were then conjugated with E. coli CA434 harbouring the plasmid to 
transfer pMTL-tet3nO and were subsequently subjected to varying concentrations of 
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aTc; no aTc, 100 ng/ml, 310 ng/ml, and 1000 ng/ml, at the start of a growth curve and 
their growth measured using a photo spectrophotometer at OD600nm.  
The results for C. difficile showed that after the initial addition of the varying 
concentrations of aTc to the starter culture, the OD dropped from the initial starting 
OD600 of 0.05 during the first 2 hours, compared to the culture with no aTc added 
which showed minimal change in OD (figure 4.22). At the 4 hour reading, 
concentrations 100 and 310 ng/ml aTc showed the same growth as the C. difficile grown 
in no aTc, however, the 1000 ng/ml culture showed a noticeable decrease in OD. This 
trend continued throughout growth until the 24 hour reading where all cultures were of 
comparable density. These results suggest that the growth of C. difficile is not affected by 
concentrations of up to 310 ng/ml aTc, but is affected by 1000 ng/ml aTc. This effect 
slows down the growth during the 8 hours which were monitored, but the same final 
OD can be reached after 24 hours.  
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Figure 4.22. Growth curve studying the ability of C. difficile ƅerm to 
grow (OD600) in the presence of varying concentrations of aTc over a 
24 hour period. An overnight culture of C. difficile was used to inoculate 
a starter culture of 10 ml LB to an OD600 0.05. The appropriate aTc 
 
152 
 
concentration was added to the starter culture (0, 100, 310, or 1000 
ng/ml) and the OD600 was measured at specific time points (2, 4, 6, 8, 
and 24 hours) after inoculation. The error bars indicate standard error 
of the means from three experiments. 
The same experiment was repeated for C. sporogenes and C. beijerinckii harbouring pMTL-
82254-noPthl/tetO. The results for C. sporogenes showed that after 2 hours, all four 
concentrations showed growth reflective of the concentration of aTc, meaning the 
fastest growing culture had no aTc present, the 2nd was supplemented with 100 ng/ml 
aTc, 3rd was C. sporogenes, and the slowest was 1000 ng/ml aTc (figure 4.23). After 
6hours, the same order of growth speed was noted, the culture with no aTc reached 
stationary phase with an OD of 1.1, whereas 100 ng/ml and 310 ng/ml aTc were still 
growing with an OD of 1 and 0.35 respectively, however the culture supplemented with 
1000 ng/ml had decreased in OD to 0.03, lower than the initial starting culture. By 10 
hours, the cultures containing 100 ng/ml and 310 ng/ml had reached stationary phase 
with OD of 1.1 and 1.03 equal to that of no aTc, in contrast, the culture supplemented 
with 1000 ng/ml decreased in OD to 0 suggesting that the cells had succumbed to the 
aTc overtime. As for C. beijerinckii, the results were considerably different (figure 4.24). 
After the first 2hours, there was no notable difference with growth between each 
FXOWXUHZLWKDOOVKRZLQJ2'·VEHWZHHQDQG$IWHUKRXUVWKHGLIIHUHQFHLQ
growth rates between the cultures became obvious, the culture without aTc increased in 
OD to 0.35 whereas all the other decreased to 0.07, 0.1, and 0.06 for 100, 310, and 1000 
ng/ml D7FUHVSHFWLYHO\$IWHUKRXUVJURZWKXQH[SHFWHGO\WKH2'·VIRUERWK
and 1000 ng/ml decreased to 0 compared to the OD of the cultures without aTc 
increasing up to 0.78, this continued with the 8 hour reading with the cultures without 
aTc reaching an OD of 1.12 and 100 ng/ml aTc increasing slightly to 0.2, however the 
 
153 
 
other two aTc concentrations remained at an OD of 0. The final reading taken after 24 
hours showed that all cultures had grown to what is assumed as stationary phase with an 
OD of 2, 2, 1.28 and 0.75 for 0, 100, 310, and 1000 ng/ml aTc. 
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Figure 4.23. Growth curve studying the ability of C. sporogenes to grow 
(OD600) in the presence of varying concentrations of aTc over a 24 hour 
period. An overnight culture of C. sporogenes was used to inoculate a starter 
culture of 10 ml LB to an OD600 0.05. The appropriate aTc concentration 
was added to the starter culture (0, 100, 310, or 1000 ng/ml) and the OD600 
was measured at specific time points (2, 4, 6, 8, and 24 hours) after 
inoculation. The error bars indicate standard error of the means from three 
experiments. 
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Figure 4.24. Growth curve studying the ability of C. beijerinckii to grow 
(OD600) in the presence of varying concentrations of aTc over a 24 hour 
period. An overnight culture of C. beijerinckii was used to inoculate a 
starter culture of 10 ml LB to an OD600 0.05. The appropriate aTc 
concentration was added to the starter culture (0, 100, 310, or 1000 
ng/ml) and the OD600 was measured at specific time points (2, 4, 6, 8, 
and 24 hours) after inoculation. The error bars indicate standard error of 
the means from three experiments. 
4.2.3.2 Testing the Clostridium Tet inducible expression system in C. difficile ¨erm 
In the first instance, it was necessary to ensure that the introduction of the tetO 
sequences into the Pfdx did not interfere with its ability to initiate RNA polymerase II-
dependant transcription of the reporter, catP. To do this, plasmids pMTL-tetO and 
pMTL-tetO1/2 were transformed into the conjugation donor CA434, and from there 
conjugated into C. difficile using the standard conjugation technique90. If the inducible 
promoters are active, they should confer resistance to thiamphenicol due to Pfdx/tetO and 
Pfdx/tetO/1 expressing catP. Therefore, as a quick test to ensure they are still working in C. 
difficile, a transconjugant of each plasmid was streaked onto BHIS supplemented with 
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thiamphenicol. The results showed that only plasmid pMTL-tet3nO containing the 
single operator configuration conferred resistance to thiamphenicol, with no colonies 
obtained for C. difficile harbouring pMTL-tetO1/2.  
To quantify expression of catP, which is directly proportional to the strength of each 
promoter, the CAT assay was implemented. The results showed that the single operator 
configuration was able to produce CatP to a level of 7,520 CAT U/ml enzyme, 
compared to very low detected expression with the double tetO configuration (Figure 
4.25).  
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Figure 4.25. Comparison of the two tetO operator configurations, 
present within Pfdx outlined in figure 4.18(B), to access their ability to 
produce CatP in C. difficile ƅerm. Each tetO construct was 
transcriptionally fused to catP in the tetracycline inducible promoter 
constructs lacking TetR production in plasmid pMTL82254. CatP 
production was quantified (CAT U/mg enzyme) after 4 hours of growth 
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past OD600 0.5. The error bars indicate standard error of the means from 
three experiments. 
As it is now known the single operator configuration of pMTL-tetO can express the 
reporter in the absence of TetR, next it was desirable to know whether the inducible 
promoter can be repressed, and induced with the addition of aTc. To do this, the 
plasmid pMTL-tet3nO was conjugated into C. difficile ¨erm and quantification of catP 
expression was repeated with a 4 hour induction time. The results showed that the 
single operator was able to repress the production of CatP to around 39 CAT U/mg 
protein when tetR was expressed from the Pthl promoter. When 316 ng/ml aTc was 
added, the repression was alleviated causing an induction of CatP production of up to 
7,523 CAT U/mg protein (figure. 4.26). This difference between expression and 
repression equates to an induction factor (IF) of 192.89. It was also noted that even 
with induction of 316 ng/ml, the construct could only reach around 76% the CatP 
production levels previously seen when no repressor molecule was being expressed. 
These results show that the construct pMTL-tet3nO is able to act as an inducible 
promoter system in C. difficile. To further analyse the Tet inducible promoter system to 
understand its characteristics, two more experiments were carried out to determine its 
ability to produce a dynamic range of CatP, and speed of induction to enable short-term 
studies on phenotype.   
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Figure 4.26. Comparison of the two constructs; pMTL-tetO and pMTL-
tet3nO, in their ability to produce CatP in the presence or absence of 
316 ng/ml aTc in C. difficile ƅerm. The two plasmids, differing in the 
presence of the Pthl transcribing tetR (pMTL-tet3nO) or absence of Pthl 
transcribing tetR (no TetR production) (pMTL-tetO), are 
transcriptionally fused to catP on plasmid pMTL82254 and were grown 
to an OD600 0.5 and subsequently induced for 4 hours with 316 ng/ml 
aTc, after which CatP production was quantified (CAT U/mg protein). 
The error bars indicate standard error of the means from three 
experiments. 
4.2.3.2.1 Dynamic induction range and time course of inducible CatP production in C. 
difficile ¨erm 
The ability to control gene expression through a range of expression levels is an 
important characteristic and one of the most important desirable characteristics. The 
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original tetracycline system is known to be very sensitive to concentrations of 
tetracycline, and as such intermediate induction levels are difficult to achieve126. To 
combat this, the system was re-designed to remove the PtetR promoter which contains 
tetO1, and replaced it with Pthl. To establish if this has affected its induction kinetics, the 
pMTL-tet3nO vector was subjected to varying concentrations of aTc.  
The results showed that CatP production is surprisingly dose-dependent in response to 
aTc induction (Figure 4.27).  Without aTc, CatP production was very tightly repressed 
to levels indistinguishable from background, with the addition of concentrations as low 
as 0.31 ng/ml aTc induction of CatP can be detected to a level of 345 CAT U/mg 
protein. Increasing the concentration of aTc in 2-log doses increases the production 
levels of CatP in a dose-dependent fashion. Around half maximum CatP production 
was seen with the addition of 10 ng/ml aTc, producing 4,100 CAT U/mg protein, 
compared to full induction with 316 ng/ml aTc at 7,000 CAT U/mg protein. Increasing 
the concentration of aTc from 316 ng/ml to 1 ng/ml does not increase the production 
of CatP, as the system seems to be saturated. These results show that the system seems 
to be more dose-dependent than the original Tet system126, with intermediate ranges of 
expression obtainable through a range of aTc concentrations between 0.31 and 316 
ng/ml. 
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Figure 4.27. Comparison of CatP production at varying 2-log 
concentrations of aTc in C. difficile ƅerm harbouring plasmid pMTL-
tet3nO. C. difficile ƅerm harbouring plasmid pMTL-tet3nO was grown 
to an OD600 0.5 and induced with varying concentrations of aTc (0.31, 1, 
3.1, 10, 31.6, 100, 316.4 or 1000 ng/ml) for 4 hours and subsequently 
analysed for CatP production (CAT U/mg protein). The error bars 
indicate standard error of the means from three experiments. 
To test if the system induces quickly, has a stable expression level, and the inducers 
bioavailability does not decrease over 6 hours, C. difficile harbouring plasmid pMTL-
tet3nO was grown to an OD600 0.5 and induced with 316 ng/ml aTc and sampled every 
hour after induction for 6 hours. The results showed that after 1 hour, pMTL-tet3nO 
was able to produce CatP quickly and strongly, to a level of 3,695 CAT U/mgprotein, 
compared to very tight repression of CatP production in the absence of aTc (figure 
4.28). The production of CatP increased over 4 hours, until expression levels reached 
maximum levels of 6,794 CAT U/mg protein. After 4 hours, the production of CatP 
stabilised and stayed within the same vicinity of production levels as the 4 hour reading. 
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These results pMTL-tet3nO is able to induce quickly, with a maximum level of 
production reached by 4 hours, and no decrease in production over time associated with 
aTc degradation. 
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Figure 4.28. Time course of CatP production after induction of C. 
difficile ƅerm harbouring pMTL-tet3nO at OD600 0.5. C. difficile 
ƅerm containing plasmid pMTL-tet3nO was grown to an OD600 0.5 
and either induced with 316 ng/ml aTc, or not induced. Samples were 
taken every hour for 6 hours after induction for each culture and CatP 
production was quantified (CAT U/mg protein). The error bars indicate 
standard error of the means from three experiments. 
4.2.3.3 Testing the Clostridium Tet inducible expression system in C. sporogenes 
NCIMB 10969 
As the Tet system was shown to work exceedingly well in C. difficile ¨erm, it was 
valuable to ascertain if the system functions in other Clostridium species due to their 
importance as pathogens or in industrial applications. C. sporogenes is an organism of 
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significant interest due to its similarity to the human pathogen C. botulinum, and its 
application in CDEPT research.  
In the first instance, we carried out the dose-dependent experiment to identify the 
dynamic range of catP expression in response to varying concentrations of aTc, which 
was also performed in C. difficile. The results showed that there was a good intermediate 
range of CatP production achieved (figure 4.29). These results were comparable to the 
same construct in C. difficile, although the system was not as sensitive to low levels of 
aTc and the strength of expression at its peak was over 4 times stronger than C. difficile. 
This increase in strength is comparable with previously seen results due to the strength 
of the C. sporogenes ferredoxin promoter being around 4 times higher in C. sporogenes 
compared to C. difficile (O. Pennington, unpublished). Without the addition of aTc, tight 
repression of CatP was seen with only 86 CAT U/mg protein being detected. The 
detected units of CAT/mg protein consistently remained below 1,000 until 10 ng/ml of 
aTc was added, which increased production from 786 CAT U/mg protein obtained 
with 3.1 ng/ml aTc, to 5,681 CAT U/mg protein. As a higher concentration of aTc was 
added, a higher level of induction was detected. At 31.6 ng/ml aTc, 17,751 CAT U/mg 
proteinwas detected, increasing to 26,564 and finally to the highest production of 
37,180 CAT U/mg protein for induction with 100 ng/ml and 316.4 ng/ml, respectively.  
It was also noted that after induction with 1 µg/ml of aTc, the levels of production of 
CatP decreased from 37,180 CAT U/mg protein for 316.4 ng/ml, to 16,121 CAT 
U/mg protein, and that the OD600 of the culture at time of sampling after induction 
with 1 µg/ml aTc was lower than all other aTc concentrations, although this difference 
was accounted for in the calculation of CAT U/mg. This decrease in CatP production 
and growth seems to correspond to the sensitivity of C. sporogenes to 1000 ng/ml aTc 
(figure 4.21). 
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Figure 4.29. Comparison of CatP production after induction at OD600 
0.5 with varying 2-log concentrations of aTc in C. sporogenes NCIMB 
10969 harbouring plasmid pMTL-tet3nO. C. sporogenes harbouring 
plasmid pMTL-tet3nO was grown to an OD600 0.5 and induced with 
varying concentrations of aTc (0.31, 1, 3.1, 10, 31.6, 100, 316.4 or 1000 
ng/ml) for 4 hours and subsequently analysed for CatP production (CAT 
U/mg protein). The error bars indicate standard error of the means from 
three experiments. 
To test if the system induces CatP production quickly, has a stable expression level, and 
the inducers bioavailability does not change over 6 hours, the plasmid pMTL-tet3nO 
was tested in the same way as it was in C. difficile, with samples being taken every 1 hour 
after induction with 316.4 ng/ml aTc. The results were very similar to that of C. difficile, 
in that the system was able to produce CatP quickly and strongly (figure 4.30). Upon 
induction with aTc, the production of CatP increased from 106 CAT U/mg protein, to 
a very respectable 16,012 CAT U/mg protein within 1 hour. After 2 hours, production 
of CatP had increased to 24,317 CAT U/mg protein, with fewer than 50 CAT U/mg 
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protein produced in the un-induced samples. This trend increased until maximum 
production was obtained at 6 hour after induction, with 31,586 CAT U/mg protein.  
The un-induced/repressed samples remained below 160 CAT U/mg protein 
throughout the time course study, with the maximum induction factor noted at 1,275.63 
for the 3 hour samples. This induction factor, if correct, represents one of the highest 
noted induction factors obtained for an inducible promoter system. This high induction 
factor is partly due to the strength of the Pfdx promoter in C. sporogenes compared to C. 
difficile. It would seem that the promoter is on average around 3-4 times stronger in C. 
sporogenes, however, is able to repress to the same levels as C. difficile. This functionality 
makes this Tet system a very powerful tool for controlling gene expression in C. 
sporogenes, as well as C. difficile.  
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Figure 4.30. Comparison of CatP production at varying time points 
after induction of C. sporogenes NCIMB 10969 harbouring plasmid pMTL-
tet3nO. C. sporogenes harbouring plasmid pMTL-tet3nO was grown to an 
OD600 0.5 and either induced with 316 ng/ml aTc, or not induced. 
Samples were taken every hour for 6 hours after induction for each 
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culture and CatP production was quantified (CAT U/mg protein). The 
error bars indicate standard error of the means from three experiments. 
4.2.3.4 Testing the Clostridium Tet inducible expression system in C. beijerinckii NCBI 
8052 and C. acetobutylicum ATCC 824 
The last two organisms chosen to test the system in were C. beijerinckii NCBI 8052 and 
C. acetobutylicum ATCC 824. These two clostridia were chosen due to their usage in the 
bio-energy field.  As a quick test, the plasmids pMTL-tetO and pMTL-tet3nO were 
conjugated into C. beijerinckii and transformed into C. acetobutylicum, and the performance 
of the Tet system was analysed.  
The results showed that in both organisms, the absence of tetR expression allows the 
Pfdx to promote high levels of catP transcription to between 4,500 and 5,000 CAT U/mg 
protein (figure 4.31). In the presence of a promoter transcribing the repressor, tetR, catP 
is tightly repressed to levels below 160 CAT U/mg protein of CatP production, 
however, the repression cannot be alleviated to a reasonable level, which was possible in 
C. difficile and C. sporogenes, with the Tet system showing induction factors of around 2 
and 4 for both C. beijerinckii and C. acetobutylicum, respectively (figure 4.31). It is 
unknown why the Tet system is unable to be induced in these organisms. It would seem 
the inducible promoter is active due to CatP production in the absence of TetR; 
however, the addition of the inducer seems to have little effect on the alleviation of the 
repression.. 
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Figure 4.31. Comparison of CatP production at 6 hours after 
induction with (A) C. acetobutylicum and (B) C. beijerinckii, harbouring 
plasmids pMTL-tet3nO and pMTL-tetO.  Cultures of C. acetobutylicum and 
C. beijerinckii containing plasmid pMTL-tet3nO were grown to an OD600 
0.5 and induced with 316 ng/ml aTc for 6 hours, after which CatP 
production was quantified (CAT U/mg protein). In parallel, the plasmids 
pMTL-tet3nO and pMTL-tetO were grown 6 hours past the same OD600 
and CatP production quantified (CAT U/mg protein). The error bars 
indicate standard error of the means from three experiments. 
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4.3  Discussion 
One of the major gaps in the repertoire of genetic tools available for Clostridium was the 
absence of an easily usable inducible promoter system which can control gene 
expression through a wide dynamic range. There have been a number of systems 
developed for Clostridium, however, each of them has their advantages and 
disadvantageous which would limit the systems versatility. The desirable characteristics 
that were sought in this study were; the ability of the system to work in multiple 
clostridia, wide dynamic range of activity, high bioavailability of the inducer, high target 
gene expression, quick induction, and tight repression.  
To achieve these characteristics, a lac repressor system was first developed which used 
LacI as a repressor. The original system had been shown to work in many organisms 
and is widely thought of as a paradigm for inducible promoters. Unfortunately the 
original system does not seem to work efficiently in C. difficile38 (Personal 
communication with Prof. Minton). To overcome this, the system was re-designed 
using clostridial components. Upon testing the system it was noticed that the stronger 
the promoter transcribing lacI, the higher the repression of our reporter CatP, however, 
the repression could not be alleviated with the addition of the inducer. This inability to 
induce the production of CatP would suggest that the inducer is not acting upon the 
LacI repressor. Although the exact mechanism is unknown, a possible reason for this 
inability to induce the inducible system could be very limited diffusion or import rate of 
IPTG into the C. difficile cells, resulting in a significantly lower intracellular IPTG 
concentration compared to extracellular levels. It is not, to our knowledge, established 
whether C. difficile can actively transport lactose, and therefore IPTG, into the cells. 
There does not seem to be a LacY homologue present within the genome, in addition 
to this, C. difficile has a Gram-positive cell wall which may limit or inhibit IPTG to enter 
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the cell via diffusion. This problem has been encountered in other bacteria such as, 
Synechocystis152, E. coli153 and Pseudomonas fluorescens153 and subsequently solved by the 
introduction of the E. coli lactose permease gene, lacY153. Other ways to circumvent this 
problem could be to develop lac repressor mutants which have a high sensitivity to 
IPTG; this approach has been used previously by employing error-prone PCR and 
selecting for IPTG sensitive mutants154. A combination of these two approaches could 
provide C. difficile with a very efficient system able to actively import IPTG, and able to 
sense very small concentrations, even as low as 1 µM of IPTG154. 
In parallel to the IPTG inducible promoter system, the utility of riboswitches, able to 
control translation through varying mRNA secondary folding conformations in 
response to specific ligands, was tested in their ability to control gene expression in C. 
difficile. In the first instance, clone 8.1 developed by Lynch et al, (2007)1 was selected, to 
which was added an NdeI site at the start codon for ease of cloning, yielding Thio1. It 
was found that Thio1 was able to repress well in E. coli and respond with an increase in 
expression when the inducer theophylline was added; however, when Thio1 was tested 
in C. difficile, no CatP production was detected. The same absence of production was 
noted when the riboswitch was removed and replaced with just the RBS. This suggested 
that the RBS employed was not active in C. difficile, in contrast to E. coli. In response to 
this, two novel riboswitches were developed by rational design to include two RBSs 
likely to function in C. difficile. Out of these two riboswitches, Thio3 was not found to 
be able to repress CatP production in the absence of theophylline, possibly due to an 
error in the construction inhibiting its ability to form its conformations effectively. The 
second riboswitch Thio2 was able to repress and express catP in response to 
theophylline to a higher induction factor than the original Thio1. The subsequent 
testing of the riboswitches Thio2 and Thio3 in C. difficile produced disappointing results. 
 
168 
 
Both the riboswitches were unable to express catP in the absence or presence of the 
inducer, theophylline. However, compared to Thio1, the RBSs alone were able to 
express catP showing the RBSs are in fact active in C. difficile. The reason for Thio1 and 
Thio·VLQDELOLW\WRZRUNLQC. difficile is not clear. It could be due to the decrease in the 
efficiency of translation in the presence of the riboswitches. In E. coli it was noted that 
the presence of the riboswitch in Thio3 decreased translation around 10-30 times 
compared to the RBS alone. In using these plasmids in C. difficile, the lower copy 
number means lower overall production of CatP; although the RBSs alone can lead to 
detectable production of CatP, the presence of the riboswitch might lower the 
translation efficiency to a level below the detectable limit of the older model photo 
spectrophotometer used for the assay. 
In the last instance, the development of a tetracycline inducible promoter system was 
investigated as it is known that tetracycline is able to enter the cell (sensitive to the 
antibiotic), thereby avoiding the hypothesised problems seen with the IPTG system. 
The system pMTL-tet3nO was very successful in repressing catP expression in the 
absence of aTc, to a level that was almost undetectable above background in C. difficile 
and C. sporogenes. Possibly due to the exclusion of the tetO1 present in the PtetR, the dose-
dependent response to varying concentrations of aTc was remarkable, with a dynamic 
range of intermediate production levels able to be achieved. This dynamic range is a big 
advantage of the system over the original tetracycline system which is known to have a 
limited intermediate range126 (figure 4.16). The Tet system also filled the other required 
characteristics of rapid induction with high levels of production seen within 1 hour, 
high bioavailability, and very tight repression in the absence of the inducer. The 
surprising result was the ~76% decrease in production of CatP in the presence of TetR. 
This decrease is more than likely due to the high constitutive expression of TetR and 
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subsequent increase in binding to the tetO which cannot be overcome with increased 
concentrations of aTc added. Although this decrease in expression is not favourable, the 
levels of CatP production is still very high and an acceptable trade-off for increased 
repression, particularly in the case of using the inducible promoter system to 
conditionally control essential genes for identification purposes. 
As a universal inducible promoter system was being sought, the construct was tested in 
C. acetobutylicum and C. beijerinckii. SXUSULVLQJO\ WKH V\VWHP GLGQ·W ZRUN DV H[SHFWHG LQ
either. The control plasmid pMTL-tetO produced high levels of CatP, and in the 
absence of the inducer aTc, the full tet3nO construct repressed to very high levels. 
However, it could not be induced to levels about 3 times above the repressed state. The 
reason for this is unknown and has similarities with the problems encountered with 
IPTG in the lac repressor system. However, aTc is known to be able to enter the cell 
due to the sensitivity of exogenously added aTc. On closer inspection, a BLAST search 
using the translated nucleotide sequence of tetA(B) (P02980) from E. coli shows that 
both organisms, as well as Clostridium ljungdahlii and Clostridium perfringens, have what 
appears to be a natural tetracycline inducible promoter system including a tetA metal-
tetracycline/H(+) antiporter. This possible natural tetracycline inducible promoter 
including tetA could be responsible for actively transporting aTc out of the cell, 
resulting in decreased availability of aTc within the cell. If this is the case, aTc could be 
removed before it is able to bind to TetR, thereby inhibiting transcription as if no/very 
low concentrations of aTc are present intracellularly. To counter this problem, it may be 
possible to inactive the hypothesised tetA in both organisms and test whether it has an 
effect on induction of CatP. Unfortunately due to time constraints, it was not possible 
to test if this would work, but would make an excellent experiment to undertake in the 
future. In conclusion, it is intended to implement this tetracycline inducible promoter 
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system to develop a method to identify essential genes using a conditional lethal 
genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
171 
 
Chapter Five 
Use of a Tet Inducible Promoter System to Conditionally Control 
Lethal Phenotypes for the Identification of Essential Genes 
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5.1  Introduction 
The identification of essential genes in C. difficile has been prevented by the limitation of 
current techniques38,41. Molecular tools such as the ClosTron are capable of insertionally 
inactivating genes, however essential genes are unable to be inactivated, making this 
system alone insufficient to identify essential genes38,41. In chapter three, a system was 
developed which employs the use of an ectopically located partial diploid strain to 
functionally complement a native essential gene, thereby negating the essentiality of the 
native gene and allowing it to be insertionally inactivated using the ClosTron. For the 
first time three essential genes were identified in C. difficile, however the identification 
was through the indirect evidence of only being able to inactivate the gene in a partial 
diploid background. For a direct method to identify essential genes, one has to use 
conditional mutational systems such as an inducible promoter46,47,72,116. 
5.1.2    Conditional mutations 
Conditional expression is achieved by placing a gene of interest under the control of an 
inducible promoter69,113,114,118,133. There are two main ways in which to control an 
essential genes transcription using an inducible promoter. The first uses either a single-
crossover integration or double allele-exchange process to replace the essential genes 
native promoter with an inducible promoter. This has been used successfully in S. 
aureus49,140,155 and B. subtilis45 to identify essential genes. However, there is a significant 
limitation to using such a strategy. In the case of the essential gene being present within 
an operon transcribed from a polycistronic mRNA, the introduction of an inducible 
promoter into the operon could potentially co-regulate genes downstream, thereby 
changing multiple parameters and making interpretation of the results difficult. This is 
particularly apparent in complex operons housing multiple essential genes and 
secondary transcriptional control systems.  
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Another strategy to circumvent this limitation is to introduce an ectopically expressed 
protected copy of the essential target gene under inducible control into the 
chromosome. This means that the native essential gene can be inactivated either by 
ClosTron or allelic exchange mutagenesis in the presence of an inducer. Once the native 
gene is inactivated, the inducible second copy is now the essential copy, similar to the 
strategy undertaken in chapter three. However in this strategy; only in the presence of 
an inducer will the cell be viable. If the essential gene is switched off due to the absence 
of an inducer, then the cell will die. This would allow direct identification of essential 
genes by studying viability in the presence or absence of an inducer45. A study like this 
has not been undertaken within C. difficile due to the lack of an effective inducible 
promoter system. With the development of the Tet system in chapter four, it is now 
possible to undertake this type of study. 
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5.1.     Aim of this study 
The use of inducible promoter systems to create conditional lethal phenotypes will 
allow the direct identification of essential genes within C. difficile. The advantage of using 
such a system is the ability to further analysis the mutation through a dynamic range of 
expression levels, as well as throughout the life cycle of the organism. Gathering far 
more information and evidence as to the function and nature of the essential gene 
compared to the method developed in chapter three. 
The aim of this chapter is to develop a genetic tool able to modulate transcription of 
ectopically located genes for the identification of essentiality and analysis of potential as 
therapeutic drug targets.  
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5.2  Results 
5.2.1    Construction of conditional lethal recombinant strains 
Conditional mutations and control of gene expression have been frequently used in 
other bacterial species for identification of essential genes, unfortunately systems such 
as; amber stop codons66,156,157, temperature sensitive mutations72,101, riboswitches1,122,143, 
and most inducible promoters have not been developed to meet our requirements or 
published for use in C. difficile38,120. In chapter four, a tetracycline inducible promoter 
system was developed which meets the requirements for conditional mutations.  
Three genes were previously identified as essential in C. difficile; CD0274, trpS, and metK. 
In order to further study the survival kinetics and nature of essentiality, CD0274 was 
chosen for the conditional lethal experiment due to the probability of the gene being 
essential to few bacterial species, making it a possible antimicrobial target100,158,159. The 
previously identified essential gene trpS was also chosen to gather further evidence that 
the system functions as would be expected. Finally, a third new target was chosen, slpA. 
In previous work unpublished in our lab, slpA was not able to be insertionally 
inactivated using the ClosTron system, the first indication that a gene could be essential. 
In C. difficile, slpA is known to encode for a surface-exposed proteinaceous layer termed 
the S-layer31,32,120. Previous studies have shown that the S-layer forms a regular two-
dimensional array which is visible by electron microscope32. This S-layer is constructed 
from a higher-molecular-mass protein (P46) of between 48 to 56 kDa, and a lower-
molecular-mass protein (P36) of between 36 to 45 kDa, encoded by the C-terminal and 
variable N-terminal of slpA, respectively31,32. It is suggested that P36, the lower-
molecular-mass protein is expressed on the exterior of the S-layer, of which it is shown 
to have adhesive properties to Caco-2 cell lines31,32. Due to its exclusive usage in C. 
difficile and its location on the exterior of the cell, it would make an attractive target for 
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development of a vaccine or a novel narrow-spectrum antimicrobial agent against C. 
difficile.  
As was the case with the three targets in chapter three, if slpA is to be under inducible 
expressed at an ectopic site, meaning the native copy is to be insertionally inactivated, 
the nucleotide sequence must be changed to protect the second copy from inactivation 
by the ClosTron system, as were the previous candidates in chapter three. To do this, 
the nucleotide sequence  around three ClosTron target sequences were altered, between 
nucleotides; 861 and 909, 1043 and 1089, and finally 1243 and 1284, to inhibit the 
recognition and subsequent integration of the group II intron targets pMTL007C-
E2:Cdi-slpA-878a, pMTL007C-E2:Cdi-slpA-1072s, and pMTL007C-E2:Cdi-slpA-1267s, 
respectively (figure 5.1). These changes are silent, meaning that the amino acid sequence 
is unchanged, and the subsequent gene product is unaltered from the native. The 
synthetic protected slpAp was designed using the gene designer software developed by 
DNA2.0 and synthesised by the same company. During the construction of the 
construct by DNA2.0, the restriction sites NdeI and Nhe,ZHUHLQWURGXFHGDWWKH·DQG
·RIWKHJHQHWRHQDEOHHDV\FORQing into our Tet system and modular vector plasmids89.  
 
177 
 
 
Figure 5.1. Protection of the synthetic partial diploid copy of the 
candidate essential gene slpA. The black box outlines the 45 bp mer 
target sequence of the three retargeted group II introns. In bold red is 
the silent nucleotide changes made in the synthetic protected copy of 
each candidate essential gene compared to the native gene required to 
SURWHFW WKH JHQH IURP WKH JURXS ,, LQWURQ·V WDUJHWLQJ PHFKDQLVP EXW
keeping the same translated amino acid sequence.  
In order to insert the essential gene under inducible control into the chromosome, the 
ACE system was used (unpublished, Heap et al). The essential genes were digested from 
plasmids; DNA2.0-slpAp, DNA2.0-Pthl-trpSp, and pMTL-DW1, cloned into 
intermediary pMTL-tet3nO, and finally into the ACE plasmid pMTL-JH18, yielding 
plasmids pMTL-ACEtet-dhaTp, pMTL-ACEtet-slpAp, and pMTL-ACEtet-trpSp, 
relating to the protected genes slpA, metK, and trpS present under tetracycline inducible 
control, respectively. 
Amino Acid
Native 851 ʹ GC TCA TAT ACA TCA GCT GAA AAT TTA GCT AAA AGA TAT GTA TTT GAT CCA - 900
Protected 851 ʹ GC TCA TAT ACA AGT GCC GAG AAC CTG GCG AAA CGC TAT GTC TTC GAC CCT - 900
Amino Acid
Native 901 ʹ GAT GAA ATT TCT GAA GCA TAT AAG GCA ATA GTA GCA TTA CAA AAT GAT GG - 950
Protected 901 ʹ GAT GAG ATC TCT GAA GCA TAT AAG GCA ATA GTA GCA TTA CAA AAT GAT GG - 950
Amino Acid
Native 1001 ʹ TT TAT CCA GAA GGT AAA AGA TTA GAA ACT AAA TCA GCA AAT GAT ACA ATA - 1050
Protected 1001 ʹ TT TAT CCA GAA GGT AAA AGA TTA GAA ACT AAA TCA GCA AAT GAC ACC ATC - 1050
Amino Acid
Native 1051 ʹ GCT AGT  CAA GAT ACA CCA GCT  AAA GTA GTT ATA AAA GCT AAT AAA TTA AA - 1100
Protected 1051 ʹ GCC AGC CAA GAC ACA CCG GCG AAG GTT GTC ATC AAG GCC AAT AAA TTA AA ʹ 1100
Amino Acid
Native 1201 ʹ TTA AGT AGT AAA TAT TAT AAT TCT GAT GAT AAA AAT GCA ATA ACT GAT AA   1250
Protected 1201 ʹ TTA AGT AGT AAA TAT TAT AAT TCT GAT GAT AAA AAT GCC ATT ACA GAC AA   1250
Amino Acid
Native 1251 ʹ A GCA GTT AAT  GAT ATA GTA TTA GTT GGA TCT  ACA TCT  ATA GTT GAT GGT C   1300
Protected 1251 ʹ G GCC GTG AAT GAC ATC GTT TTA GTG GGT AGT ACC TCT ATA GTT GAT GGT C   1300
S     Y      T      S       A       E      N     L       A     K      R      Y     V     F      D      P
D     E      I       S      E      A     Y      K      A      I      V      A     L     Q      N     D     ?
Y      P      E      G      K      R      L      E       T      K      S      A     N     D      T      I
A      S      Q      D      T      P      A      K      V      V     I      K      A      N     K      L
L      S      S      K     Y     Y     N      S     D      D     K      N     A      I       T      D     K 
A      V      N      D     I      V     L      V      G      S      T       S      I      V      D     G
CT Target 878a
CT Target 1072s
CT Target 1267s
slpA
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Construction of the inducible partial diploid strain was carried out using ACE as 
previously described in section 3.2.4. Each plasmid was conjugated into C. difficile 
630ƅerm using the donor strain E. coli CA434 and standard conjugation techniques90. 
The resulting transconjugants were selected for on BHIS supplemented with 
thiamphenicol and C. difficile supplement. After 24 hours, transconjugants started to 
become large enough to pick, therefore two transconjugants for each plasmid were re-
streaked onto fresh media. For each plasmid, three individual colonies with the larger 
phenotype representing individually derived single-crossover recombinants were 
purified and enriched by sub-cloning on fresh BHIS supplemented with thiamphenicol 
and C. difficile supplement (figure 2A).  
The next step was selection of the second-crossover event occurring between the 
smaller right hand homology arms. Each of the 3 individually derived single-crossover 
recombinants were re-streaked onto C. difficile minimal media supplemented with 5-
FOA and uracil. After 24 hours, 5-FOA resistant colonies were large enough to pick, 
and were selected to undergo patch plating on BHIS or BHIS supplemented with 
thiamphenicol to identify the cells that are thiamphenicol sensitive, therefore, have lost 
the knock-in plasmid stopping further recombination events. Each of the colonies was 
screened by PCR using primers that amplified across the insertion locus to confirm 
allelic exchange has taken place at the desire site. PCR screening confirmed that all 
colonies screened had undergone the desired allele exchange (figure 2B). 
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Figure 5.2. DNA integration of candidate essential gene slpA under 
inducible control in the pyrE locus of C. difficile ¨erm (A) Selection of 
the double-crossover clones using plasmid pMTL-ACEtet-slpAp. The 
first recombination event is directed by the long right-hand homology 
arm consisting of 1500 bp downstream of pyrE on the C. 
pyrD pyrE CD0288
slpA
pyrK CD0189
CD0288
oricatP
300 bp 1200 bp
pyrD pyrE CD0288pyrK CD0189
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difficile¨ermchromosome. The resulting single-crossover clones have 
their replication deficiency conferred by pIM13 alleviated allowing them 
to grow quicker than the freely-replicating plasmid containing cells. 
Subsequently, the second crossover event between the 300 bp left 
homology arm of pMTL-ACEtet-slpAp containing an internal fragment 
of pyrE completes the allelic-exchange. Two possible outcomes can 
occur, the parent strain or the double-crossover clone. To select only for 
the desired event, selection on 5-FOA allows only pyrE- strains (double-
crossover clones) to grow. (B) PCR screening of 3 clones of 
pyrE::tet3nO-trpS and pyrE::tet3nO-slpA using primers Cdi630-pyrE-F2 
and Cdi630-CD0189-R2 which anneal on the parent chromosome 
flanking the insertion site. MW is a 2-log DNA Ladder (NEB) molecular 
weight marker, lane 1 is water only negative control, lane 2 is parent 
(expected size ~2 Kbp) C. difficile ¨erm DNA control, lanes 3-5 are 
pyrE::tet3nO-trpS candidate clones (expected size ~ 4.2 Kbp), and lanes 
6-8 are pyrE::tet3nO-slpA candidate clones (expected size ~ 5.4 kbp). (C) 
PCR screening of6 pyrE::tet3nO-dhaT candidate clones using the same 
primers and order as (B) (expected size ~4.6 kbp).  
Having generated inducible partial diploid strains, to ensure that the ectopically located 
essential genes essentiality is under inducible control, the native copy must be 
inactivated. There are two ways in which to do this, the first uses an allele exchange 
method to in-frame delete the native gene (unpublished, Cartman et al). However due to 
time restrictions of this project, it was decided to use the alternative quicker method, 
the ClosTron system38,41, to insertionally inactivate the native copy as was done in 
chapter three. As none of the three essential genes are present in the middle of an 
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operon, the insertion of the group II intron should limit polar effects on other genes; 
therefore the in-frame deletion method has no significant advantage over the ClosTron 
method in this instance.  
To insertionally inactivate slpA, three target sites; 878a, 1072s, and 1267s were identified 
with their appropriate group II intron retargeting sequences. Two targets, 878a and 
1267s were constructed by DNA2.0 and cloned into the ClosTron plasmid pMTL007C-
E2, yielding ClosTron target plasmids; pMTL007C-E2:Cdi-slpA-878a and pMTL007C-
E2:Cdi-slpA-1267s. Two targets were chosen in case one target was not able to 
insertionally inactivate slpA. In the first instance, plasmid pMTL007C-E2:Cdi-slpA-
1267s was chosen. For the two other target genes, the ClosTron plasmids pMTL007C-
E2:Cdi-dhaT-548a and pMTL007C-E2:Cdi-trpS-436a were chosen to insertionally 
inactivate targets CD0274 and trpS, respectively. 
Each ClosTron plasmid was conjugated into its appropriate strain, i.e. pMTL007C-
E2:Cdi-slpA-1267s was conjugated into strain C. difficile ƅerm::tet-slpAp which 
contains a second protected copy of slpA under tetracycline inducible control, using 
standard conjugation techniques90. After the conjugation time had elapsed, the 
conjugation slurry was plated onto BHIS supplemented with thiamphenicol, C. difficile 
supplement and most importantly, 316 µg/ml aTc. aTc is added due to the ClosTron 
being able to insertionally inactivate the native essential gene at this stage; therefore the 
protective second copy must be expressed allowing the insertion to not be lethal to the 
cell. After 24 hours, the transconjugants were visible and large enough to pick, so 
independent colonies were sub-cultured to ensure purity and re-streaked onto BHIS 
supplemented with erythromycin, C. difficile supplement, and 316 µg/ml aTc. Within 24 
hours erythromycin resistance colonies were large enough to pick, suggesting that the 
group II intron has inserted into the chromosome thereby activating the RAM38,41. To 
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ensure that that the insertion was into the desired gene, PCR screening for the desired 
ClosTron insertion using primers which flank the target gene, appropriate to each strain 
was carried out. Unfortunately, all the amplicons were of the native genes size, 
suggesting the insertion into the target gene had not taken place. 
The conjugations were repeated a total of 5 times, and a total of 5 erythromycin 
resistant colonies representative of possible ClosTron integrants were screened for each 
of the three targets mentioned above, including three more ClosTron plasmids; 
pMTL007C-E2:Cdi-slpA-878a, pMTL007C-E2:Cdi-dhaT-623a, and pMTL007C-E2:Cdi-
trpS-460a, to increase the possibility of integration. Again no integrants into the desired 
gene were obtained. This result suggests that the target genes cannot be inactivated in 
these strains. It could be possible the inducible promoter system is not able to express 
the second protected target gene to a high enough level to functionally complement the 
native, thereby allowing the native gene to be inactivated.  
In order to overcome this deficiency, the inducible promoter system including each of 
the target genes was cloned into plasmid pMTL82151, and conjugated into C. difficile 
630ƅerm. Placing the inducible promoter system and target gene on a plasmid should 
multiply the expression of the gene by the copy number of the plasmid, thereby 
increasing the overall expression of the target genes.  The ClosTron plasmids; 
pMTL007C-E2:Cdi-slpA-1267s, pMTL007C-E2:Cdi-dhaT-548a, and pMTL007C-
E2:Cdi-trpS-436a were subsequently conjugated into the appropriate C. difficile 
transconjugants, and the ClosTron procedure was carried out with minor 
modifications38,41. As the second copy must be expressed before the native can be 
inactivated, aTc must be supplemented into the media when selecting for integrants to 
induce transcription. However, as was noted in chapter three, over-production of 
CD0274 produced instability in the cell, therefore a range of aTc; 10 ng/ml, 31 ng/ml, 
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and 310 ng/ml, was added to the media to deliver a range of expression for each target 
gene. Double-transconjugants were obtained for both 10 ng/ml and 31 ng/ml aTc and 
verified by PCR, but unfortunately at the time of writing, no integrants into the desired 
target gene had been obtained. Due to time constraints, not enough work has been 
carried out on the method to establish if this method is viable.  
5.2.2.   Problems with culture collection C. difficile ƅerm strain 
It must be noted, at the end of this work which includes certainly the double-
transconjugants attempts, the C. difficile ƅerm strain from our culture collection stock 
had started to act peculiarly. The strain took over 8 hours to grow to an OD600 of 0.5, as 
opposed to 4 hour normally, and reached a maximum OD600 of 0.6 after 24 hours, as 
opposed to normally in excess of OD6001.1, also the plasmid pMTL-tet3nO did not 
produce CatP at all when induced the cells from the same stock. After conferring with 
my colleagues, we noticed that other colleagues had noted this stock had a decreased 
sporulation rate, growth rate, and was unable to grow in some media. It might be 
possible that the strain in our collection had accumulated mutations which have caused 
these multiple deficiencies. This could account for the inability to insertionally inactivate 
the native essential genes as the Tet system might not work as would be expected. In 
light of these observations, the stock which was used was discarded, and a backup stock 
was used as a replacement. Unfortunately, I was unable to repeat this work due to time 
constraints. 
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5.3  Discussion 
Evaluation of antimicrobial targets has historically been carried out by screening 
compounds that inhibit target bacteria3,160-163. However, the drive for novel targets has 
led to new methods being developed to identify novel essential genes, and subsequent 
rational screening or design to inhibit there product46,59,78,164,165. This process of reverse 
targeting takes into account specific mechanisms of action more than blindly screening 
for compounds and allows specific metabolic pathways to be targeted. The ability to 
control essential genes by inducible promoter systems is a powerful tool in not only 
identifying essential genes, but also to differentiate bacteriostatic and bactericidal 
antimicrobial targets116. Conditional expression allows the target genes transcription to 
be controlled by the addition or subtraction of an inducer. Gene transcription, and 
subsequent protein expression, can be decreased or turned off via an inducible 
promoter, mimicking the binding of an antimicrobial agent to the essential genes 
product. The resulting conditional mutants can then be monitored by survival kinetics 
to identify if the target gene is an essential gene, and what type of target it is (figure 
5.3)116. 
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Figure 5.3. Hypothesised survival kinetics of bacteria after exposure by 
different types of antimicrobial targets. The different types of responses 
are indicated, with the bacteriostatic and bactericidal responses (Log10 
cfu/ml) required for an effective antimicrobial. Taken from reference116. 
In this chapter, it was attempted to introduce the Tet system developed in chapter four, 
in combination with a conditionally expressed second protected copy of a target 
essential gene inserted into the chromosome in the pyrE locus. This second copy allows 
subsequent inactivation of the native copy, and therefore functional complementation 
of the native copy, a strategy which was shown to work with a constitutively expressed 
essential gene in chapter three, except in this strategy the target gene is under inducible 
control. Unfortunately, the desired procedure was not shown to work within the time 
frame of this project. It proved possible to construct the three conditional partial 
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diploid strains containing; slpA, trpS, and CD0274 under tetracycline inducible control, 
but a ClosTron integrant in the native target gene of each respective strain could not be 
obtained. The reason for this inability to inactivate the native gene is unknown but 
could be due to the inducible promoter system not being able to express each target 
gene to a high enough level to be able to functionally complement the essential native 
copy if it were to be inactivated. There are a few different ways to ascertain if this is the 
reason for the system not working. In the previous chapter, the Tet system was not 
integrated into the chromosome to test its characteristics in a single copy context. It 
could be possible the system does not function as well in the chromosome as it does on 
a plasmid. Additionally, it was not shown that the target genes were in fact being 
expressed in the cell. One way to achieve this would be to tag the target genes in the 
chromosome (His·Tag or Streptavidin) and show by western blot that the candidate 
essential proteins are being produced. This was not carried out at the time due to time 
constraints, but would be an excellent experiment to narrow down the reasons for this 
experiment not working, and possibly modifying the Tet system to overcome it.  
Working on the assumption that the Tet system was not strong enough to express the 
target genes to a high enough level to functionally complement the native gene, we 
decided to place each target gene controlled by the Tet system onto a plasmid, and use a 
plasmid based system to create a partial diploid. The plasmid based system could allow 
the copy number of the plasmid to multiply the expression level of each target gene, 
allowing the second copy to functionally complement the native. This approach was not 
possible in chapter three with CD0274; however, it might have been due to high 
expression levels expression, which can be controlled in this system with the addition of 
varying concentrations of the inducer. The three target genes were easily conjugated 
into the cell, followed by their respective ClosTron plasmids. Double-transconjugants 
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containing the partial diploid and the ClosTron plasmid were obtained for each strain, 
but the subsequent integration into the native target genes were not. The reason for this 
is unknown but could be linked to the peculiarities noticed in the strain of C. difficile 
ƅerm being used. 
Peculiarities were noticed in the phenotype of the culture collection strain which were 
used in [parts] of this study. In later experiments, including the last work in this chapter, 
the culture collection strain of C. difficile ƅerm behaved differently. These differences 
could be due to accumulation of mutations in the strain caused by constant use within 
the group. Our group keeps all strains in triplicate with only one being used at a time, 
and the other two as backups in the eventuality something like this happens. As such 
the first backup stock was tested by comparing the growth speed between the two 
stocks, with the backup acting as would be expected. As such, the backup stock was 
used to replace the current stock. However, this replacement happened after this work 
had been completed. It is unknown if/when these mutations arose, and as such, it is not 
known how much of this work is affected. If this is the reason for the experiment not 
working, repeating the experiment with fresh stocks should overcome this problem. 
With further work, this type of system could be a powerful tool to identify not only 
essential genes, but also the type of antimicrobial drug target. This extra information 
would be hugely advantageous in applying an efficient antibiotic regime for treating 
CDI. In most cases, bactericidal antimicrobials outperform bacteriostatic 
antimicrobials166. It has also been suggested that the use of bactericidal antimicrobials 
decreases the emergence of drug resistance and bacteriostatic drugs, to have efficacy, 
must be augmented by host defences to clear the infection167. These advantageous over 
bacteriostatic targets would point to targeting and development of bactericidal targets, 
as they would be the choicest targets for the treatment of CDI.  
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Chapter Six 
General Discussion 
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6.1. Key Findings of This Work 
6.1.1. Identification of C. difficile essential genes 
To-date, there has not been a single C. difficile essential gene identified in the literature. 
The reason for this shortcoming is partly due to the limitations of current genetic tools. 
In 2007, Heap et al38, developed the first genetic tool to efficiently and consistently 
inactivate genes in Clostridium, however this tool, the ClosTron, is insufficient alone to 
identify essential genes. In order to identify essential genes in C. difficile, a novel method 
must be developed. This requirement for a novel tool combined with the importance of 
identifying C. difficile essential genes forms the basis of this study. 
To identify candidate essential genes with which to develop a novel method to confirm 
gene essentiality in C. difficile, we first used bioinformatic methods to screen the C. 
difficile genome. Based upon the knockout-rate prediction51, essential genes evolve at 
lower rates compared to nonessential genes; we compared all the known essential genes 
in B. subtilis to identify homologues, and as such candidates, in C. difficile. Using the 
translated amino acid sequence of B. subtilis essential genes52, we used the BLAST tool 
to identify 208 candidate essential genes in C. difficile. To narrow down the candidate 
essential genes for experimental analysis, the introduction of four criteria; sequence 
similarity, size of the gene, genomic context, and potential for antimicrobial targeting, 
was taken into account. Although these strict criteria were used for this study, it does 
not limit the potential of the method to identify essential genes, only increases the 
possibility of successfully identifying essential genes against which to develop a method. 
Based upon this, we selected the genes metK and trpS to analyse experimentally as they 
are known potential broad-spectrum drug targets, increasing the possibility of being 
essential in C. difficile97,98.  
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The main limitation of in silico screening is the inability of the method to identify 
candidate essential genes which have evolved to be essential within a limited number of 
species. Due to the nature of C. difficile infection and the high recurrence rate after 
treatment being associated with an altered gut microflora caused by broad-spectrum 
antimicrobials, the development of a narrow-spectrum antimicrobial would be highly 
advantageous37. Therefore, the only narrow-spectrum candidate essential gene identified 
in the literature was also selected. CD0274 has been proposed to be only essential in C. 
difficile and C. butyricum39,40. It was previously found that inactivation of the candidate 
essential gene CD0274, a proposed 1,3 propandiol dehydrogenase, was associated with a 
lethal phenotype, the first sign that a gene may be essential39,40. However, confirmation 
of essentiality requires further evidence, and a tool able to provide this.  
 In other bacterial species, a common way to identify essential genes is to employ the 
use of a partial diploid system. By combining already established tools in C. difficile, it 
was possible to develop a similar novel strategy to functionally characterise essentiality 
of candidate essential genes, CD0274, metK, and trpS.  
The simplest way to construct a partial diploid is to deliver the second copy of the gene 
on a plasmid into the cell via conjugation50. Unfortunately, the simplest approach to 
constructing the C. difficile partial diploid also proved to be the most troublesome. We 
noted that it was difficult to produce stable CD0274 transconjugants, with 
transconjugants showing very restricted growth in liquid media, and pin-prick size 
colonies on agar with an inability to passage the transconjugants on fresh agar. The 
reason for this instability is unknown, but could be due to a high level of expression of 
CD0274 within the cell. CD0274 is thought to be involved in detoxification of 
methylglyoxal (MG), a toxic metabolite produced as a side-product of glycolysis40,168,169. 
Under certain conditions there is an excessive production of toxic sugar phosphates 
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produced during glycolysis40,168,169. To prevent accumulation of these toxic sugar 
phosphates, carbon flow is diverted via the MG bypass which allows the organism to 
survive. Regulation of the toxic metabolite is kept under strict control in most bacteria; 
however, C. difficile lacks many of these protective features making it a possible drug 
target99,169,170. It is this lack of control which may cause this instability in C. difficile. A 
high level of expression of CD0274 may disrupt the natural regulation and subsequent 
MG detoxification, causing toxic side effects. To circumvent this instability, the 
alternative method to produce a partial diploid was undertaken, and the candidate 
essential gene was introduced into the chromosome using the newly developed allele 
exchange method, ACE (Heap et al, unpublished).  
The alternative ACE method was successful in producing a stable partial diploid 
CD0274 strain, as such; the native CD0274 was insertionally inactivated using the 
ClosTron system with ease. This ability to inactivate CD0274 a total of 140 times 
demonstrates the gene can be inactivated, only in the presence of the second copy, 
SURYLGLQJVWURQJHYLGHQFHRI&'·VHVVHQWLDOLW\7RH[HPSOLI\WKLVPHWKRGIXUWKHU
the two other candidate essential genes were analysed in the same way. The results 
showed that both the genes, trpS and metK, were able to be inactivated only in the 
presence of the second copy. This result not only provides strong evidence that the 
candidates are essential, but also provides evidence that this method is able to identify 
essential genes with relative ease. An advantage of using this system is its simplicity in 
constructing the strains and analysing the results. Because the methods used in this 
study, i.e. ACE and the ClosTron, are viable in not only other Clostridium, but a wide 
range of bacterial species, this novel method could be used to identify essential genes in 
any species in which the established techniques will work, these currently include; C. 
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perfringens, C. botulinum, and C. tetani to name but a few pathogenic Clostridium where no 
essential genes have currently been identified. 
There are two disadvantageous of using such a system over other methods. The first is 
the evidence acquired is indirect, i.e., the measure of essentiality of the gene in the 
presence of a second copy. There could be an, albeit low, possibility, that the presence 
of the second copy allows the native gene to be inactivated when the gene is in fact not 
essential. The second limitation is the static ectopic gene expression level. This static 
expression limits the amount of information which can be acquired about the function 
of the essential gene, and what kind of antimicrobial target inhibition of the gene 
product would pertain to. It has been suggested that bactericidal antimicrobials 
outperform their bacteriostatic counterparts in their ability to clear an infection, and 
decrease the emergence of drug resistance167. This therefore means the ability to 
differentiate between bacteriostatic and bactericidal targets would be valuable to 
prioritise essential genes for antimicrobial targeting. 
6.1.2. Development of a tetracycline inducible promoter to identify and differentiate 
bacteriostatic and bactericidal antimicrobial targets. 
The conditional modulation of gene expression levels is proven to be a powerful tool in 
determining the function of a gene product in bacterial growth and 
pathogenesis49,59,116,121. This ability allows valuable information to be extrapolated by 
modulating gene expression up or down via the addition or subtraction of an inducer. 
In contrast to using the ClosTron system to inactivate a gene, resulting in a total loss of 
function, modulating expression can provide important information on the functional 
importance of a gene product116. In the case of essential genes, it can identify 
conditional lethal phenotypes and provide information on functional importance or 
viability and evaluation of inhibition for therapeutic targeting.  
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Inducible promoters are well characterised in many organisms, unfortunately at the start 
of this study, there was no suitable inducible promoter system for C. difficile. In order to 
select an inducible promoter system to identify and characterise essential genes in C. 
difficile, there were certain characteristics which would be required; wide dynamic range 
of activity, tight repression, good inducer bioavailability, high target gene expression, 
quick induction, and the ability of the system to work in multiple Clostridium. In C. 
perfringens, a lactose inducible promoter system was developed, however, the inducer 
lactose was metabolised after 75 minutes leading to subsequent decrease in induction171. 
This poor bioavailability of lactose excludes the possibility of using such a system in C. 
difficile for essential gene identification; therefore, a new inducible promoter system must 
be developed. We selected the Tet inducible promoter system as it is known to meet all 
the requirements which we were looking for, with the exception of a wide dynamic 
range126, and was unknown if it would work in Clostridium at the start of this study.   
We redesigned the Tet system using clostridial components mirroring the architecture 
of the Tet system present upon pRMC2 with one fundamental difference132. In 
pRMC2·V 7HW V\VWHP WKHUH LV WZR tetOs present within divergent promoters, one 
promoter transcribing the target gene and the other tetO present within the promoter 
transcribing tetR, the gene encoding the tetracycline repressor132. Due to this 
operator/promoter configuration, in the absence of an inducer, TetR is able to repress 
not only the target gene, but also production of TetR. This means that there is very low 
levels of TetR present within the cell. This very low base level of repressor allows very 
small concentrations of inducer to activate target gene expression, making the system 
very sensitive to induction, manifesting as a limited dynamic range. To extend the 
dynamic range of expression, we separated the target gene and tetR promoters and 
removed the tetO from the tetR promoter.  
 
194 
 
This new configuration allowed high independent constitutive expression of tetR and 
subsequent tight repression of the target gene in C. difficile and C. sporogenes. In response 
to varying concentrations of aTc, the system also showed a good dynamic range of 
expression in C. difficile and C. sporogenes compared to previously published Tet systems. 
In addition, we were able to elicit high levels of induction quickly, enabling short term 
studies to be carried out. These results indicate that the Tet system (tet3nO) meets all 
the required characteristics to be used for essential gene identification in C. difficile.  
In the final study in chapter five, we transcriptionally fused the inducible promoter 
system to two of the previously identified essential genes, CD0274 and trpS. These 
genes were chosen as CD0274, if essential in very few organisms, would make an 
excellent candidate narrow-spectrum antimicrobial target. On the other hand, trpS, a 
tryptophanyl-tRNA synthetase, is found in all bacterial species and is known to be a 
good antimicrobial target, therefore would be an auspicious example to exemplify the 
method98. In addition to these two, we selected a third and final gene, slpA. Previous 
studies in our laboratory failed to inactivate slpA, the first indication a gene may be 
essential. SlpA is of interest as it is the main component of C. difficile·V S-layer and 
unique to C. difficile, representing another candidate narrow-spectrum antimicrobial 
target31,32.  
To introduce the transcriptionally fused inducible candidate essential genes into the C. 
difficile genome, the ACE method which was successful in chapter three was selected. 
The three genes were introduced into the pyr locus easily, however, the attempts at 
inactivating the native candidate genes was unsuccessful. It seemed as if the native 
copies were still essential and an inactivation provided a nonviable cell. The reason for 
this is unknown, but could be due to the inducible promoter system not working as 
would be expected, stopping functional complementation. Another possible reason 
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could be peculiarities with our laboratory strain of C. difficile 630ƅerm, which are outlined 
in chapter five. Either way, further charDFWHULVDWLRQRIWKHLQGXFLEOHSURPRWHUV\VWHP·V
properties within the chromosome and its ability to express the candidate essential 
genes will identify the problem with the system, which hopefully should be able to be 
rectified.  
Although we have developed this system to be used to identify essential genes in C. 
difficile, the system is not limited to such studies. Inducible promoters can be used in any 
study which requires the conditional/modulation of expression of any target gene.  
6.2. Potential of CD0274, metK and trpS as Novel Therapeutic Targets. 
Essential gene products represent candidate antimicrobial targets as the loss of 
functionality leads to a loss of cell viability. In order to be an effective antimicrobial 
target, a gene must be required for growth in vivo, as well as in vitro. An example is the 
fatty acid synthesis genes fabF and fabM of Staphylococcus agalactiae which are essential for 
growth in laboratory media, but only confer an advantage in human serum and in vivo 
infection due to the presence of fatty acids, limiting their ability to be used as targets for 
the treatment of septicaemia172. Unfortunately, our studies only identified CD0274, 
metK, and trpS, to be essential for C. difficile in laboratory media, however, the function 
of the products of these essential genes suggests that they are required for survival, and 
as such, may have potential as targets for the treatment of CDI.  
We chose trpS and metK to exemplify the method because they are known to be essential 
in other bacterial species, and have been identified to make good novel antimicrobial 
targets97,98. The prospects of using these two broad-spectrum targets of other bacterial 
species increase the possibility that these two essential genes will also provide good 
antimicrobial targets against C. difficile. However, they might be effective targets against 
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C. difficile; they might not be effective targets for the treatment of CDI. The main 
predisposing factor for CDI is broad-spectrum antimicrobial therapy, which often 
eradicates beneficial flora in the gut, allowing C. difficile to flourish. Following treatment 
for CDI with therapeutic antimicrobials such as; vancomycin and metronidazole, the 
gut flora is subsequently destroyed again, allowing C. difficile to relapse and cause disease 
again.  
There has been considerable interest in a narrow-spectrum antimicrobial target which is 
able to act upon C. difficile alone, allowing the native gut microflora to replenish and 
inhibit CDI relapse5,12,111. The most promising of the novel C. difficile antimicrobials is 
fidaxomicin, an RNA inhibitor which is almost purely specific for C. difficile. In 
comparison against vancomycin, fidaxomicin showed similar efficacy in treating a 
patient, and significantly lower rate of relapse, highlighting the effectiveness of a 
narrow-spectrum antimicrobial37. In previous studies in C. difficile, a species-specific 
candidate essential gene was serendipitously identified39,40.  
Liyanage et al, (2001)40, identified CD0274 (they annotated as gldA) as a candidate 
essential gene, thought to be involved in detoxification of toxic metabolite MG. MG is 
produced from dihydroxyacetone phosphate (DHAP) via MG synthase (MGS), 
encoded for by mgsA168-170. There are other proposed routes in higher organisms but 
variations in bacteria are very poorly documented173. Hopper and Cooper were the first 
to purify MGS from E. coli in 1971 and found it to be homotropically activated by 
DHAP and allosterically inhibited by its other product, inorganic phosphate174. The 
intricacy of MG regulation mechanisms is increased by various glycolytic intermediates 
being able to regulate MG levels through changes in concentration, as commonly seen 
with many other catabolic pathways. A significant characteristic of MG is its cytotoxic 
effect169,170. The exact mechanism of action of MG in inhibiting bacterial cell growth or 
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causing death is unclear, but it has been proposed that MG interferes with protein 
synthesis through interactions with 7-methylguanosine which is a residue present within 
16s and 23s RNA, thereby preventing DNA replication initiation169,170. The electrophile 
can react with the nucleophilic centres of proteins, DNA, and RNA. It has also been 
shown to react with the side-chains of the amino acids; cysteine, lysine, arginine, and the 
base guanine, and to a lesser extent with the bases adenine and cytosine169,170. 
Detoxification of MG would seem to be disrupted by the inactivation of CD0274, 
causing the loss of cell viability through the aforementioned toxicity of MG 
accumulation. It is this loss of viability which would be an attractive attribute combined, 
ZLWK WKH VSHFLILFLW\RI&'·V HVVHQWLDOLW\&'4 would make a strong candidate 
novel antimicrobial target for the treatment of CDI. 
6.3. The Future of Essential Gene Identification in C. difficile 
The identification of essential genes is paramount for the development of antimicrobial 
drugs for the treatment of CDI. In this study, we used bioinformatic approaches to 
identify candidate essential genes, and subsequently developed a novel method to 
provide strong evidence of essentiality of three C. difficile genes, CD0274, trpS, and metK. 
However, these are only three from potentially hundreds of essential genes present 
within the C. difficile genome. The ability to use forward genetic studies to screen the 
entire genome for essential genes has become popular and has been successful in other 
bacterial species44,59,75,78,80,175. With the advent of a mariner-based transposon system for 
C. difficile, it is now possible to carry out such a system in C. difficile42. There is two main 
ways by which to approach this, by using a TraDIS system77 or a TnTetOut system80. 
The TraDIS system, which was described in chapter one, has proven to be a powerful 
method to identify candidate essential genes in S. Typhi by their inability to be 
inactivated77. This type of method, although time consuming, would not only provide 
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the frequency of insertion for every gene, but also produce a mutant in every gene 
within the C. difficile genome. The main limitation of using this system is that DJHQH·V
inability to be inactivated does not equate to the gene being essential, it only defines the 
gene as a candidate. To provide further evidence for essentiality, each gene identified as 
a candidate must be analysed by either the strategy taken in chapter three, or 
alternatively chapter five.  
To circumvent this limitation, an adaptation of the TnAraOut transposon system could 
be adopted. Instead of the PBAD inducible promoter system, it would be possible to 
substitute the PBAD system for the Tet inducible promoter system developed in chapter 
four. By using the mariner-based transposon system harbouring tKH7HWV\VWHPDWWKH·
facing outwards, any transcriptionally fused essential genes would be dependent on the 
addition of aTc for cellular viability80,81. This dependence allows high through-put 
screening of a transposon mutant library to directly identify every possible essential 
gene within C. difficile, with no need for any further methods to be used.  
6.4. Proposed Future Work 
6.4.1. Conditional lethal phenotypes 
The methods developed in this project for identifying essential genes, and for further 
analysing gene function, have great potential far beyond the scope of this project. In my 
opinion, the inducible promoter system developed in chapter four is the best outcome 
RIWKLVZRUNDOORZLQJDQ\WDUJHWJHQH·VH[SUHVVLRQWREHPRGXODWHGWRVWXG\WKHJHQH·V
function. In the terms of using conditional expression for essential gene identification as 
employed in chapter five, if the complications of conditionally controlling lethal 
SKHQRW\SHVFRXOGEHIL[HGWKHPHWKRGZRXOGSURYLGHVWURQJGLUHFWHYLGHQFHRIDJHQH·V
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essentiality and its nature as an antimicrobial target.  Therefore, continuation of this 
study would be extremely valuable.  
To complete the development of conditional lethal phenotypes, the following issues 
must be addressed; 
x Characterisation of the Tet system in the genome to ensure the system works; this can 
be accomplished by introducing the tet3nO construct expressing catP in the pyr locus 
using ACE. 
x Determine if the essential genes are being expressed within the chromosome in chapter 
five by tagging each gene with a His·Tag and demonstrating expression using Western 
blots. 
x If the inducible promoter is not strong enough to express the essential genes to a high 
enough level, either replace the Pthl running tetR to decrease the concentration of TetR, 
thereby allowing a lower concentration of aTc to induce a maximum response without 
being toxic to the cell, or by moving the functional complementation system onto a 
plasmid, allowing the plasmid copy number to multiply expression of the essential gene 
to achieve the required concentration to functionally complement. 
6.4.2. Broad-host range Clostridium inducible promoter system 
The development of a broad-host range Clostridium vector would still be a very powerful 
tool for analysing gene function in other Clostridium, as one currently does not exist. The 
Tet system we developed worked very well in C. difficile and C. sporogenes; however, we 
were unable to elicit an induction of the system in C. beijerinckii and C. acetobutylicum. The 
reason for this is unknown, but could be due to the inducer being actively transported 
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out of the cell by a native tetA(B) gene present within construct C. acetobutylicum and C. 
beijerinckii.  
To determine if the presence of the tetA gene is responsible for the system not working 
in both these organism, and to further analyse the Tet system as a Clostridium inducible 
promoter system, the following actions must be undertaken; 
x Inactivation of the native tetA gene in C. beijerinckii and C. acetobutylicum using the 
ClosTron system would determine tetA·VHIIHFWRQWKH7HWV\VWHP·VDELOLW\WRFRQWUROWKH
expression of catP. 
x )XUWKHUDQDO\VLVRI WKH LQGXFLEOHSURPRWHU V\VWHP·VFKDUDFWHULVWLFV LQRWKHU Clostridium 
would determine its ability to act as a universal Clostridium inducible promoter system. 
6.5. Concluding Remarks 
It is clear that our knowledge of essential genes in C. difficile is elementary at best. 
However, now that we have the tools available to us, we can start identifying and 
XQGHUVWDQGLQJ WKH QDWXUH DQG HIIHFWV HVVHQWLDO JHQHV KDYH XSRQ D FHOO·V viability. In 
addition, the work carried out in this study has identified a potential novel narrow-
spectrum antimicrobial drug target for the treatment of CDI. With the range of tools at 
our disposal constantly expanding, the path is opening up to thoroughly understand this 
´HVVHQWLDOµDVSHFWRIC. difficile, and the subsequent development of effective therapeutic 
antimicrobial drugs is sure to follow. 
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Appendix 
Appendix 1. All candidate essential genes of C. difficile based upon in silico 
analysis of similarity to B. subtilis essential genes52.  
NF = Not Found 
Gene 
CD 
Number Protein Homology Size Annotation 
dnaA CD0001 Identities = 278/448 (62%), Positives = 350/448 (78%) 1317 bp 
 
dnaB NF 
   
dnaC CD3657 Identities = 224/431 (51%), Positives = 325/431 (75%) 1329 bp dnaB 
dnaD NF 
   
dnaE CD3397 Identities = 473/1198 (39%), Positives = 699/1198 (58%) 3570 bp 
 
dnaG CD1454 Identities = 186/606 (31%), Positives = 342/606 (56%) 1827 bp 
 
dnaI CD0410 Identities = 50/162 (31%), Positives = 85/162 (52%) 852 bp 
 
dnaN CD0002 Identities = 124/360 (34%), Positives = 215/360 (60%) 1209 bp 
 
dnaX CD0016 Identities = 192/480 (40%), Positives = 303/480 (63%) 1.6Kbp 
 
yqeN NF 
   
holB CD3549 Identities = 95/304 (31%), Positives = 161/304 (52%) 936 bp 
 
ligA CD3309 Identities = 365/667 (54%), Positives = 498/667 (74%) 2Kbp 
 
pcrA CD0328 Identities = 355/754 (47%), Positives = 496/754 (66%) 2265 bp 
 
polC CD1305 Identities = 678/1420 (48%), Positives = 942/1420 (66%) 4299 bp 
 
priA CD2586 Identities = 324/830 (39%), Positives = 501/830 (60%) 2490 bp 
 
ssb CD3662 Identities = 41/105 (39%), Positives = 61/105 (58%) 435 bp 
 
gyrA CD0006 Identities = 471/811 (58%), Positives = 638/811 (79%) 2427 bp 
 
gyrB CD0005 Identities = 407/634 (64%), Positives = 508/634 (80%) 1902 bp 
 
hbs CD3496 Identities = 50/92 (54%), Positives = 69/92 (75%) 276 bp hupA 
parC CD0006 Identities = 322/731 (44%), Positives = 490/731 (67%) 2427 bp gyrA 
parE CD0005 Identities = 341/633 (54%), Positives = 452/633 (71%) 1902 bp gyrB 
smc CD1250 Identities = 449/1222 (37%), Positives = 734/1222 (60%) 3555 bp 
 
topA CD1274 Identities = 390/691 (56%), Positives = 501/691 (72%) 2.1KBp 
 
ypuG NF 
   
ypuH NF 
   
ydiO CD3147 Identities = 56/218 (26%), Positives = 90/218 (41%) 1626 bp 
 
ydiP CD0927 Identities = 63/171 (37%), Positives = 93/171 (54%) 1074 bp 
 
rpoA CD0098 Identities = 209/311 (67%), Positives = 255/311 (82%) 948 bp 
 
rpoB CD0066 Identities = 783/1183 (66%), Positives = 957/1183 (81%) 3717 bp 
 
rpoC CD0067 Identities = 785/1184 (66%), Positives = 940/1184 (79%) 3486 bp 
 
sigA CD1455 Identities = 248/371 (66%), Positives = 297/371 (80%) 1173bp 
 
cca CD2466 Identities = 90/202 (45%), Positives = 135/202 (67%) 1347 bp 
 
cspR CD0566 Identities = 89/159 (55%), Positives = 117/159 (73%) 471bp 
 
(m)rnc CD0053 Identities = 50/120 (42%), Positives = 80/120 (67%) 396 bp 
 
rnpA CD3679 Identities = 45/101 (44%), Positives = 72/101 (71%) 345bp 
 
trmD CD1256 Identities = 121/226 (53%), Positives = 168/226 (74%) 696bp 
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trmU CD1281 Identities = 152/360 (42%), Positives = 223/360 (62%) 1086 bp 
 
yycF NF 
   
yycG NF 
   
yhdL CD0355 Identities = 15/56 (27%), Positives = 31/56 (55%) 1191 bp 
 
nusA CD1307 Identities = 193/313 (61%), Positives = 255/313 (81%) 1115bp 
 
rplA CD0062 Identities = 157/228 (69%), Positives = 186/228 (82%) 699 bp 
 
rplB CD0076 Identities = 189/274 (69%), Positives = 222/274 (81%) 831 bp 
 
rplC CD0073 Identities = 126/206 (61%), Positives = 160/206 (78%) 630 bp 
 
rplD CD0074 Identities = 117/207 (57%), Positives = 148/207 (71%) 654 bp 
 
rplE CD0084 Identities = 124/178 (70%), Positives = 153/178 (86%) 543 bp 
 
rplF CD0086 Identities = 106/179 (59%), Positives = 135/179 (75%) 543 bp 
 
rplI CD3658 Identities = 75/147 (51%), Positives = 108/147 (73%) 450 bp 
 
rplJ CD0063 Identities = 78/165 (47%), Positives = 110/165 (67%) 507 bp 
 
rplL CD0064 Identities = 77/121 (64%), Positives = 98/121 (81%) 366 bp 
 
rplM CD0104 Identities = 72/139 (52%), Positives = 98/139 (71%) 432 bp 
 
rplN CD0082 Identities = 98/122 (80%), Positives = 111/122 (91%) 369 bp 
 
rplO CD0089 Identities = 93/147 (63%), Positives = 113/147 (77%) 444 bp 
 
rplP CD0080 Identities = 103/143 (72%), Positives = 122/143 (85%) 432 bp 
 
rplQ CD0099 Identities = 70/118 (59%), Positives = 84/118 (71%) 342 bp 
 
rplR CD0087 Identities = 79/122 (65%), Positives = 97/122 (80%) 369 bp 
 
rplS CD1257 Identities = 76/114 (67%), Positives = 95/114 (83%) 351 bp 
 
rplT CD0687 Identities = 73/117 (62%), Positives = 91/117 (78%) 357 bp 
 
rplU CD1161 Identities = 61/103 (59%), Positives = 79/103 (77%) 312 bp 
 
rplV CD0078 Identities = 67/111 (60%), Positives = 85/111 (77%) 336 bp 
 
rplW CD0075 Identities = 60/95 (63%), Positives = 70/95 (74%) 291 bp 
 
rplX CD0083 Identities = 64/101 (63%), Positives = 82/101 (81%) 309 bp 
 
rpmA CD1163 Identities = 68/93 (73%), Positives = 78/93 (84%) 291 bp 
 
rpmB CD2562A Identities = 30/61 (49%), Positives = 42/61 (69%) 189 bp 
 
rpmC CD0080A Identities = 39/62 (63%), Positives = 51/62 (82%) 204 bp 
 
rplD CD0074 Identities = 117/207 (57%), Positives = 148/207 (71%) 654 bp 
 
rplE CD0084 Identities = 124/178 (70%), Positives = 153/178 (86%) 543 bp 
 
rplF CD0086 Identities = 106/179 (59%), Positives = 135/179 (75%) 543 bp 
 
rpmGA CD0058A Identities = 32/49 (65%), Positives = 39/49 (80%) 150 bp rpmG 
rpmGB CD0058A Identities = 25/49 (51%), Positives = 32/49 (65%) 150 bp rpmG 
rpmH CD3680 Identities = 27/42 (64%), Positives = 31/42 (74%) 138 bp 
 
rpmI CD0686 Identities = 40/62 (65%), Positives = 47/62 (76%) 195 bp 
 
rpmJ CD0094A Identities = 36/37 (97%), Positives = 37/37 (100%) 114 bp 
 
rpsB CD2140 Identities = 168/236 (71%), Positives = 205/236 (87%) 714 bp 
 
rpsC CD0079 Identities = 123/212 (58%), Positives = 168/212 (79%) 816 bp 
 
rpsD CD0097 Identities = 102/208 (49%), Positives = 139/208 (67%) 624 bp 
 
rpsE CD0088 Identities = 122/168 (73%), Positives = 142/168 (85%) 510 bp 
 
rpsF CD3663 Identities = 37/91 (41%), Positives = 62/91 (68%) 279 bp 
 
rpsG CD0069 Identities = 117/156 (75%), Positives = 138/156 (88%) 471 bp 
 
rpsH CD0085 Identities = 90/132 (68%), Positives = 114/132 (86%) 199 bp 
 
rpsI CD0105 Identities = 90/130 (69%), Positives = 101/130 (78%) 393 bp 
 
rpsJ CD0072 Identities = 83/103 (81%), Positives = 95/103 (92%) 312 bp 
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rpsK CD0096 Identities = 102/132 (77%), Positives = 118/132 (89%) 399 bp 
 
rpsL CD0068 Identities = 103/136 (76%), Positives = 116/136 (85%) 423 bp 
 
rpsM CD0095 Identities = 75/122 (61%), Positives = 101/122 (83%) 372 bp 
 
rpsN CD0084A Identities = 26/43 (60%), Positives = 34/43 (79%) 186 bp 
 
rpsO CD1316 Identities = 57/82 (70%), Positives = 67/82 (82%) 258 bp 
 
rpsP CD1253 Identities = 56/90 (62%), Positives = 74/90 (82%) 273 bp 
 
rpsQ CD0081 Identities = 59/80 (74%), Positives = 63/80 (79%) 255 bp 
 
rpsR CD3661A Identities = 37/61 (61%), Positives = 48/61 (79%) 228 bp 
 
rpsT CD2473 Identities = 35/88 (40%), Positives = 51/88 (58%) 267 bp 
 
rpsU CD2446a Identities = 34/55 (62%), Positives = 45/55 (82%) 180 bp 
 
alaS CD1282 Identities = 418/880 (47%), Positives = 593/880 (67%) 2640 bp 
 
argS CD0711 Identities = 170/602 (28%), Positives = 285/602 (47%) 1701 bp 
 
asnS CD2245 Identities = 161/455 (35%), Positives = 245/455 (54%) 1398 bp asnC 
aspS CD2739 Identities = 330/590 (56%), Positives = 434/590 (74%) 1788 bp 
 
cysS CD0052 Identities = 258/463 (55%), Positives = 343/463 (74%) 1407 bp 
 
gltX CD0051 Identities = 218/485 (44%), Positives = 324/485 (66%) 1482 bp 
 
glyQ CD2433 Identities = 201/288 (70%), Positives = 245/288 (85%) 879 bp 
 
glyS CD2432 Identities = 293/694 (42%), Positives = 442/694 (64%) 2067 bp 
 
hisS CD2740 Identities = 195/415 (47%), Positives = 283/415 (68%) 1263 bp 
 
ileS CD2618 Identities = 265/822 (32%), Positives = 418/822 (50%) 3108 bp 
 
leuS CD2521 Identities = 388/821 (47%), Positives = 537/821 (65%) 2421 bp 
 
lysS CD3552 Identities = 287/497 (58%), Positives = 384/497 (77%) 1530 bp 
 
metS CD3540 Identities = 354/660 (53%), Positives = 465/660 (70%) 1938 bp 
 
pheS CD0699 Identities = 195/341 (57%), Positives = 259/341 (76%) 1029 bp 
 
pheT CD0700 Identities = 319/813 (39%), Positives = 479/813 (59%) 2394 bp 
 
proS CD0049 Identities = 279/547 (51%), Positives = 380/547 (69%) 1716 bp 
 
serS CD0014 Identities = 258/418 (61%), Positives = 322/418 (77%) 1272 bp 
 
trpS CD2610 Identities = 181/330 (54%), Positives = 242/330 (73%) 1002 bp 
 
tyrS CD1521 Identities = 107/386 (27%), Positives = 194/386 (50%) 1209 bp 
 
valS CD3256 Identities = 467/891 (52%), Positives = 630/891 (70%) 2667 bp 
 
gatA CD3117 Identities = 35/152 (23%), Positives = 57/152 (38%) 861 bp bglG 
gatB CD1041 Identities = 17/61 (28%), Positives = 27/61 (44%) 3828 bp aadA 
gatC CD1384 Identities = 15/43 (35%), Positives = 27/43 (63%) 792 bp 
LamB/YcsF  
family protein 
fmt CD2584 Identities = 152/311 (48%), Positives = 216/311 (69%) 930 bp 
 
frr CD2137 Identities = 101/185 (54%), Positives = 144/185 (77%) 558 bp 
 
fusA CD0070 Identities = 486/685 (71%), Positives = 568/685 (83%) 2067 bp 
 
infA CD0094 Identities = 56/72 (78%), Positives = 64/72 (89%) 219 bp 
 
infB CD1309 Identities = 360/584 (62%), Positives = 452/584 (77%) 1941 bp 
 
prfA CD3484 Identities = 205/351 (58%), Positives = 278/351 (79%) 1065 bp 
 
prfB CD0144 Identities = 179/339 (52%), Positives = 251/339 (74%) 987 bp 
 
tsf CD2139 Identities = 162/302 (54%), Positives = 208/302 (69%) 912 bp 
 
tufA CD0058 Identities = 309/397 (78%), Positives = 340/397 (86%) 1194 bp 
 
spoVC NF 
   
groEL CD0194 Identities = 388/526 (74%), Positives = 453/526 (86%) 1629 bp 
 
groES CD0193 Identities = 55/92 (60%), Positives = 74/92 (80%) 285 bp 
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map CD0092 Identities = 162/248 (65%), Positives = 201/248 (81%) 747 bp map1 
ffh CD1252 Identities = 287/450 (64%), Positives = 358/450 (80%) 1353 bp 
 
ftsY CD1251 Identities = 158/303 (52%), Positives = 226/303 (75%) 1281 bp 
 
prsA CD2263 Identities = 87/228 (38%), Positives = 128/228 (56%) 1143 bp 
annotated wrong,  
prsA CD3500 
secA CD2792 Identities = 394/784 (50%), Positives = 558/784 (71%) 2346 bp 
Also highly  
similar to  
CD0143, secA1 
secE CD0059 Identities = 18/54 (33%), Positives = 33/54 (61%) 222 bp 
 
secY CD0090 Identities = 181/427 (42%), Positives = 265/427 (62%) 1269 bp prlA 
accA CD1936 Identities = 164/302 (54%), Positives = 225/302 (74% 945 bp 
 
accB CD1939 Identities = 62/156 (40%), Positives = 93/156 (60%) 453 bp 
 
accC CD1938 Identities = 245/443 (55%), Positives = 323/443 (73%) 1362 bp 
 
accD CD1937 Identities = 139/276 (50%), Positives = 186/276 (67%) 855 bp 
 
acpA CD1062 Identities = 36/74 (49%), Positives = 51/74 (69%) 228 bp 
 
acpS CD3466 Identities = 50/122 (40%), Positives = 74/122 (60%) 381 bp 
 
birA CD3558 Identities = 125/323 (39%), Positives = 200/323 (62%) 
  
fabD CD1181 Identities = 142/290 (49%), Positives = 197/290 (68%) 951 bp 
 
fabF CD1184 Identities = 258/409 (63%), Positives = 327/409 (80%) 1239 bp 
 
fabG CD1182 Identities = 142/245 (58%), Positives = 188/245 (77%) 750 bp 
 
cdsA CD2135 Identities = 96/273 (35%), Positives = 142/273 (52%) 780 bp 
 
gpsA CD2630 Identities = 177/337 (52%), Positives = 242/337 (71%) 1032 bp glyC 
pgsA CD0173 Identities = 78/250 (31%), Positives = 120/250 (48%) 1068 bp 
 
yhdO NF 
   
yerQ CD2060 Identities = 89/282 (31%), Positives = 158/282 (56%) 900 bp 
 
plsX CD1178 Identities = 145/313 (46%), Positives = 220/313 (70%) 1023 bp 
 
gcaD CD3515 Identities = 234/451 (52%), Positives = 330/451 (73%) 1380 bp glmU 
glmS CD0120 Identities = 267/613 (43%), Positives = 413/613 (67%) 1833 bp 
 
ybbT NF 
   
yvyH NF 
   
asd CD3224 Identities = 153/331 (46%), Positives = 216/331 (65%) 1002 bp 
 
dapA CD3223 Identities = 125/277 (45%), Positives = 186/277 (67%) 882 bp dapA1 
dapB CD3229 Identities = 78/270 (29%), Positives = 136/270 (50%) 756 bp dapB2 
dapF CD2590 Identities = 91/277 (32%), Positives = 158/277 (57%) 831 bp 
 
ykuQ NF 
   
ykuR NF 
   
alr NF 
   
ddl CD1626 Identities = 134/360 (37%), Positives = 199/360 (55%) 1101 bp vanG 
racE CD3562 Identities = 114/268 (42%), Positives = 174/268 (64%) 807 bp murI 
mraY CD2654 Identities = 144/311 (46%), Positives = 215/311 (69%) 969 bp 
 
murAA CD0123 Identities = 250/419 (59%), Positives = 331/419 (78%) 1272 bp murA 
murB CD3402 Identities = 111/282 (39%), Positives = 177/282 (63%) 915 bp 
 
murC CD3518  Identities = 147/441 (33%), Positives = 226/441 (51%)  1353 bp 
 
murD CD2653 Identities = 170/454 (37%), Positives = 273/454 (60%) 1356 bp 
 
murE CD2664 Identities = 206/471 (44%), Positives = 293/471 (62%) 1455 bp 
 
murF CD2655 Identities = 169/456 (37%), Positives = 257/456 (56%) 1374 bp 
 
murG CD2651 Identities = 141/359 (39%), Positives = 224/359 (62%) 1230 bp 
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tagA NF 
   
tagB NF 
   
tagD NF 
   
tagF NF 
   
tagG NF 
   
tagH NF 
   
tagO NF 
   
divlB NF 
   
ftsA NF 
   
ftsL/divIC NF 
   
ftsW CD1152  Identities = 113/350 (32%), Positives = 183/350 (52%)  1131 bp mrdB 
ftsZ CD2646  Identities = 230/387 (59%), Positives = 293/387 (75%)  1161 bp 
 
pbpB CD2656  Identities = 217/676 (32%), Positives = 335/676 (49%)  1980 bp spoVD 
rodA CD2652  Identities = 103/285 (36%), Positives = 151/285 (52%)  1131 bp spoVE 
mreB CD1145  Identities = 209/332 (62%), Positives = 275/332 (82%)  1062 bp mreB2 
mreC CD1146 Identities = 69/246 (28%), Positives = 110/246 (45%) 900 bp 
 
eno CD3170  Identities = 322/427 (75%), Positives = 364/427 (85%)  1293 bp 
 
fbaA CD3448  Identities = 124/285 (43%), Positives = 178/285 (62%)  852 bp gatY 
pfkA CD3395 Identities = 191/319 (60%), Positives = 251/319 (79%) 960 bp 
 
pgm CD3171  Identities = 286/516 (55%), Positives = 376/516 (72%)  1153 bp gpmL 
prsA CD2263  Identities = 87/228 (38%), Positives = 128/228 (56%)  1143 bp 
 
tkt CD3459  Identities = 93/253 (36%), Positives = 139/253 (54%)  828 bp 
 
tpiA CD3172  Identities = 150/247 (60%), Positives = 193/247 (78%)  744 bp 
 
dxr CD2130  Identities = 203/383 (53%), Positives = 281/383 (73%)  1155 bp 
 
dxs CD1207  Identities = 306/623 (49%), Positives = 417/623 (66%)  1866 bp 
 
ispE CD3566 Identities = 124/254 (49%), Positives = 175/254 (69%) 891 bp 
 
yacM NF 
   
yacN NF 
   
yqfY NF 
   
yqiD NF 
   
hepS NF 
   
hepT CD1205  Identities = 70/226 (30%), Positives = 114/226 (50%)  888 bp ispA 
menA NF 
   
menB CD0800  Identities = 89/256 (34%), Positives = 137/256 (53%)  783 bp crt1 
menC CD1389  Identities = 101/361 (27%), Positives = 179/361 (49%)  1068 bp 
 
menD NF 
   
menE CD2852  Identities = 123/510 (24%), Positives = 221/510 (43%)  1515 bp dltB 
menH NF 
   
resA CD3010  Identities = 49/113 (43%), Positives = 65/113 (57%)  bp 
 
resB NF 
   
resC NF 
   
trxA CD1690  Identities = 44/102 (43%), Positives = 70/102 (68%)  318 bp 
trxA1 multiple  
present 
trxB CD2356  Identities = 144/312 (46%), Positives = 207/312 (66%)  948 bp 
trxB3 multiple  
present 
yumC NF 
  
trxB  
adk CD0091  Identities = 123/216 (56%), Positives = 162/216 (75%)  651 bp 
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gmk CD2588  Identities = 97/199 (48%), Positives = 141/199 (70%)  618 bp 
 
guaB CD2335  Identities = 170/493 (34%), Positives = 250/493 (50%)  1500 bp 
 
hprT CD2691  Identities = 93/165 (56%), Positives = 130/165 (78%)  528 bp hpt 
nrdE CD2995  Identities = 357/697 (51%), Positives = 492/697 (70%)  2100 bp 
 
nrdF CD2994 Identities = 173/318 (54%), Positives = 230/318 (72%) 972 bp 
 
ymaA NF 
   
cmk CD1816   Identities = 102/204 (50%), Positives = 148/204 (72%)  651 bp 
 
pryG NF 
   
tmk NF 
   
tyaG NF 
   
dfrA NF 
   
folD CD0720  Identities = 121/276 (43%), Positives = 180/276 (65%)  873 bp 
 
gylA CD2726  Identities = 262/414 (63%), Positives = 313/414 (75%)  1245 bp 
 
nadE CD0794  Identities = 95/256 (37%), Positives = 141/256 (55%)  756 bp 
 
ppnK CD1049  Identities = 70/270 (25%), Positives = 138/270 (51%)  801 bp 
 
yqeJ NF 
   
yueK CD3543  Identities = 232/473 (49%), Positives = 329/473 (69%)  1431 bp 
 
metK CD0130  Identities = 294/396 (74%), Positives = 348/396 (87%)  1194 bp 
 
csd NF 
   
yurU NF 
   
yurV NF 
   
yurX NF 
   
yurY NF 
   
yrvO NF 
   
mrpA NF 
   
mrpB NF 
   
mrpC NF 
   
mrpD NF 
   
mrpF NF 
   
ppaC CD0333  Identities = 108/237 (45%), Positives = 154/237 (64%)  1599 bp 
 
era CD2437  Identities = 165/295 (55%), Positives = 48/295 (74%)  894 bp 
 
obg CD1164 Identities = 219/429 (51%), Positives = 310/429 (72%) 1278 bp 
 
ylqF NF 
   
yphC NF 
   
yqeH NF 
   
ysxC NF 
   
gcp CD0152  Identities = 183/336 (54%), Positives = 251/336 (74%)  1017 bp 
 
odhB CD0038  Identities = 101/306 (33%), Positives = 157/306 (51%)  1047 bp acoC 
pdhA CD0036  Identities = 100/324 (30%), Positives = 164/324 (50%)  969 bp acoA 
ydiC CD0149  Identities = 73/234 (31%), Positives = 127/234 (54%)  450 bp 
 
ykqC NF 
   
yneS CD2631  Identities = 80/183 (43%), Positives = 110/183 (60%)  615 bp 
 
ymdA CD1329  Identities = 327/498 (65%), Positives = 416/498 (83%)  1563 bp 
 
yloQ CD2576  Identities = 140/301 (46%), Positives = 189/301 (62%)  885 bp 
 
yqjK CD2539  Identities = 90/308 (29%), Positives = 149/308 (48%)  918 bp elaC 
ywlC CD3482  Identities = 164/333 (49%), Positives = 227/333 (68%)  1062 bp 
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yacA NF 
   
ydiB CD0149  Identities = 69/145 (47%), Positives = 92/145 (63%)  453 bp 
 
ylaN NF 
   
yqeI CD1165  Identities = 38/96 (39%), Positives = 59/96 (61%)  369 bp 
  
